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Preterm labour (PTL) is defined as labour before 37 completed weeks of gestation. 
Despite advances in medical research, PTL remains a major clinical problem. Preterm 
birth (PTB) rates range from approximately 5-18% worldwide. Importantly, PTB is 
the leading cause of childhood morbidity and mortality. PTL is difficult to predict and 
the aetiology is poorly understood but infection and inflammation are believed to be 
major factors. It has been suggested that the presence of intrauterine infection or 
inflammation may initiate the pathological, preterm activation of the inflammatory 
cascade associated with term labour. Therefore, PTL therapeutics should aim to inhibit 
these inflammatory pathways. Statins, 5-hydroxy-3-methylglutaryl-coenzyme A 
(HMG-CoA) reductase inhibitors, are potent inhibitors of cholesterol biosynthesis, 
which act on the mevalonate pathway. In addition to their lipid-lowering effects, statins 
also have anti-inflammatory and anti-contraction properties.  
The hypothesis of this thesis was that statins will prevent PTB by reducing 
inflammation. The aims of this thesis were firstly to investigate the effect of the statins, 
simvastatin and pravastatin, on inflammation and contractility in a pregnant human 
myometrial cell line. Secondly, to determine whether simvastatin and/or pravastatin 
can prevent PTB or improve neonatal outcome in a lipopolysaccharide (LPS)-induced 
mouse model of PTB. 
Myometrial cells were either co-treated with LPS and simvastatin/pravastatin, pre-
treated with simvastatin/pravastatin or treated with simvastatin/pravastatin post-LPS 
stimulation. The effect of statin treatment on the mRNA expression and the release of 
inflammatory mediators was then investigated. Simvastatin treatment reduced LPS-
induced inflammation by both lowering the expression of pro-inflammatory mediators 
and increasing the expression of anti-inflammatory mediators. Pravastatin treatment 
did not alter the expression of inflammatory mediators following LPS stimulation.  
The effect of simvastatin on the contraction of myometrial cells was investigated by 
embedding the cells in rat tail collagen to form gels. As these are smooth muscle cells, 
basal contraction was observed causing the gel size to reduce. When LPS was 




Simvastatin attenuated the contraction of the myometrial cells, both alone and in the 
presence of LPS. These effects were reversed by the addition of mevalonate pathway 
metabolites, mevalonate and geranylgeranyl pyrophosphate (GG-PP) but not by 
farnesyl pyrophosphate (F-PP). Simvastatin also lowered levels of phosphorylated 
myosin light chain (pMLC) in the myometrial cells, which is essential for smooth 
muscle contraction. Again, this effect was abolished by mevalonate and GG-PP but 
not F-PP. It is hypothesised that simvastatin attenuated myometrial cell contraction by 
inhibiting Rho isoprenylation by GG-PP, preventing Rho-associated kinase (ROCK) 
activation, which then prevented the phosphorylation of MLC. 
A mouse model of intrauterine LPS-induced PTB was utilised to investigate the effect 
of statin treatment on PTB and fetal survival. Mice received an intraperitoneal 
injection of pravastatin (10µg) or simvastatin (20µg or 40µg) on gestational day (D)16. 
This was followed by ultrasound-guided intrauterine injection of LPS (1µg) on D17 
and another pravastatin/simvastatin treatment two hours later. When mice were treated 
with LPS, 77.8% of mice delivered preterm. When mice received LPS and 20µg 
simvastatin, 50% delivered preterm. However, when mice were treated with LPS and 
40µg simvastatin, 40% delivered preterm, more pups were born alive and uterine pro-
inflammatory mRNA expression was downregulated. Conversely, pravastatin did not 
prevent PTB or improve the percentage of live born pups.  
In summary, simvastatin treatment exerted anti-inflammatory and anti-contraction 
effects on human myometrial cells in vitro. The anti-contractile properties were likely 
due to the inhibition of the Rho/ROCK pathway. Furthermore, in our LPS-induced 
mouse model of PTB, fewer mice delivered preterm with simvastatin treatment, 
simvastatin attenuated LPS-induced pup mortality and reduced uterine inflammatory 






Preterm labour is when labour begins before 37 weeks of pregnancy. Premature babies 
are not fully developed, which can lead to a number of health complications. Common 
causes of preterm labour are infection and inflammation. Statins are drugs that are used 
for the prevention of heart disease, as they lower cholesterol. However, they are also 
believed to have other beneficial effects, such as reducing inflammation.  
The hypothesis of this thesis was that statins will prevent early birth by reducing 
inflammation. This thesis investigated the effect of two statins, simvastatin and 
pravastatin, on inflammation and contraction in human myometrial cells. Furthermore, 
the effect of these statins was investigated in a mouse model of preterm birth. 
The myometrium is the smooth muscle tissue found in the uterus. This tissue contracts 
during labour. Myometrial cells, donated from a woman at the end of pregnancy, were 
given lipopolysaccharide (LPS), which is a bacterial component that causes 
inflammation. These cells were treated with simvastatin and pravastatin. Simvastatin 
reduced the expression of genes that are linked to promoting inflammation. 
Simvastatin also increased the expression of genes that are associated with reducing 
inflammation. Conversely, pravastatin treatment did not increase or decrease genes 
associated with inflammation.  
To study the contraction of the myometrial cells, the cells were mixed with collagen 
to form a solid gel. As the cells contracted, this caused the gel to shrink in size. When 
the cells were treated with simvastatin, the gel did not reduce in size suggesting that 
simvastatin stopped the contraction.  
The effects of simvastatin and pravastatin were also investigated in a mouse model 
where preterm birth was induced by causing inflammation in the uterus with LPS. 
Simvastatin prevented preterm delivery in some mice, as well as increasing the number 
of pups that were born alive. Simvastatin treatment also reduced inflammation in the 
uterus of the mouse. Pravastatin treatment did not prevent the mice delivering early, 




In summary, simvastatin treatment may be a novel therapy for preterm labour as it 
reduced inflammation and prevented the contraction of human myometrial cells. In 
addition, simvastatin treatment prevented preterm birth in some mice, increased pup 
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BMI Body mass index  
BPD Bronchopulmonary dysplasia  
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CH3OH Methanol  
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LC-MS/MS Liquid chromatography-tandem mass spectrometry  
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LPS Lipopolysaccharide  
MAPK Mitogen-activated protein kinase  
MHC II Major histocompatibility complex class II  
MIP Macrophage inflammatory protein  
MLC Myosin light chain  
MLCK Myosin light chain kinase  
MLCP Myosin light chain phosphatase  
MMP Matrix metalloproteinase 
mRNA Messenger RNA 
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NAC N-acetyl cysteine  
NaCl Sodium chloride  
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NF-κB Factor nuclear factor kappa B  
NK cells Natural killer cells  
NO Nitric oxide  
NSAIDs Non-steroidal anti-inflammatory drugs 
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NVS Named veterinary surgeon  
OATP1B1 Organic anion transporter protein-1B1  
P/S Penicillin/streptomycin  
PBS Phosphate buffered saline 
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PECAM Platelet endothelial cell adhesion molecule  
PG Prostaglandin  
PGF Placental growth factor  
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PI3K Phosphatidylinositol-3 kinase  
PIP2 Phosphatidylinositol 4, 5-bisphosphate  
PLC Phospholipase C  
pMLC Phosphorylated myosin light chain  
pPROM Preterm premature rupture of membranes  
PR Progesterone receptors  
PTB Preterm birth  
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RNA Ribonucleic acid 
ROCK Rho-associated kinase 
ROS Reactive oxygen species  
RT Reverse transcription 
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sENG Soluble endoglin  
sFlt-1 Soluble fms-like tyrosine kinase  
SP-A Surfactant protein-A  
SR Sarcoplasmic reticulum  
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SSZ Sulfasalazine  
StAmP Statins to Ameliorate early onset Preeclampsia  
STAT Signal transducer and activator of transcription 
TBST Tris buffered saline TWEEN® 20  
T-cells T-lymphocytes  
TDI Tissue Doppler Imaging  
Th cells T helper cells  
TIMPs Tissue inhibitors of metalloproteinases 
TLR Toll-like receptor 
TMB Tetramethylbenzidine  
TNF Tumour necrosis factor  
Tregs Regulatory T-cells  
Tyk Tyrosine kinase  
VCAM-1 Vascular cell adhesion molecule 1  
VEGF Vascular endothelial growth factor  
VLDL       Very low-density lipoprotein 
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Chapter 1: Literature review 
1.1 The role of inflammation in labour 
Inflammation is a highly coordinated process, which is characterised by the infiltration 
of leukocytes and plasma proteins into affected tissues. The major cells of the immune 
system, such as monocytes, macrophages, neutrophils, basophils, dendritic cells, mast 
cells, T-lymphocytes (T-cells) and B-lymphocytes (B-cells), are involved in the 
complex regulation of inflammation (Turner et al. 2014). In the instance of microbial 
infection, inflammation is triggered by receptors, such as Toll-like receptors (TLR). 
This results in the production of a range of inflammatory mediators, for example 
chemokines and cytokines (Medzhitov 2008). 
Human labour is an inflammatory process, associated with the influx of immune cells 
into the utero-placental compartment and the increase of mediator production locally 
(Bollapragada et al. 2009). Labour is initiated by the shift from a quiescent to a pro-
inflammatory environment. This instigates a three-step process, characterised by 
myometrial contractility, cervical ripening and fetal membrane rupture (Romero et al. 
1994; Rinaldi et al. 2011). Cytokines are essential for the initiation and regulation of 
this process (Bowen et al. 2002). 
1.1.1 Inflammation of maternal tissues 
1.1.1.1 Myometrium 
The association between myometrial inflammation and labour was recognised in the 
1980s and there is a significant body of work reporting that spontaneous term labour 
is associated with the large influx of inflammatory cells into the myometrium 
(Junqueira et al. 1980; Azziz et al. 1988). For example, macrophages and neutrophils 
are abundant in the human myometrium during labour, compared to women not in 
labour. These cells are present predominantly in the glandular epithelium of the lower 
uterine segment (Thomson et al. 1999; Kemp et al. 2002a). Infiltrating leukocytes are 
the source of interleukins (IL), such as IL-6 and IL-8, as well as tumour necrosis factor 
(TNF) and the leukocyte enzymes, matrix metalloproteinases (MMP)-8 and MMP-9, 
in the human labouring myometrium (Osmers et al. 1995; Elliott et al. 2000; Young et 
al. 2002). 
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A transcriptional profile of human myometrial samples, comparing women 
experiencing spontaneous labour at term and women not in labour, was determined by 
gene microarray analysis. A wide range of genes linked to inflammatory signalling 
were upregulated with labour, many of which were chemokines. For example, 
chemokines with the C-X-C motif, such as CXCL3, CXCL5, CXCL8/IL-8, and CCL2 
and CCL20 with the C-C motif, were upregulated. CXCL8/IL-8, which plays an 
important role in neutrophil chemotaxis, was the most highly expressed gene 
(Bollapragada et al. 2009).  
During labour, the endothelial cell adhesion molecules, E-selectin and vascular cell 
adhesion molecule 1 (VCAM-1), are upregulated in the blood vessels of the human 
lower uterine segment. These molecules mediate leukocyte adhesion to cytokine-
activated vessel endothelium during inflammation. This suggests that the increase of 
these molecules may be an important step in stimulating the infiltration of leukocytes 
into the lower uterine segment during labour (Winkler et al. 1998). Intercellular 
adhesion molecule 1 (ICAM-1) mRNA expression is upregulated in the myometrium 
during labour. This expression has been localised to the vascular endothelium and in 
leukocytes. Platelet endothelial cell adhesion molecule (PECAM) mRNA expression 
is also significantly upregulated in myometrium during pregnancy, compared to non-
pregnant samples, but this expression does not change at labour onset. PECAM has 
been localised to the vascular endothelium and has been identified on leukocytes. 
Therefore, these molecules may facilitate the infiltration of leukocytes into the 
myometrium prior to the onset of labour (Ledingham et al. 2001). 
During pregnancy in the mouse, leukocytes also infiltrate the myometrium prior to the 
onset of labour. This is accompanied by the mRNA upregulation of inflammatory 
mediators, such as Tnf, Il-1β, Il-6, Cxcl1 and Cxcl2, during labour (Shynlova et al. 
2013).  
1.1.1.2 Peripheral circulation 
Monocytes and neutrophils are primed in the peripheral blood in both term and preterm 
labour (PTL) (Yuan et al. 2009). Specifically, there is an increase in 
nonclassical/intermediate monocytes in the peripheral blood of pregnant women 
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compared to non-pregnant women (Melgert et al. 2012). These cells are thought to 
replenish tissue-resident macrophages and produce pro-inflammatory mediators, such 
as IL-1β, IL-8, chemokine ligand (CCL)-2 and CCL5 (Gordon and Taylor 2005; 
Ancuta et al. 2009; Hamilton et al. 2013). Total leukocyte counts were found to be 
significantly higher in women who had a spontaneous preterm birth (PTB), compared 
to those who did not (Heng et al. 2014). 
In a study performed on pregnant rats, the chemotactic responsiveness of peripheral 
leukocytes increased later in gestation, prior to the onset of labour. These leukocytes 
had increased Ccl2 mRNA expression (also referred to as monocyte chemotactic 
protein 1; Mcp-1). The chemotactic activity of the uterus increased at term, with an 
upregulation of Ccl2 mRNA expression. This suggests that peripheral leukocyte 
responsiveness increases prior to term to facilitate their infiltration into the uterine 
tissues in order to stimulate the labour process (Gomez-Lopez et al. 2013b). 
Interestingly, when neutrophils are depleted before term in the mouse, the timing and 
success of labour are unaffected (Timmons and Mahendroo 2006). Specifically, 
female mice with a null mutation in transcription factor CCAAT/enhancer binding 
protein ɛ (C/EBPɛ), which is expressed in lymphoid cells and granulocytes such as 
neutrophils, eosinophils and basophils, cannot generate functional neutrophils but they 
can reproduce normally (Yamanaka et al. 1997). Furthermore, gestational length is not 
affected by blocking chemokine receptor 2 (CCR2) in mice, suggesting CCR-
dependent leukocyte recruitment is not essential for successful labour (Menzies et al. 
2012). Therefore, neutrophil infiltration does not appear to be essential for the 
induction of labour in mice. 
Alternatively, studies have looked at the importance of immune cells in the context of 
PTB in mouse models. Shynlova et al. (2014) targeted the activation of mouse 
peripheral maternal immune cells with a broad spectrum chemokine inhibitor. A 
reduced incidence of lipopolysaccharide (LPS)-induced PTB was reported in addition 
to reducing both immune cell infiltration into maternal tissues and inflammatory 
mediator secretion. Rinaldi et al. (2014) found that neutrophil depletion did not delay 
delivery in an LPS-mediated PTB mouse model despite having an important role in 
the inflammatory response in the intrauterine tissues. Filipovich et al. (2015) further 
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corroborated this finding by reporting that the depletion of all granulocytes in an 
Escherichia coli (E. coli) model of PTB did not prevent early birth. Therefore, 
neutrophil infiltration is not essential for the induction of infection-induced PTB in the 
mouse. However, macrophage depletion was found to successfully prevent PTB in a 
mouse model induced by LPS (Gonzalez et al. 2011). This suggests that macrophages 
play a crucial role in PTB in the mouse. This may also relate to term labour.  
1.1.1.3 Amniotic fluid 
IL-1β, IL-6, IL-8, granulocyte-colony stimulating factor (G-CSF) and interferon 
gamma (IFN-γ) concentrations are all increased in the amniotic fluid during labour 
(Romero et al. 1990; Romero et al. 1991; Olah et al. 1996; Kemp et al. 2002b). The 
bioavailability of chemokine macrophage inflammatory protein 3α (MIP-3α)/CCL20, 
which is involved in the chemotaxis of immune dendritic cells, effector/memory T-
cells and B-cells, is also increased in the amniotic fluid with spontaneous term and 
PTL (Hamill et al. 2008). The abundance of these mediators is further elevated by 
intrauterine infection. The presence of IL-1β in amniotic fluid, in particular, has been 
associated with PTB (Saito et al. 1993). Elevated IL-6 levels in the amniotic fluid can 
be indicative of chorioamnion microbial colonisation, even if an amniotic fluid culture 
is negative (Andrews et al. 1995). 
1.1.1.4 Amnion/chorion  
Cytokine abundance is increased in the fetal membranes during both term and PTL 
(Keelan et al. 1999). There is a significant increase in leukocyte recruitment to human 
fetal membranes during parturition, with an increase in IL-1β, IL-6, IL-8, MIP-1α and 
TNF release (Elliott et al. 2001b; Young et al. 2002; Gomez-Lopez et al. 2009). IL-8 
has been specifically localised to leukocytes in the chorion but was not detected in the 
amnion of the membranes (Young et al. 2002). Furthermore, in vitro studies with fetal 
membrane explants from labouring women suggested that chemotaxis is selective for 
specific leukocyte subpopulations, such as monocytes, T-cells, B-cells and natural 
killer (NK) cells (Gomez-Lopez et al. 2009). Normal and premature rupture of 
membranes differ in regional chemotactic activity and related chemokine/cytokine 
production, which may suggest differential mechanisms of rupture. For example, the 
rupture of membranes during term labour is associated with an increase in T-cell 
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attraction, exhibiting elevated levels of IL-8. Conversely, during the premature rupture 
of membranes there is an increase in CXCL10 and granulocyte-macrophage colony-
stimulating factor (GM-CSF), which is linked to granulocyte attraction (Gomez-Lopez 
et al. 2013a). 
1.1.1.5 Choriodecidua  
An important role for decidual activation in the initiation of labour was first suggested 
in the 1980s (Casey and MacDonald 1988). The choriodecidua is reported to be 
responsible for granulocyte, T-cell, monocyte and NK cell chemoattraction (Gomez-
Lopez et al. 2011). Leukocytes infiltrate the decidua during term labour and PTL and 
play a role in stimulating inflammatory mediators involved in decidual activation 
(Osman et al. 2003; Hamilton et al. 2012). Macrophage numbers are increased in term 
and PTL but neutrophil abundance is only significantly increased in the decidua in 
PTL with infection (Hamilton et al. 2012). Elevated IL-6 and IL-8 concentrations have 
been identified in the chorionic-decidual tissues with labour (Keelan et al. 1999). 
In a study of human choriodecidual samples there was an increase in the production of 
chemokines, such as IL-8, CCL2, CCL4, CCL5 and CXCL10, with term labour. The 
expression of chemokines was most commonly observed in the decidual stromal cells. 
IL-8, CCL2, CCL5, and CXCL10 were identified in the immune cells within the 
decidual stroma. In PTL, CCL4, CCL5, CXCL1 and CXCL6 mRNA concentrations 
were upregulated. The upregulation of these mediators suggests that chemokines may 
regulate decidual leukocyte recruitment during labour (Hamilton et al. 2013).  
1.1.1.6 Placenta 
There is limited evidence of placental inflammation. Cytokine concentrations were not 
altered in placental tissues collected from women following term labour (Keelan et al. 
1999). However, an in vitro study investigating the effect of bacterial products on 
placental explants found an elevation of IL-1β, IL-6, IL-8 and IL-10 release 
(Griesinger et al. 2001). 
In summary, labour is associated with an influx of leukocytes into the maternal-fetal 
tissues, such as the myometrium, amnion/chorion and the choriodecidua. There is also 
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an increase in inflammatory cytokines and chemokines in these tissues, as well as in 
the peripheral circulation and the amniotic fluid. 
1.1.2 Inflammatory mediators 
Extracellular molecular regulators, for example cytokines and chemokines, are 
responsible for immune cell recruitment as well as controlling the intracellular 
signalling that characterises inflammation (Turner et al. 2014). 
1.1.2.1 Cytokines 
Cytokines work through a network of interactions to modulate both acute and chronic 
inflammation. Cytokines can be classified by whether they act on cells of the innate or 
adaptive immune response, or promote or antagonise inflammation. Furthermore, they 
can be classified depending on their signalling receptors. Pro-inflammatory cytokines 
include IL-1β, IL-6, TNF and the interferon (IFN) subsets of cytokines, whereas IL-
10, IL-19 and IL-20 are considered anti-inflammatory cytokines (Turner et al. 2014). 
Examples of cytokines associated with adaptive immunity include IL-2, IL-3, IL-4, 
IL-5, IL-13, IL-15 and GM-CSF. The inflammatory mediators most commonly 
associated with labour include IL-1, IL-6, IL-8 and TNF (Farina and Winkelman 
2005). 
Key pro-inflammatory cytokines, such as IL-1 and TNF, signal through type 1 
cytokine receptors, which are structurally divergent from other cytokine receptors 
(Turner et al. 2014). IL-1β and TNF are early responders to infection, followed by IL-
6 and later, IL-10 to reduce inflammation (Arango Duque and Descoteaux 2014; 
Friedrich et al. 2015). IL-1β is mainly produced by macrophages, B-cells and dendritic 
cells and targets B-cells, NK cells and T-cells. This pro-inflammatory cytokine 
promotes the proliferation and differentiation of cells (Turner et al. 2014). TNF is 
produced by and acts on macrophages to activate phagocytosis (Turner et al. 2014).  
IL-6 production is stimulated by TNF and IL-1β release (Friedrich et al. 2015). IL-6 is 
produced by many cells, including T helper cells (Th) cells, macrophages, endothelial 
cells and fibroblasts. This inflammatory cytokine targets activated B-cells and plasma 
cells, causing immunoglobulin G (IgG) production and the differentiation of B-cells 
into antibody-producing plasma cells. Classical IL-6 receptor signalling takes place 
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via the IL-6 receptor (IL-6R) α chain (gp80, CD126) and the signal transducing 
component, gp130 (CD130). Gp130 is ubiquitously expressed but the IL-6R is 
restricted to lymphocytes and hepatocytes (Peters et al. 1998; Turner et al. 2014). The 
IL-6R can also be released from the cell surface in a soluble form to bind IL-6 and this 
complex then signals through gp130. This trans-signalling allows IL-6 to target cells 
that do not have the IL-6R. Gp130 activates Jak kinase (Jak)-1, Jak2 and tyrosine 
kinase (Tyk)-2 to activate the signal transducer and activator of transcription (STAT) 
and p38 mitogen-activated protein kinase (MAPK) signalling cascades (Hunter and 
Jones 2015). IL-6 is generally considered to be a pro-inflammatory cytokine, although 
it can also have anti-inflammatory effects (Tilg et al. 1997). The pro-inflammatory 
activities of IL-6 are mediated by the more common trans-signalling, while the anti-
inflammatory effects of IL-6 are mediated by classical signalling (Scheller et al. 2011). 
The anti-inflammatory cytokine IL-10 can inhibit the activation and function of T-
cells, B-cells, monocytes and macrophages. IL-10 can also mediate the differentiation 
and function of regulatory T-cells (Tregs), which are key to controlling immune 
responses (Moore et al. 2001). IL-10 inhibits cytokine production and mononuclear 
cell function to exert anti-inflammatory effects (Turner et al. 2014). IL-10 signals 
through a type II cytokine receptor, which is a heterotetrameric receptor complex 
composed of two α and two β subunits. The binding of IL-10 to this receptor activates 
the JAK/STAT signalling pathway (Shouval et al. 2014). 
1.1.2.2 Chemokines   
Chemokines are small proteins (8-12kDa), which are sub-divided by the position of 
N-terminal cysteine residues. The most well-known are the C-X-C family, where the 
cysteine residues are separated by an amino acid, and the C-C family, with adjacent 
cysteine residues (Turner et al. 2014). The primary function of chemokines is to recruit 
leukocytes to the site of infection or injury but these mediators can also play a role in 
homeostatic functions (Turner et al. 2014). Signal transduction of chemokines is via 
members of the seven-transmembrane, G-protein-coupled receptor (GPCR) family 
(Moser et al. 2004). Chemokines act by inducing the expression of integrins, such as 
β2-integrin lymphocyte function-associated antigen 1 (LFA-1), which stimulate the 
diapedesis of leukocytes through the vascular endothelium (Constantin et al. 2000). 
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The migration and tissue specificity of leukocytes is due to the expression of particular 
chemokines, receptors and adhesion molecules.  
CXCL8/IL-8, in particular, has been extensively studied. The primary role of IL-8 in 
inflammation is the recruitment of neutrophils and it is the most highly expressed 
chemokine in the myometrium during labour (Bollapragada et al. 2009; Turner et al. 
2014). Excessive signalling of cytokines and chemokines can result in chronic 
conditions and autoimmune diseases, such as rheumatoid arthritis, type I diabetes, 
psoriasis and asthma (Pope et al. 2005; Park and Pillinger 2007; Rosa et al. 2008; 
Portugal-Cohen et al. 2012).  
1.1.2.3 Prostaglandins 
Prostaglandins, such as PGE2 and PGF2α, are another class of inflammatory mediators 
that play an important role in the initiation of labour and the stimulation of uterine 
contractions (Crankshaw and Dyal 1994; Gibb 1998). Prostaglandins are synthesised 
by the release of arachidonic acid by phospholipase A2, which is then converted to 
PGH2 by cyclooxygenase 1 and 2 (COX-1, -2). COX-2 expression is upregulated in 
the human myometrium and fetal membranes prior to the onset of labour, suggesting 
a role for this enzyme in the initiation of parturition (Slater et al. 1999a; Slater et al. 
1999b). Specific prostaglandins are then produced from the conversion of PGH2 
(Simmons et al. 2004; Sykes et al. 2014).  
Prostaglandin synthesis can be stimulated in the myometrium by inflammatory 
cytokines. However, prostaglandins themselves also have pro-inflammatory actions 
(Hertelendy et al. 1993; Molnar et al. 1993; Pollard and Mitchell 1996). PGF2α, which 
is produced by the decidua, can activate the decidua as well as directly stimulating 
myometrial contractions and upregulating decidual MMP-2 and MMP-9 expression. 
This action of PGF2α may then enhance leukocyte migration into the decidua and 
stimulate the release of IL-1β (Schonbeck et al. 1998; Ulug et al. 2001). PGE2 plays a 
role in cervical remodelling by reducing collagen concentration, as well as increasing 
the synthesis of proteoglycans in the cervix (Ekman et al. 1986; Norman et al. 1993). 
PGE2 also stimulates IL-8 release from the cervix (Denison et al. 1999). Furthermore, 
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PGE2 has been linked to the rupture of fetal membranes by stimulating an increase in 
MMP-9 (McLaren et al. 2000). 
1.1.2.4 MMPs 
MMPs are a family of zinc-dependent proteinases (Nagase and Woessner 1999). They 
are secreted into the extracellular matrix as proenzymes and their activity is tightly 
regulated by a range of mechanisms, such as proteolytic activation, the action of 
inducers and direct inhibition by tissue inhibitors of metalloproteinases (TIMPs) (Van 
Wart and Birkedal-Hansen 1990; Qin et al. 1997; Riley et al. 1999; Ulug et al. 2001). 
MMPs play an important role in the remodelling of the myometrial extracellular matrix 
to allow for uterine contraction (Roh et al. 2000). For example, MMP-9 is upregulated 
by IL-1β and TNF in the remodelling of the human myometrium during labour (Roh 
et al. 2000). MMP-2 and MMP-9 activity increase dramatically during labour and their 
activity is even higher in cases of PTL (Xu et al. 2002; Yonemoto et al. 2006). MMPs 
also facilitate both normal and pathological fetal membrane rupture (Tsatas et al. 
1999).  
To summarise, inflammatory mediators, such as cytokines, chemokines, 
prostaglandins and MMPs, are responsible for the shift from an anti-inflammatory to 
pro-inflammatory environment. Therefore, these mediators are implicated in the 
initiation of labour and stimulation of myometrial contractions. 
1.1.3 Transcription factors in labour 
1.1.3.1 NF-B 
A key regulator of the inflammatory pathways associated with labour is the 
transcription factor nuclear factor kappa-B (NF-κB). A multitude of inflammatory 
mediators, such as IL-1β, IL-6, IL-8 and TNF, contain NF-κB recognition elements in 
their promotor regions (Lindstrom and Bennett 2005). NF-κB dimers are anchored in 
the cytoplasm by the IκB inhibitory proteins. The NF-κB canonical pathway is 
triggered by microbial products as well as pro-inflammatory cytokines, such as IL-1 
and TNF. This causes rapid phosphorylation of IκBα and IκBβ, followed by 
polyubiquitination and degradation through the 26S proteasome. The NF-κB dimer is 
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then free to translocate to the nucleus, where it activates gene transcription (Zandi et 
al. 1997).  
NF-κB activity has been identified in both the upper and lower myometrium, as well 
as the amnion, prior to the onset of term labour (Khanjani et al. 2011; Lim et al. 2012). 
NF-κB activity is associated with an increase of COX-2 and MMP-9 production in 
term human myocytes (Choi et al. 2007). In addition, NF-κB is crucial for increased 
expression of the IL-8 gene in cells of the human amnion and cervical epithelium 
(Elliott et al. 2001a). 
1.1.3.2 AP-1 
The activator protein 1 (AP-1) family of transcription factors also play a role in the 
regulation of inflammation. AP-1 is made up of dimeric basic leucine zipper (bZIP) 
proteins consisting of Fos (cFos, FosB, Fra-1, Fra2) and Jun (cJun, JunB, JunD) 
activating transcription factor subunits (Karin et al. 1997; Shaulian and Karin 2002). 
In a study of the rat myometrium, c-fos, fosB, fra-1, fra-2 and junB were upregulated 
during labour. AP-1 transcription factor mRNA levels were also upregulated when 
labour was induced with progesterone receptor antagonist, RU486 (Mitchell and Lye 
2002). AP-1 activation occurs at labour onset in the mouse and drives the production 
of pro-inflammatory mediators in an LPS-induced mouse model of PTB (MacIntyre et 
al. 2014). 
The role of AP-1 in human parturition has recently emerged. TNF stimulated an 
increase in AP-1 activity in human myometrial cells. In addition, cFos and JunB 
mRNA and protein expression were increased in the human myometrium at term (Lim 
and Lappas 2014). Mechanical stretch of human myometrial cells and amnion 
epithelial cells has also been associated with AP-1 activation (Shynlova et al. 2002; 
Mohan et al. 2007). 
1.1.4 Steroid hormones  
1.1.4.1 Progesterone 
Progesterone, a steroid hormone acting through nuclear progesterone receptors (PR), 
is crucial for myometrial quiescence during pregnancy. Administration of the PR 
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antagonist RU486 causes pregnancy loss in both humans and mice. In humans, 
progesterone is initially produced by the corpus luteum and then by the placenta. In a 
number of species, such as the mouse, the withdrawal of progesterone initiates the 
labour process. However, a systemic drop in progesterone levels is not observed in 
humans. Although, it has been proposed that there is a functional progesterone 
withdrawal, which may be mediated by a shift in the ratio of PR subtypes (Allport et 
al. 2001; Condon et al. 2003; Merlino et al. 2007). 
Progesterone responsiveness is mediated by the relative expression of PR-A and PR-
B receptor subtypes in the human myometrium at term and functional progesterone 
withdrawal may result from an increase in the ratio of PR-A to PR-B (Mesiano et al. 
2002; Merlino et al. 2007). Another study reported a reduction in PR coactivator 
expression in the mouse and human uterus prior to term, which may impair PR 
function causing a functional progesterone withdrawal (Condon et al. 2003). 
The PR itself has an anti-inflammatory role by inhibiting NF-κB activation and 
subsequent COX-2 gene expression, which leads to the inhibition of myometrial 
contractility (Hardy et al. 2006). A mutual repressive action has been identified 
between NF-κB and the PR (Kalkhoven et al. 1996).  
Progesterone also promotes uterine quiescence by affecting the electrical activity of 
myometrial cells by increasing the expression of calcium (Ca2+) and potassium (K+) 
voltage-gated channels. This dampens the electrical activity of the myometrial cells, 
downregulating contraction-associated proteins, such as connexin 43 (CX43), and the 
proteins involved in actin and myosin interactions (Zhao et al. 1996; Soloff et al. 
2011). 
1.1.4.2 Oestrogen  
Pregnancy has been described as a hyperestrogenic condition. The concentration of 
oestrogen increases with gestation and the placenta is the main source of this steroid 
hormone (Kota et al. 2013). The increased expression of oestrogen receptor alpha 
(ERα) in the term myometrium may induce functional oestrogen activation and may 
also be linked to functional progesterone withdrawal (Mesiano et al. 2002). Oestrogens 
induce a number of changes to the myometrium during pregnancy, such as increasing 
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PGE2 and PGF2α synthesis, increasing oxytocin activity, increasing the synthesis of 
CX43 and upregulating calmodulin, which is involved in the contraction of smooth 
muscle (Pinto et al. 1964; Ham et al. 1975; Petrocelli and Lye 1993). 
1.1.5 Myometrial contractions 
Uterine contractility is a complex and dynamic process that occurs in both non-
pregnant and pregnant states. Contractions are a function of the myometrial layer of 
the uterus, which is composed of smooth muscle cells. The non-pregnant myometrium 
contracts to enhance the sloughing of the endometrium during menses and to assist the 
passage of sperm. Throughout pregnancy the uterus remains quiescent until labour, 
when the uterus contracts vigorously to expel the fetus. As the balance between 
oestrogen and progesterone shifts, morphological changes to the myometrium initiate 
active contractions. Contractions vary in frequency, amplitude and tone and are 
predominantly regulated by intracellular Ca2+ concentration ([Ca2+]i) (Pehlivanoglu et 
al. 2013). 
1.1.5.1 The role of inflammation 
As previously discussed, labour is associated with the increase of pro-inflammatory 
mediators, such as IL-1β, IL-6, IL-8 and TNF, and an influx of leukocytes into the 
myometrium (Young et al. 2002). These mediators play an important role in the 
stimulation of myometrial contractions.  
When mouse uterine strips were stimulated with LPS, the amplitude, but not the 
frequency, of contraction increased (Mackler et al. 2003). Human myometrial cell 
contraction was also enhanced in vitro by LPS. This effect was mediated by the Ras 
homology (Rho)/Rho-associated kinase (ROCK) pathway (Hutchinson et al. 2014). In 
a co-culture of human monocytes and myometrial cells, there was evidence of 
synergistic pro-inflammatory cytokine secretion, while myometrial cell contraction 
was enhanced (Rajagopal et al. 2015). IL-1β stimulation of human myometrial cells 
increased Ca2+ entry into cells in vitro, increasing their excitability. This suggests that 
inflammatory mediators can affect Ca2+ flux in myometrial cells, which may impact 
on myometrial contractility (Tribe et al. 2003).  
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The anti-inflammatory actions of both dexamethasone and IL-10 inhibited IL-1β-
induced uterine contractions in pregnant rhesus monkeys. Specifically, oestradiol 
concentration was reduced by dexamethasone treatment and IL-10 reduced the release 
of the pro-inflammatory cytokine TNF and inhibited leukocyte migration (Sadowsky 
et al. 2003).  
Therefore, myometrial contractions can be stimulated by inflammatory mediators as 
well as inhibited by anti-inflammatory agents. This suggests that inflammation is key 
to the initiation of myometrial contractions.  
1.1.5.2 Oxytocin 
Oxytocin, a peptide hormone, is critical to the regulation of the myometrium during 
pregnancy. The expression and production of the oxytocin receptor increases as 
pregnancy progresses and peaks during labour (Fuchs et al. 1991; Kimura et al. 1996). 
Oxytocin increases myometrial contractility by stimulating an increase in [Ca2+]i 
(Sanborn et al. 1998). Stimulation of human decidua explants with IL-1β has been 
shown to indirectly increase the secretion of oxytocin via COX-2 and prostaglandin 
production (Friebe-Hoffmann et al. 2007). Furthermore, oxytocin can activate NF-κB 
in human myometrial cells, via the oxytocin receptor, and upregulate IL-8, CCL6, IL-
6 and COX-2 gene expression (Kim et al. 2015). The production of these inflammatory 
mediators will then contribute to the stimulation of contractions.  
1.1.5.3 CX43 
The formation of gap junctions allows for intercellular communication. These 
junctions are composed of connexin (CX) proteins (Sohl and Willecke 2004). CX43 
(43kDa) is a contraction-associated protein localised to smooth muscle cells and plays 
a key role in the establishment of synchronous contractions (Oyamada et al. 1994; 
Hutchings et al. 2009). Parturition is delayed when Cx43 is ablated in mouse 
myometrial smooth muscle cells, emphasising the importance of intercellular 
communication for uterine contractility (Doring et al. 2006). CX43 mRNA expression 
increases with gestation in both the human and animal myometrium and increases 
further during labour (Chow and Lye 1994; Orsino et al. 1996). CX43 abundance is 
also increased in the human and mouse myometrium during PTL (Balducci et al. 1993; 
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Chang et al. 2012). Therefore, CX43 is considered important for synchronous 
contractions in both term and PTL. 
1.1.6 Excitation contraction coupling  
The excitation-contraction coupling of smooth muscle cells can be stimulated by two 
main mechanisms: by the activation of Ca2+ signalling cascades or by the Rho/ROCK 
pathway, where Ca2+ sensitivity of the cell is altered (Berridge 2008). 
1.1.6.1 Ca2+ signalling cascades 
Myometrial cell contraction is facilitated by the cross-bridging of the myofilaments 
actin and myosin. This is instigated by the increase of [Ca2+]i and completed by the 
phosphorylation of myosin light chain (pMLC) (Figure 1.1). [Ca2+]i can increase by 
the influx of Ca2+ from the extracellular fluid via voltage-gated L-type Ca2+ channels 
and/or Ca2+ can be released from the sarcoplasmic reticulum (SR), which contains the 
intracellular stores of Ca2+ (Pehlivanoglu et al. 2013). 
The main source of Ca2+ in the myometrium is by extracellular entry through voltage-
gated L-type Ca2+ channels (Shojo and Kaneko 2001; Kupittayanant et al. 2002). Ca2+ 
can also be released from the SR by the binding of a uterine agonist to a specific GPCR 
anchored to the plasma membrane (Phaneuf et al. 1993). This stimulates membrane 
phospholipase C (PLC), which cleaves phosphatidylinositol 4,5-bisphosphate (PIP2) 
to diacylglycerol (DAG) and inositol trisphosphate (IP3). This causes the release of 
Ca2+ from the SR into the cytoplasm (Taylor et al. 1991; Luckas et al. 1999). The 
increase in [Ca2+]i generates an action potential, of which two have been detailed in 
the myometrium. Simple action potentials are characterised by depolarisation followed 
by rapid repolarisation. More complicated action potentials involve depolarisation 
with a sustained plateau (Khan et al. 2001; Bursztyn et al. 2007). Alternatively, a feed-
forward loop has also been identified in the myometrium whereby increasing [Ca2+]i 
sensitises other Ca2+ channels to open  (Shojo and Kaneko 2001; Kupittayanant et al. 
2002; Wray et al. 2003). 
When there is a substantial increase in [Ca2+]i this activates calmodulin, a protein 
located in the cytosol. Calmodulin forms a complex with four Ca2+ ions, which leads 
to the activation of the enzyme myosin light chain kinase (MLCK) (Johnson et al. 
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1996). MLCK then phosphorylates 20kDa MLCs, leading to actin and myosin cross-









Figure 1.1. The molecular pathways in smooth muscle contraction. Actin and myosin cross-bridge 
formation is essential for smooth muscle contraction. This relies on the phosphorylation of myosin light 
chains (MLC) by myosin light-chain kinase (MLCK). G protein-coupled receptors (GPCR) activate the 
contractile pathways. Ca2+ enters the cytosol from either the extracellular space, through voltage-gated 
Ca2+ channels, or by IP3-dependent release from the sarcoplasmic reticulum (SR). A Ca2+/calmodulin 
(CaM) complex forms and activates MLCK. Relaxation is favoured by myosin light-chain phosphatase 
(MLCP) as the active subunit removes the phosphoryl group from the MLC. When MLCP is inhibited, 
this allows contraction. MLCP can be repressed via direct inhibition by PKC-dependent CPI-17 or 
inhibitory phosphorylation of the myosin phosphatase target subunit (MYPT) by Rho kinase (ROCK). 
PLC, phospholipase C; PIP2, phosphatidylinositol 4,5-bisphosphate; DAG, diacylglycerol; IP3, inositol 
trisphosphate. Reprinted from Reddi et al. (2015) under a Creative Commons license.  
1.1.6.2 Calcium sensitisation and the Rho/ROCK pathway 
Rho proteins are members of the small GTPase family, which includes the three 
isoforms RhoA, RhoB and RhoC. RhoA is the most studied of the isoforms as it has 
an important function in smooth muscle contraction (Figure 1.1) (Wheeler and Ridley 
2004). The inactive form of RhoA is bound to guanosine diphosphate (GDP) and found 
in the cell cytosol. Active RhoA is bound to guanosine trisphosphate (GTP) and is 
located in the cell membrane. GTPase-activating proteins (GAPs) facilitate the binding 
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of GDP to RhoA, whereas guanine nucleotide exchange factors (GEFs) regulate 
RhoA-GTP binding (Van Aelst and D'Souza-Schorey 1997; Moon and Zheng 2003). 
Guanine nucleotide dissociation inhibitors (GDIs) form a complex with RhoA 
facilitating its diffusion between the cytosol and the cell membrane (Michaelson et al. 
2001).  
ROCK is a serine/threonine-specific kinase that is found in the cell cytoplasm. It has 
two isoforms, ROCK I and ROCK II, which are both expressed in smooth muscle cells 
and ROCK II has been the most implicated in contraction. ROCK is an effector of 
RhoA. When RhoA becomes activated, ROCK migrates to the cell membrane to form 
a complex with the active RhoA-GTP, causing autophosphorylation and ROCK 
activation (Leung et al. 1995; Matsui et al. 1996; Nakagawa et al. 1996).  
It is well established that RhoA/ROCK is a key molecule in GPCR-mediated Ca2+ 
sensitisation, leading to smooth muscle contraction (Kureishi et al. 1997; Uehata et al. 
1997; Puetz et al. 2009). Ca2+ sensitisation takes place when an agonist, such as 
oxytocin or PGF2α, induces an increase in [Ca
2+]i (McKillen et al. 1999; Woodcock et 
al. 2004; Woodcock et al. 2006; Shmygol et al. 2007). Following the stimulation of 
GPCRs by an agonist, the Rho/ROCK pathway is activated. ROCK phosphorylates 
myosin light chain phosphatase (MLCP), inhibiting this enzyme from having a 
relaxation effect on MLC (Kitazawa et al. 1989; Noda et al. 1995; Aguilar and Mitchell 
2010; Aguilar et al. 2012). ROCK inhibits MLCP by phosphorylating its myosin 
phosphatase target subunit 1 (MYPT1) or via the inhibitory protein CPI-17. 
Alternatively, ROCK can phosphorylate MLC directly, by MLCK-like activity, to 
induce contraction (de Godoy and Rattan 2011).  
1.1.7 Initiation of labour  
1.1.7.1 Uterine stretch 
As pregnancy progresses, the uterus must remodel and increase dramatically in size 
while maintaining quiescence. Intrauterine pressure increases but the uterus must adapt 
to counteract any wall tension. It has been hypothesised that labour is initiated when 
this adaptive mechanism is overcome. A study inducing mechanical stretch to rat 
myometrial cells caused an increase in CCL2 release. This effect was attenuated by 
                                                  The effect of statin treatment on preterm labour 
17 
Chapter 1: Literature review 
 
progesterone pre-treatment, suggesting antagonism between mechanical stretch and 
progesterone on cytokine release in the uterus (Shynlova et al. 2008).  
An in vitro study investigating the effect of human myometrial cell mechanical stretch 
found an elevation in the release of the inflammatory mediators IL-6, IL-8 and 
CXCL1. There was also an increase in leukocyte adhesion to the endothelium of 
vessels in the uterus. This suggests that mechanical stretch can lead to leukocyte 
recruitment to the myometrium (Lee et al. 2015). 
Uterine overdistension was modelled in non-human primates by the inflation of an 
intra-amniotic balloon. There was a significant increase in IL-1β, TNF, IL-8, CCL2, 
PGE2 and PGF2α in the amniotic fluid preceding labour. When this stress on the uterus 
is very great, it can cause PTL (Adams Waldorf et al. 2015). Therefore, uterine stretch 
may stimulate the initiation of the labour process by increasing immune cell infiltration 
into the uterus and increasing the production of pro-inflammatory mediators. 
1.1.7.2 Fetal signalling 
It has also been proposed that the fetus produces signals that initiate the labour process. 
Surfactant protein-A (SP-A) is secreted by the fetal lungs into the amniotic fluid. In 
mice, SP-A abundance increases in the amniotic fluid as term approaches and this is 
thought to signal parturition. However, in relation to humans, reports in the literature 
disagree on the concentration of SP-A in the amniotic fluid towards term and at the 
onset of labour (Chaiworapongsa et al. 2008; Reinl and England 2015).  
In SP-A deficient mice, labour is only delayed for approximately 12 hours 
(Montalbano et al. 2013). Gao et al. (2015) investigated the effect of steroid receptor 
coactivators 1 and 2 (SRC-1, -2), which are transcriptional regulators of SP-A. It was 
found that labour was substantially delayed in dams with SRC-1/2-deficient fetuses. 
These mothers exhibited reduced NF-κB activation, reduced PGF2α levels and a 
reduction in contraction-associated genes. Therefore, the fetal lung production of SP-
A, mediated by SRC-1/2, is essential for parturition to progress normally in mice. The 
results from this model highlight the importance of fetal signalling for the initiation of 
parturition in the mouse, which may be relatable to humans (Gao et al. 2015). 
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1.2 Preterm labour 
1.2.1 Epidemiology  
The World Health Organisation definition of PTB is delivery before 37 completed 
weeks of gestation. This can be further subdivided into extremely preterm (<28 
weeks), very preterm (28-32 weeks) and moderate to late PTB (32-36 weeks) (WHO 
1977). PTB is a serious public health problem, which accounts for 11.1% of births 
worldwide. This rate varies from approximately 5% of births in European countries to 
18% in some African countries (Blencowe et al. 2012). Furthermore, PTB is currently 
the leading cause of mortality in children under five years of age (Harrison and 
Goldenberg 2015). In England and Wales, the economic burden of neonatal intensive 
care followed by ongoing health and educational support is estimated to be >£2.9 
billion (Mangham et al. 2009; Howson et al. 2013). 
In high income countries, approximately one third of PTBs are medically indicated. 
This occurs when there is risk to the mother or fetus that outweighs the benefit of 
continuing the pregnancy. For example, in conditions such as preeclampsia and 
diabetes. The remainder of PTBs are spontaneous, where women can present with PTL 
with cervical dilation or preterm premature rupture of membranes (pPROM) (Rubens 
et al. 2014). 
Spontaneous PTL is very difficult to predict. Maternal risk factors include previous 
PTB, extremes in maternal age and body mass index (BMI), multiple gestation, use of 
assisted reproductive technologies and low socioeconomic status (Rubens et al. 2014). 
Race is also an important risk factor as women classified as black, African-American 
or Afro-Caribbean are at greater risk of PTB than other racial groups (Goldenberg et 
al. 2008).  
The aetiology of PTL is poorly understood. It can be initiated by multiple mechanisms, 
such as infection, decidual senescence, uterine overdistension, cervical disease, stress 
or the breakdown of maternal-fetal tolerance (Romero et al. 1994; Goldenberg et al. 
2008; Romero et al. 2014). 
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1.2.2 Infection and inflammation as a cause of PTB 
Intrauterine infection is believed to be present in 25-40% of PTBs. However, this is 
likely to be an underestimate as infections are often sub-clinical and cannot be detected 
by conventional culturing techniques (Goldenberg et al. 2008). Chorioamnionitis is the 
most common presentation of intrauterine inflammation and is characterised by 
inflammation of the chorion, amnion and placenta. This inflammatory condition is 
usually a result of bacterial infection (Goldenberg et al. 2008).  
Exposure to intrauterine infection and/or inflammation can cause fetal inflammatory 
response syndrome (FIRS), which is responsible for fetal organ injury, resulting in 
neonatal morbidity and mortality (Gotsch et al. 2007). Bacteria or inflammatory 
mediators may reach the fetal circulation by placental transmission into the umbilical 
cord or indirectly via the amniotic fluid, causing damage to multiple fetal organ 
systems (Figure 1.2) (Adams Waldorf and McAdams 2013). Chorioamnionitis is 
associated with an increased risk of respiratory distress syndrome, bronchopulmonary 
dysplasia (BPD), intraventricular haemorrhage, patent ductus arteriosus and 
necrotising enterocolitis in exposed neonates (Been et al. 2013; Galinsky et al. 2013; 
Seliga-Siwecka and Kornacka 2013). 
The most common route of infection is via microbial ascension from the vagina. The 
microbes proliferate in the amniotic fluid and invade the chorioamniotic membranes 
(Kim et al. 2009). However, it is also possible that there could be a haematogenous 
dissemination of infection or microorganisms could be introduced during an invasive 
procedure or originate in the fallopian tubes (Bastek et al. 2011). Various bacterial 
organisms, and in rare cases viral and fungal organisms, are associated with the 
pathogenesis of chorioamnionitis. Examples of bacteria found in the amniotic fluid are 
species of Ureaplasma, Mycoplasma, Fusobacterium, Streptococcus, Bacteroides and 
Prevotella. (DiGiulio et al. 2010; DiGiulio 2012). Genital mycoplasmas, Ureaplasma 
urealyticum and Mycoplasma hominis, are the most frequent microbes in cases of 
culture-confirmed chorioamnionitis (Waites et al. 2005). Chorioamnionitis is 
polymicrobial in most cases (DiGiulio 2012). 
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PTL may be triggered by a fetal and/or maternal response to chorioamnionitis. The 
invading bacteria release endotoxins and exotoxins, which are recognised by TLRs 
presented on the surface of cells such as leukocytes and epithelial cells (Holmlund et 
al. 2002). This leads to the activation of transcription factors, such as NF-κB and AP-
1, which in turn stimulate the production of the cytokines and chemokines IL-1β, IL-
6, IL-8 and TNF, leading to the production of prostaglandins and leukocyte chemotaxis 
to the uterine tissues (Goldenberg et al. 2000). Infection prevents prostaglandin 
dehydrogenase from inactivating prostaglandins, allowing the bioactive 
prostaglandins to prematurely initiate contractions (van Meir et al. 1997). These events 
initiate the labour process, whereby prostaglandins stimulate myometrial contractions 
and MMPs assist in cervical ripening and fetal membrane rupture. PTL has been 
associated with a shift from an anti-inflammatory to a pro-inflammatory state at the 
maternal-fetal interface. It has also been suggested that an imbalance between innate 
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Figure 1.2. Intrauterine inflammation and fetal injury. Human parturition is an inflammatory 
process stimulated by mediators such as cytokines, chemokines and prostaglandins. However, the 
presence of inflammation earlier in gestation can cause PTL and exposure of the fetus to an adverse 
environment. Inflammatory mediators may reach the fetal circulation by placental transmission into the 
umbilical cord or indirectly via the amniotic fluid. Amniotic fluid-exposed tissues, such as the fetal skin 
and lung, can drive the fetal inflammatory response. Prolonged exposure to inflammatory mediators can 
result in fetal injury. The fetus is susceptible to lung injury and bronchopulmonary dysplasia (BPD), as 
well as brain white matter lesions and neurological conditions, such as cerebral palsy. Reprinted from 
Boyle et al. (2017) under a Creative Commons license. 
 
1.2.3 Fetal injury  
Premature neonates are at risk of a number of health complications due to the 
immaturity of multiple organ systems (Rubens et al. 2014). The severity of these health 
problems inversely correlate with gestational age at birth (WHO 1977). Premature 
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babies have an increased risk of cognitive and neurological impairment, for example 
cerebral palsy, as well as an increased risk of respiratory and gastrointestinal 
complications (Marlow et al. 2005; Goldenberg et al. 2008). Prematurity also 
predisposes to chronic diseases in adulthood such as obesity, diabetes and hypertension 
(Rubens et al. 2014). Interestingly, there are also sex-specific differences as male sex 
is an independent risk factor for adverse pregnancy outcome, including PTB (Di Renzo 
et al. 2007; Ferrero et al. 2016). It has been suggested that this could be due to the 
larger size and birthweight of males. Furthermore, factors associated with male sex 
may predispose to infection-mediated PTB (MacGillivray and Davey 1985; McGregor 
et al. 1992). Premature males are at greater risk of morbidity and mortality, with poorer 
neurological and respiratory outcomes than females at two years (Peacock et al. 2012). 
As previously mentioned, fetal injury can result from the exposure of the fetus to 
inflammatory mediators. Brain white matter lesions have been associated with the 
presence of pro-inflammatory mediators in the amniotic fluid. Elevated levels of IL-
1β and IL-6 in the amniotic fluid have been used to identify premature neonates at risk 
of these lesions (Yoon et al. 1997a). TNF signalling has been described as toxic to 
developing oligodendrocytes in vitro (Li et al. 2008). In a mouse model of intrauterine 
inflammation, fetal brain injury was reported even in the absence of PTB, with altered 
fetal neuronal morphology and neurotoxicity identified following this in utero insult 
(Burd et al. 2011; Elovitz et al. 2011). Intrauterine inflammation also causes long term 
changes to the mouse brain, with morphological alterations identified by MRI and 
effects on behaviour observed into adulthood (Dada et al. 2014). Inflammation may 
cause brain injury by direct insult to oligodendrocytes and neurons or as secondary 
injury via microglial cell activation. This would result in the secretion of pro-
inflammatory cytokines, causing damage to the surrounding cells (Burd et al. 2012). 
Fetal lung injury can also be caused by elevated levels of inflammatory mediators in 
the amniotic fluid. For example, high levels of TNF, IL-1β, IL-6 and IL-8 have been 
found in the amniotic fluid of women who had babies with the chronic lung disease, 
BPD (Yoon et al. 1997b; Ambalavanan et al. 2011). However, a meta-analysis found 
only a modest association between chorioamnionitis and BPD (Hartling et al. 2012). 
Infection-induced fetal lung injury has been studied in some detail in the sheep. In a 
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chronically catheterised sheep model of the extreme preterm period, intra-amniotic 
LPS exposure caused fetal skin and lung inflammation, as well as systemic 
inflammation (Kemp 2014; Kemp et al. 2016). The fetus rapidly generated a robust 
inflammatory response driven by amniotic fluid-exposed tissues, such as the lung. 
Fetal blood cells responded to the systemic inflammation but these cells did not 
contribute to the acute production of inflammatory mediators (Kemp et al. 2016). 
Furthermore, a primate model of transient choriodecidual infection confirmed indirect 
lung injury as a result of elevated inflammatory mediators. This led to the 
downregulation of pathways for angiogenesis, morphogenesis and cellular growth and 
development in the fetal lung (McAdams et al. 2012). 
1.2.4 Prevention and treatment of PTL 
1.2.4.1 Tocolytics 
As PTL is very difficult to predict, treatments have focussed on tocolytic therapies that 
aim to temporarily inhibit myometrial contractions. Tocolytic administration increases 
the likelihood of completing a 48 hour corticosteroid treatment to accelerate fetal lung 
development (Alston et al. 2016). However, tocolytic treatments are largely ineffective 
at substantially delaying PTB and fail to improve the outcome of the premature 
neonates (Haas et al. 2012; Haas et al. 2014). Commonly used tocolytics include 
betamimetics, calcium channel blockers, oxytocin receptor antagonists and COX 
inhibitors. Magnesium sulphate may also be administered as it is thought to have 
neuroprotective properties (Haas et al. 2014). 
Calcium channel blockers, such as nifedipine, inhibit contractions by blocking the 
influx of Ca2+ into myometrial cells, preventing the phosphorylation of MLC. They 
are superior to treatment with betamimetics due to their ability to prolong pregnancy 
and are associated with fewer neonatal and maternal adverse effects. These drugs may 
also offer some benefit over magnesium sulphate and oxytocin receptor antagonists 
(Flenady et al. 2014a; Flenady et al. 2014b). Overall, calcium channel blockers are 
considered the preferred first-line tocolytic in terms of multiple key outcomes (Haas 
et al. 2009; Haas et al. 2012). A recent Cochrane review found that magnesium 
sulphate did not postpone delivery nor did it have any beneficial neonatal or maternal 
outcomes. This was despite a previously pooled analysis of five trials, with 6145 
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infants, finding a statistically significant neuroprotective effect (Doyle et al. 2009; 
Crowther et al. 2014). Therefore, this treatment is not currently recommended for 
tocolysis as further trials are needed to establish optimal dosing and treatment 
regimens for any potential beneficial effects (McNamara et al. 2015). Another recent 
Cochrane review did not find a benefit for the use of COX inhibitors, in comparison 
to other tocolytics, despite this treatment having some benefit in postponing birth 
compared to placebo (Reinebrant et al. 2015). Importantly, tocolytic treatments do not 
target the underlying cause of PTL and there is no benefit of prolonging a pregnancy 
if the in utero environment is adverse for the fetus (Haas et al. 2012). 
1.2.4.2 Antibiotics 
As intrauterine infection is a common cause of PTB, antibiotics can be administered. 
Two randomised clinical trials investigated the short and long term effects of certain 
antibiotics. 
The ORACLE I randomised trial investigated the effect of broad spectrum antibiotics 
on women with pPROM. Treatment with erythromycin was associated with prolonged 
pregnancy and neonatal health benefits, such as fewer cerebral abnormalities prior to 
discharge. However, co-amoxiclav was associated with neonatal necrotising 
enterocolitis (Kenyon et al. 2001a). The children from the ORACLE I trial were 
followed up at seven years of age. There was little effect of antibiotic treatment on the 
health of these children at this age (Kenyon et al. 2008a). Due to the prolongation of 
pregnancy and improvements of short-term neonatal morbidities, the routine 
prescription of antibiotics was recommended for the treatment of pPROM in the 2013 
Cochrane review, with the exception of co-amoxiclav (Kenyon et al. 2013). 
The ORACLE II randomised trial investigated the effect of erythromycin and co-
amoxiclav on women with spontaneous PTL with intact membranes but with no 
evidence of clinical infection. Antibiotic treatment was associated with a lower 
occurrence of maternal infection but this treatment did not lower the rates of the 
primary outcome measures, which included neonatal death, chronic lung disease and 
major cerebral abnormality. It was concluded that antibiotics should not be prescribed 
for spontaneous PTL without infection (Kenyon et al. 2001b). The seven year follow-
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up study for ORACLE II presented adverse outcomes in the children from mothers 
treated with antibiotics. Erythromycin treatment was associated with an increased risk 
of functional impairment in these children. Furthermore, both erythromycin and co-
amoxiclav treatment increased the risk of cerebral palsy (Kenyon et al. 2008b). The 
results of this review highlight the need for the assessment of long term 
neurodevelopmental outcome. This is particularly important in cases of intrauterine 
infection as delaying delivery could cause additional harm by prolonging exposure of 
the fetus to an adverse, infectious/inflammatory environment leading to increased fetal 
injury.  
1.2.4.3 Progesterone 
Progesterone is crucial for the maintenance of pregnancy. The potential of 
progesterone as a treatment for threatened PTL was first suggested in 1960 (Fuchs and 
Stakemann 1960). A multitude of clinical trials have investigated the effects of several 
progesterone derivatives, routes of administration and dosage regimens, with variable 
outcomes. 
Vaginal progesterone was reported to reduce uterine contractions in high risk women 
and reduce PTB incidence (da Fonseca et al. 2003). Intramuscular injection of 
progesterone was also shown to reduce PTB in a trial of women who had a history of 
PTB (Meis et al. 2003). Trials have also reported that vaginal progesterone reduces 
PTB in women with a short cervix (Fonseca et al. 2007; Hassan et al. 2011; Romero 
et al. 2012). 
In contrast, the administration of vaginal progesterone to women at high risk of PTB 
attenuated cervical shortening but did not prolong gestation compared to the placebo 
group (O'Brien et al. 2007; O'Brien et al. 2009). A small randomised trial for the use 
of weekly progesterone treatment in women with pPROM did not prolong gestation 
(Briery et al. 2011). Furthermore, neither vaginal nor intramuscular injection of 
progesterone prevented PTB in multiple gestations (Briery et al. 2009; Norman et al. 
2009; Combs et al. 2010; Combs et al. 2011; Rode et al. 2011).  
Meta-analyses have concluded that prophylactic progesterone treatment may reduce 
the incidence of PTB in women at high risk but there is limited information on long 
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term neonatal outcome. Therefore, larger randomised controlled trials investigating 
long term outcomes are required (Dodd et al. 2005; Mackenzie et al. 2006; Rode et al. 
2009). The 2013 Cochrane review further emphasised the need for longer term 
childhood outcomes and to refine the timing, dosage and administration of 
progesterone treatment (Dodd et al. 2013). 
The most convincing results thus far come from a recent, large, double-blind, 
randomised, placebo controlled trial of prophylactic vaginal progesterone treatment. 
The outcome of this trial was that the risk of PTB was not reduced by progesterone 
nor was neonatal outcome improved in women who were at high risk. The trial did not 
find any long term benefit of this treatment in children at 2 years of age (Norman et al. 
2016). This is the largest study to date comparing the obstetric, neonatal and childhood 
outcomes of vaginal progesterone treatment in women at high risk of PTB. The results 
of the trial have instigated an update to the NICE guidelines regarding the use of 
prophylactic progesterone for the prevention of PTB.  
1.2.4.4 Anti-inflammatory agents 
Targeting the inflammation commonly associated with PTL may be an ideal approach 
to delay delivery and, importantly, prevent fetal injury. Inflammatory cascades are 
most commonly activated as a result of bacterial invasion. Bacteria activate pattern 
recognition receptors, such as TLRs, leading to the activation of NF-κB and MAPK 
signalling pathways, which initiates an inflammatory cascade. These steps promote the 
pathological, preterm initiation of labour (Ng et al. 2015). Below is a summary of some 
inhibitors of these pathways, which may be novel treatments for the prevention of 
PTB.  
Non-specific NF-B inhibitors 
Antioxidant, N-acetyl cysteine (NAC) inhibits the activity of NF-κB (Zafarullah et al. 
2003). In an LPS-induced mouse model of PTB, NAC reduced PTB rates, reduced 
uterine inflammation and prevented white matter injury (Chang et al. 2011). NAC also 
attenuated NF-κB activation in the mouse uterus and reduced the expression of 
contraction-associated protein COX-2 (Chang et al. 2012). NAC inhibited NF-κB 
DNA-binding activity as well as reducing the release of inflammatory mediators, such 
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as IL-6, IL-8 and TNF, in LPS-stimulated human fetal membranes in vitro (Lappas et 
al. 2003). NAC has also been tested clinically in women with a previous PTB who had 
been treated for bacterial vaginosis. Oral NAC treatment reduced the recurrence of 
PTB in this small cohort (Shahin et al. 2009). Further human trials are required to 
validate these results. 
NF-κB activation can also be blocked by directly inhibiting the activity of the IκB 
kinase (IKK) complex. Sulfasalazine (SSZ) is a salicylate drug that is commonly used 
to treat the pain and swelling associated with rheumatoid arthritis (Weber et al. 2000). 
SSZ is safe for use in pregnancy (Rahimi et al. 2008). SSZ treatment reduced rates of 
early delivery in an E. coli-induced mouse model of PTB, as well as increasing the 
litter size and weight of the pups (Nath et al. 2010). Co-treatment of human fetal 
membranes with LPS and SSZ ex vivo inhibited the nuclear translocation of NF-κB 
and attenuated LPS-induced cytokine accumulation in both the maternal and fetal 
compartments. However, chronic apoptosis and loss of function of the tissue was 
observed following SSZ treatment, raising concerns of prolonged treatment with this 
drug (Keelan et al. 2009). 
Novel cytokine suppressive anti-inflammatory drugs (CSAIDs) 
CSAIDs inhibit cytokine production by directly targeting the signalling molecules of 
the NF-κB and p38 MAPK pathways. This makes these agents more specific for 
reducing inflammation in the context of PTL than other anti-inflammatory drug 
classes, such as non-steroidal anti-inflammatory drugs (NSAIDs). 
The p38 MAPK inhibitor, SKF-86002, reduced PGE2 gene and protein expression, 
reduced IL-1β production and reduced COX-2 expression in LPS-stimulated human 
fetal membranes in vitro (Sullivan et al. 2002). A more specific p38 MAPK inhibitor, 
SB202190, which acts by competitively inhibiting adenosine triphosphate (ATP) 
binding, reduced LPS-induced IL-6, TNF, PGE2 and PGF2α release from human 
placenta and fetal membranes (Lappas et al. 2007). Another inhibitor, SB239063, 
inhibited γ-irradiation-killed E. coli-induced IL-6, TNF and PGE2 release from both 
the maternal and fetal compartments of human fetal membranes (Stinson et al. 2014). 
However, MAPKs are also involved in cellular functions, such as motility, and 
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inhibiting this pathway may affect trophoblast migration and differentiation in the 
placenta (Qiu et al. 2004; LaMarca et al. 2008; Vaillancourt et al. 2009). Furthermore, 
these drugs are not yet approved for human use. 
For classical NF-κB activation, the regulatory subunit NF-κB essential modulator 
(NEMO) is required in addition to the IKKα and IKKβ subunits. IKKα and IKKβ have 
NEMO-binding domains, which allows regulation of the IKK complex assembly (Solt 
et al. 2009). A NEMO-binding domain inhibitor (NBDI) peptide can disrupt the 
binding of IKKβ and NEMO. In an ovine model, NBDI has been shown to prevent 
both LPS and Ureaplasma parvum-induced production of PGE2 by the fetal 
membranes. However, there was no effect of NBDI on inflammatory mediator release 
from human fetal membranes stimulated by γ-irradiation-killed E. coli (Stinson et al. 
2014).  
Other specific IKKβ inhibitors include TPCA-1 and parthenolide, which were found 
to inhibit cytokine production in the human choriodecidua when stimulated with LPS 
with no cytotoxicity side effects (De Silva et al. 2010). Intra-amniotic administration 
of TPCA-1 in an ovine model of chorioamnionitis reduced PGE2 production in the 
amniotic fluid but did not reduce the systemic fetal inflammation induced by LPS 
(Ireland et al. 2015). 
TLR4 antagonists 
TLRs are key recognition components of pathogen-associated molecular patterns 
(Poltorak et al. 1998). TLR4 antagonism is only applicable in cases of PTL that have 
been induced by Gram-negative bacteria. For example, TLR4 plays a role in LPS-
induced PTB in mice and antagonism of this receptor delays PTB and prevents 
perinatal death in mice (Elovitz et al. 2003; Li et al. 2010; Chin et al. 2016). A TLR4 
antagonist also attenuated LPS-induced uterine contractility, as well as reducing IL-8, 
TNF, PGE2 and PGF2α release in the amniotic fluid of rhesus monkeys (Adams 
Waldorf et al. 2008). TLR4 can be antagonised by molecules such as eritoran 
tetrasodium and TAK-242 (resatorvid) but neither of these have been studied in the 
context of PTL (Hawkins et al. 2004; Matsunaga et al. 2011). TLR antagonists may be 
a novel treatment of PTL, in association with antibiotics, to treat intrauterine infection.  
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TNF biologics 
TNF inhibitor drugs are routinely used to treat inflammatory conditions such as 
rheumatoid arthritis, psoriasis and ulcerative colitis. There are conflicting reports 
regarding the efficacy of using antibodies against TNF to prevent LPS-induced PTB 
and improve neonatal outcome in mice (Fidel et al. 1997; Holmgren et al. 2008). There 
is little evidence of congenital abnormalities following anti-TNF treatment in 
pregnancy. However, clinical cases suggest that anti-TNF treatments can cross the 
placenta after the second trimester, reaching the fetal circulation, and are detectable in 
the neonatal system for weeks after birth. This may increase the risk of infection in 
theses infants and alter their response to vaccines (Djokanovic et al. 2011; Nielsen et 
al. 2013). Small levels of anti-TNF drugs have also been detected in breast milk 
(Gisbert and Chaparro 2013). Therefore, antagonising TNF may not be an ideal 
method of reducing inflammation in cases of threatened or active PTL. 
IL-1 receptor antagonists 
IL-1β is a key inflammatory cytokine associated with PTL. It is produced in gestational 
tissues and is linked to the local upregulation of proteins associated with myometrial 
contraction. Administration of IL-1 to pregnant mice has be shown to induce PTB 
(Romero and Tartakovsky 1992). Therefore, a number of studies have investigated the 
effect of IL-1 receptor antagonists on infection-induced PTB, with varying outcomes. 
An early study demonstrated that pre-treatment with an IL-1 receptor antagonist (IL-
1Ra) prevented IL-1-induced PTB in mice (Romero and Tartakovsky 1992). However, 
the IL-1Ra did not prevent PTB in an LPS-induced mouse model (Fidel et al. 1997). 
In addition, PTB was not prevented in transgenic mice overexpressing the IL-1Ra 
when labour was induced by IL-1β or LPS (Yoshimura and Hirsch 2005).  
Although the IL-1Ra has been unable to prevent PTB in a number of mouse models, 
there is evidence to suggest that this antagonist has neuroprotective effects. For 
example, the IL-1Ra prevented LPS-induced fetal mortality, white matter damage and 
motor behavioural alterations in rats and reduced neurotoxicity in a mouse model of 
intrauterine inflammation (Girard et al. 2010; Leitner et al. 2014).  
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Recently, a novel, small, non-competitive IL-1R-biased ligand (rytvela/101.10) was 
found to delay PTB in mouse models induced by IL-1β, LPS or lipoteichoic acid, 
without inhibiting NF-κB. This treatment lowered the expression of pro-inflammatory 
and contraction-associated genes in the uterus. This specific IL-1R-biased ligand 
reduced the expression of c-jun, a component of the AP-1 transcription factor, and 
inhibited the Rho/ROCK pathway (Nadeau-Vallee et al. 2015). 
These studies emphasise the complexity of cytokine signalling during pregnancy and 
labour. It is unlikely that the inhibition of one cytokine will be sufficient to inhibit 
preterm delivery and reduce adverse effects to the fetus. Shynlova et al. (2014) targeted 
the activation of maternal peripheral immune cells with a broad spectrum chemokine 
inhibitor in an LPS-induced mouse model of PTB. This treatment reduced immune 
cell infiltration into maternal tissues, reduced inflammatory mediator secretion and 
attenuated PTB. This strategy may hold more promise than targeting specific pro-
inflammatory mediators. 
IL-10 treatment 
IL-10 may be a useful therapeutic for reducing the inflammation associated with PTL. 
It is well documented that IL-10 is an anti-inflammatory cytokine that is capable of 
suppressing the production of pro-inflammatory mediators, such as IL-1β, IL-6, IL-8, 
TNF and CCL2 (Couper et al. 2008). IL-10 is expressed at the maternal-fetal interface 
and is thought to have an immunoregulatory role during pregnancy (Lin et al. 1993; 
Bennett et al. 1997). 
IL-10 has an important role in labour and neonatal outcome, as evidenced by a study 
using IL-10 null mice. Fetal loss was elicited in IL-10 null mice using a 10-fold lower 
dose of LPS compared to wild-type mice (Robertson et al. 2006). Fetal growth 
restriction was observed in more of the surviving fetuses of IL-10 null mice, in 
comparison to wild-type mice, and an increase in pro-inflammatory mediators was 
identified in the maternal serum, uterus and placenta. These effects were reversed in 
the IL-10 null mice by the administration of exogenous IL-10. Interestingly, when IL-
10 was administered to the wild-type mice, this prevented LPS-induced fetal loss 
(Robertson et al. 2006). 
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In a rat model of LPS-induced fetal growth restriction and fetal loss, IL-10 treatment 
reduced fetal death, protected against growth restriction and reduced TNF release in 
the uterus (Rivera et al. 1998). IL-10 treatment prevented PTB and normalised pup 
weight in another rat model stimulated by LPS. This treatment was effective when 
given simultaneously with LPS and also when given 24 hours after LPS (Terrone et 
al. 2001). This anti-inflammatory cytokine may also have neuroprotective effects as 
IL-10 treatment prevented white matter lesions in pups born to rats inoculated 
intrauterine with E. coli (Rodts-Palenik et al. 2004). This may have been as a result of 
IL-10 suppressing the activation of microglia or by suppressing macrophage 
infiltration (Pang et al. 2005). In non-human primates, IL-10 attenuated IL-1β-induced 
uterine contractions by reducing prostaglandin production and TNF levels were also 
reduced in the amniotic fluid (Sadowsky et al. 2003). Therefore, exogenous IL-10 
treatment may be useful for reducing inflammation in cases of threatened or active 
PTL. However, additional studies are required to validate these findings. 
An alternative to supplementing with just one anti-inflammatory cytokine would be to 
administer a mediator that is specific to resolving inflammation. Rinaldi et al. (2015a) 
investigated the use of a key anti-inflammatory and pro-resolution mediator, 15-epi-
lipoxin A4, in an LPS-induced mouse model of PTB. Although PTB was not prevented, 
15-epi-lipoxin A4 reduced rates of fetal death. Therefore, promoting the resolution of 
inflammation may be a novel method to prevent fetal injury.  
As well as effective treatments, improved methods of identifying at risk mothers and 
fetuses are also required. One strategy that shows promise is the use of new ultrasound 
techniques, such as Tissue Doppler Imaging (TDI), to identify signs of fetal 
inflammation (Di Naro et al. 2010; Stock et al. 2016). Genotype may influence the 
therapeutics used for PTB prevention and treatment and although the evidence to date 
is limited, there is increasing indication that pharmacogenomics may play a role in 
PTB. By integrating clinical information, environmental influences and genotype, a 
more comprehensive strategy to personalised medicine could be optimised (Manuck 
2016). 
In summary, tocolytic therapies are useful for delaying labour to allow for the 
administration of corticosteroids but these treatments do not treat the underlying cause 
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of PTL and there is no benefit to delaying birth if it does not improve neonatal 
outcomes. Recent clinical trial reports have questioned the efficacy of vaginal 
progesterone treatment, which did not delay PTB in high risk women or improve the 
long term health of the premature offspring when assessed at two years of age. In cases 
of intrauterine infection, it may be appropriate to treat women with antibiotics. 
However, the addition of an anti-inflammatory therapeutic or CSAIDs may help to 
reduce the local inflammation and prevent fetal injury. Effective therapies for the 
prevention and treatment of PTL are urgently required. These must target the 
underlying mechanisms, such as inflammation. Importantly, they must prevent 
neonatal morbidity and mortality. 
1.2.5 Animal models of PTB  
Animal models are crucial for exploring the underlying mechanisms of spontaneous 
PTB and for the development of therapeutics as it is difficult to perform such studies 
in humans. As animals rarely experience natural spontaneous PTB, models must be 
created where PTB is induced, usually by the administration of bacterial agents. 
Animal models of PTB vary in their physiology, the methods of labour induction and 
fetal physiology. The advantages and disadvantages of different animal models have 
been extensively reviewed (Elovitz and Mrinalini 2004; Mitchell and Taggart 2009; 
Nielsen et al. 2016). This information is summarised below. 
1.2.5.1 Sheep 
Sheep are a useful model due to their large size. The uterine cavity is similar to that of 
a human, as is the fetal weight at birth and the gestational length (144-152 days) is 
more comparable to human gestation than in other animal models, such as rodents. 
There has also been substantial development of surgical techniques that allow catheters 
to be implanted into to the fetus in utero so that both maternal and fetal serum levels 
can be monitored during a study. Myometrial contractility can also be assessed directly 
(Elovitz and Mrinalini 2004). During pregnancy in the sheep, the primary source of 
progesterone is the corpus luteum, before the placenta takes over, which is comparable 
to humans. However, sheep do experience progesterone withdrawal, which humans do 
not, and the placental morphology is very different between these species (Mitchell 
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and Taggart 2009). Furthermore, sheep are expensive, which means group numbers 
for studies may be limited (Elovitz and Mrinalini 2004).  
In the sheep, the fetus plays a critical role in the timing of parturition. Glucocorticoid 
concentrations increase exponentially in the fetal plasma in the last month of gestation 
(Poore et al. 1998). The initial studies highlighting the importance of the fetal 
pituitary–adrenal axis in pregnancy were performed by Liggins in the 1960s. These 
studies confirmed that the administration of cortisol or glucocorticoids could induce 
labour in the sheep (Liggins 1968; Liggins 1969). However, glucocorticoids do not 
have a major role in parturition in humans and do not induce labour in women.  
In recent years, interest has changed from the role of hormones to the role of 
inflammation in studies of PTB. Consequently, many studies have investigated the 
effect of intra-amniotic infection on the ovine fetal inflammatory response using 
inflammatory and infectious agents such as LPS, E. coli, Ureaplasma parvum and 
Candida albicans (Kallapur et al. 2001; Kramer et al. 2002; Collins et al. 2010; Kemp 
2014; Stock et al. 2016). Therefore, the ovine model is very useful for the 
understanding of fetal response to infection and fetal maturation but this is not 
considered an ideal model for the study of parturition. 
1.2.5.2 Rodents 
Rodents are useful models as they are inexpensive and tolerate surgery well (Elovitz 
and Mrinalini 2004). Unlike humans, they have a very short gestation but this allows 
for a number of experiments to be performed in a shorter period of time (Mitchell and 
Taggart 2009). Mice can also be genetically manipulated, which is useful when 
investigating the mechanisms associated with parturition. In contrast to humans, the 
corpus luteum is a continuous source of progesterone in rodents and both rats and mice 
experience progesterone withdrawal, which precedes labour (Mitchell and Taggart 
2009). Another dissimilarity with the human physiology is that rodents have a 
bicornuate uterus. In terms of fetal differences, myelination occurs later in rodents than 
in humans (Elovitz and Mrinalini 2004). Rodent offspring are less mature than humans 
at birth and based on some parameters, the murine neonatal period is used to model 
the third trimester of human fetal development (Clancy et al. 2001). Rats are also more 
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resistant to inflammatory insult than humans and some studies have failed to reliably 
induce PTB with LPS or E. coli in these animals (Fang et al. 2000; Hirsch et al. 2009).  
A number of bacteria and bacterial components have been utilised in the study of 
infection-induced PTB in mice. For example, LPS, E. coli, lipoteichoic acid, 
Chlamydia, Fusobacterium, Ureaplasma, ligands for TLR2 and TLR3 and bacterial γ-
D-glutamyl-meso-diaminopimelic acid (iE-DAP) (Nielsen et al. 2016). The anti-
progesterone agent RU486 has also been used to induce PTB and investigate non-
infectious mechanisms of PTB (Dudley et al. 1996). Other methods of PTB induction 
in mice include PGF2α, SF-A and fetal fibronectin (Nielsen et al. 2016). 
1.2.5.3 Non-human primates 
As the most similar to humans, non-human primates are very useful when modelling 
human parturition. Gestational length is similar to that of humans and there is no 
progesterone withdrawal in maternal serum (Mitchell and Taggart 2009). The placenta 
is the source of progesterone during pregnancy, as it is in humans, and fetal maturation 
is also comparable. Catheters can be implanted for continuous monitoring of the fetus 
and myometrial contractions can be assessed directly (Elovitz and Mrinalini 2004).  
Primates are useful for the study of potential tocolytic treatments, as well as 
investigating the effect of inflammatory cytokines and infectious agents (Gravett et al. 
1994; Sadowsky et al. 2003; Sadowsky et al. 2006). For example, PTL can be induced 
in rhesus monkeys by LPS, IL-1β or TNF. PTL can be inhibited by dexamethasone, 
IL-10 and TLR4 antagonists in these models (Sadowsky et al. 2006; Adams Waldorf 
et al. 2008). Although primates are the most relatable to humans, these experiments 
are costly, they come with difficulties regarding ethics and can be impractical due to 
the housing and professional care that these animals require. 
1.2.5.4 Routes of administration of agents to induce PTB 
Infectious or inflammatory agents can be administered systemically or locally in 
models of PTB. The main systemic route is by intraperitoneal injection to the mother. 
Intraperitoneal administration of LPS can induce PTB in mice (Robertson et al. 2006; 
Salminen et al. 2008; Shynlova et al. 2014). However, this model is more 
representative of conditions such as sepsis or pneumonia. Women experiencing PTL 
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do not normally have symptoms or evidence of systemic infection. Therefore, animal 
models of localised infection or inflammation more accurately mimic the human 
condition.  
The administration routes of localised infection/inflammation include intra-amniotic, 
intrauterine and intravaginal (Gravett et al. 1994; Elovitz et al. 2003; Gonzalez et al. 
2011). Elovitz et al. (2004) have discussed the advantages and disadvantages of these 
methods in some detail. Mouse models of intrauterine infection have been widely 
utilised in the last decade. This involves a laparotomy procedure where the uterus is 
removed from the dam and an intrauterine injection of a bacterial agent or an 
endotoxin, such as LPS, is performed between two amniotic sacs. This procedure has 
recently been refined by the use of ultrasound to guide the intrauterine injection, 
establishing a less invasive model (Rinaldi et al. 2015b). This new procedure has now 
been utilised for the intra-amniotic administration of inflammatory agents (Gomez-
Lopez et al. 2016). To date, there have been mixed reports regarding the reliability of 
intravaginal LPS administration to induce PTB in mice and it is unknown how LPS 
could circumvent the strong physical and immunological barrier of the cervix 
(Gonzalez et al. 2011; Gonzalez et al. 2014; Rinaldi et al. 2015b).  
In conclusion, PTB is still a significant public health problem. Despite huge 
advancements in medical research, PTL remains difficult to predict and treatments are 
ineffective. PTB, in many cases, results in neonatal mortality or a lifetime of varying 
degrees of morbidity for the offspring. Useful and relatable animal models will be key 
to development of much needed novel therapeutics that must target the inflammation 
associated with PTL and thus, prevent fetal injury. 
1.3 Statins 
Statins are 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) reductase inhibitors. These 
drugs are potent inhibitors of cholesterol biosynthesis and reduce the risk of 
cardiovascular events. Statins also have antioxidant, immunomodulatory, anti-
inflammatory and anti-contraction properties. As a result of these pleiotropic effects, 
statins may be ideal candidates for the treatment for pregnancy disorders. In the 
following section the development of statins, their pharmacokinetics and their 
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pleiotropic effects will be discussed. In addition, their application in pregnancy 
disorders to date and their safely profile will be covered.   
1.3.1 Cholesterol 
Cholesterol is defined as an alicyclic, unsaturated alcohol, which is present in all cells 
and is essential for the functioning of all human organs. Cholesterol is a precursor of 
bile acids, as well as the precursor to many adrenal and steroid hormones. The liver is 
the principal site of endogenous cholesterol production but cholesterol can also be 
absorbed from foods that are high in fat (Cornforth and Popjak 1958).  
Following its production in the liver, cholesterol is released into the circulation. 
Lipoproteins transport cholesterol in plasma, delivering it to cells around the body 
(Fredrickson et al. 1967). Lipoproteins are categorised by density: very low-density 
lipoprotein (VLDL), intermediate-density lipoprotein (IDL), low-density lipoprotein 
(LDL) and high-density lipoprotein (HDL) (Olson 1998). Two types of lipoproteins 
are predominantly responsible for carrying cholesterol to and from cells, LDL and 
HDL. High levels of LDL particles or “bad cholesterol” increase the risk of developing 
atherosclerosis, which is the leading cause of cardiovascular disease. The LDL 
receptor is found in coated pits in most cells and is responsible for the endocytosis of 
LDL into the cell. Free cholesterol is released into the cytoplasm, which inhibits the 
synthesis of new LDL receptors and inhibits the synthesis of more cholesterol by 
preventing the production of HMG-CoA reductase (Goldstein and Brown 1977; Olson 
1998). In contrast, HDL is anti-atherosclerotic and anti-inflammatory. HDL is often 
referred to as “good cholesterol” as this particle removes free cholesterol from cells 
and delivers it to the liver for excretion (Elshourbagy et al. 2014).  
1.3.2 Cholesterol biosynthesis: The mevalonate pathway 
The mevalonate pathway is a key metabolic pathway that produces isoprenoids. These 
naturally occurring, organic chemicals are crucial for a multitude of cellular functions, 
such as cholesterol biosynthesis and electron transport, as well as the synthesis of 
glycoproteins, intracellular molecules and steroid hormones (Goldstein and Brown 
1990).  
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The main stages of cholesterol biosynthesis are detailed as follows (Figure 1.3). 
Acetoacetyl-Coenzyme A (CoA) condenses with acetyl-CoA to form HMG-CoA. The 
enzyme HMG-CoA reductase catalyses the conversion of HMG-CoA into mevalonate, 
as three acetate units condense to form this six-carbon intermediate. This is the rate-
limiting step of the pathway and thus the common site of therapeutic intervention with 
drugs, such as statins. Mevalonate is then converted into activated isoprene units 
(Goldstein and Brown 1990). Isoprenoid precursors include isopentenyl 
pyrophosphate (I-PP), geranyl pyrophosphate (G-PP), farnesyl pyrophosphate (F-PP) 
and geranylgeranyl pyrophosphate (GG-PP) (Buhaescu and Izzedine 2007). F-PP is 
the last compound in the isoprenoid metabolic pathway with the potential to be 
incorporated into either sterol or non-sterol end products (Bradfute and Simoni 1994). 
F-PP is converted and dimerised to form squalene. Finally, cyclisation of squalene then 
forms a steroid nucleus, with a final series of changes, including oxidations, removal 
or migration of methyl groups, to produce cholesterol (Cornforth and Popjak 1958; 
Bloch 1965; Buhaescu and Izzedine 2007). 
Statins also have cholesterol-independent effects due to their inhibition of F-PP and 
GG-PP synthesis. F-PP and GG-PP play important roles in the post-translational 
modification of intracellular signalling molecules, such as the small GTPases. This 
includes Rho, Rac and cell division control protein 42 homolog (Cdc42), which are 
associated with superoxide production, cell proliferation, cell growth, gene expression, 
protein glycosylation and remodelling of the actin cytoskeleton (Buhaescu and 
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Figure 1.3. The mevalonate pathway. The pathway begins by acetoacetyl-CoA condensing with 
acetyl-CoA to form HMG-CoA. The conversion of HMG-CoA to form mevalonate, catalysed by HMG-
CoA reductase, is the rate-limiting step of this pathway. Statins are competitive inhibitors of HMG-CoA 
reductase. Cholesterol is synthesised from the isoprenoid component F-PP. F-PP is also the precursor 
to GG-PP. F-PP and GG-PP are involved in the isoprenylation of small GTPases, such as Rho, Rac and 
Ras. These intracellular molecules regulate cellular processes, such as proliferation, migration and 
oxidative stress. eNOS: endothelial nitric oxide synthase. Adapted from Costa et al. (2016).  
 
1.3.3 The discovery of statins 
Akira Endo first identified inhibitors of cholesterol biosynthesis in 1976. He derived 
two compounds, ML-236A and ML-236B, from the Penicillium citrinum mold that 
infects certain Japanese oranges (Endo et al. 1976b). Endo reported that ML-236B 
competitively inhibited HMG-CoA reductase, the enzyme that is the rate limiting step 
in cholesterol biosynthesis. ML-236B was capable of inhibiting the activity of HMG-
CoA reductase at nanomolar concentrations (Endo et al. 1976a). This compound was 
later named compactin or mevastatin (Endo 2008). 
Endo et al. (1977) reported that cholesterol synthesis was reduced in rodents by the 
uptake of compactin by the liver. However, compactin did not lower plasma 
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cholesterol levels in rodents as most circulating cholesterol in these animals is not in 
the LDL form. In addition, compactin treatment increased hepatic HMG-CoA 
reductase abundance 8-10 fold, which counteracted the inhibitory effect of the drug. 
Although, compactin did lower the plasma levels of LDL cholesterol in hens, rabbits 
and dogs (Endo et al. 1979).  
In 1978, Brown et al. demonstrated that compactin could inhibit the activity of HMG-
CoA reductase in fibroblasts collected from patients with familial 
hypercholesterolemia (Brown et al. 1978). In the first human application of compactin, 
the drug reduced serum cholesterol levels by an average of 27% in 11 patients with 
primary hypercholesterolemia, over a period of 4-8 weeks (Yamamoto et al. 1980). 
However, the clinical development of compactin was discontinued later that year. This 
was due to toxicity concerns following a study in dogs where the drug was believed to 
have caused lymphomas, albeit at exceptionally high doses (Endo 2010).  
Merck Research Laboratories also began screening HMG-CoA reductase inhibitors 
and isolated a compound with a similar structure to compactin from the fungus 
Aspergillus terreus. This compound was called mevinolin but would later be renamed 
lovastatin (Alberts et al. 1980; Endo 2010). When lovastatin was given to dogs there 
was an increase in liver LDL receptors, which subsequently led to a marked reduction 
in plasma LDL levels (Brown and Goldstein 1981). Further studies by Merck Research 
Laboratories demonstrated that circulating LDL cholesterol concentration was reduced 
by lovastatin treatment in healthy men, while HDL concentration was unaffected 
(Tobert et al. 1982). 
Large scale clinical trials administering lovastatin to high risk patients began in 1984. 
The results demonstrated a dramatic reduction in LDL cholesterol levels with limited 
side effects. US Food and Drug Administration (FDA) approval was given to 
lovastatin in 1987 (Endo 2010). 
Following the development of lovastatin, six additional statins have been introduced. 
This includes two semi-synthetic statins, simvastatin and pravastatin, and four 
synthetic statins, fluvastatin, atorvastatin, rosuvastatin and pitavastatin. Another 
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synthetic statin, cerivastatin, was discontinued due to reports of myopathy (Endo 
2008). 
The landmark clinical trial, the Scandinavian Simvastatin Survival Study (1994), 
established the association between statin-reduced cholesterol levels and the reduction 
in cardiovascular events. The results of this trial and others have consistently reported 
that statins lower plasma LDL cholesterol levels by 25-35% and reduce the risk of 
cardiovascular events by 25-30% (Shepherd et al. 1995). 
Statins are the largest selling class of drug worldwide (Endo 2010). The initiation of 
statin use in the UK increased rapidly from 1995 (0.51 per 1,000 person-years at risk) 
peaking in 2006 (19.83 per 1,000 person-years). This declined by 2013 (10.76 per 
1,000 person-years). The prevalence of prescriptions increased hugely from 1995 (2.36 
per 1,000 person-years) to 2013 (128.03 per 1,000 person-years) (O'Keeffe et al. 
2016). 
1.3.4 Pharmacokinetics of statins 
Due to uncertainties regarding the efficacy of lovastatin, semi-synthesised statins were 
developed. Lovastatin had an additional methyl group added to its structure to create 
simvastatin (Figure 1.4). This increased the hydrophobicity of the molecule, leading 
to more potent inhibition of HMG-CoA reductase (Mol et al. 1986). The differences 
in chemical structures of statins influence their absorbance, distribution, metabolism 
and their excretion from the body (Schachter 2005). Lovastatin and simvastatin are 
both inactive prodrugs due to their closed lactone ring structures. These molecules are 
mainly activated in the liver or, occasionally, in the gastrointestinal tract (Sirtori 2014). 
Then came the development of the semi-synthetic molecule, pravastatin, which was 
the first statin to have an open ring structure (Yoshino et al. 1986). The synthetic 
statins, fluvastatin, atorvastatin, rosuvastatin and pitavastatin, also have open ring 
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Figure 1.4. Statin structures. The original statins, compactin and lovastatin, were modified to produce 
the semi-synthetic statins, pravastatin and simvastatin. The synthetic statins, fluvastatin, atorvastatin, 
pitavastatin and rosuvastatin, were created later. Lovastatin and simvastatin have closed lactone ring 
structures (red circles), whereas the other statins have open ring structures. Pravastatin contains a polar 
hydroxyl group (blue rectangle), which makes this compound very hydrophilic. The other statins are 
more lipophilic. Adapted from Sirtori (2014). 
Statins inhibit the activity of HMG-CoA reductase by binding to its active site, 
sterically preventing HMG-CoA from binding to the enzyme. The hydrophobic 
compounds of statins block the HMG-binding pocket, as well as a portion of the CoA-
binding site. Statins bind tightly to HMG-CoA reductase due to a larger number of van 
der Waals interactions, with a much higher affinity than HMG-CoA (Istvan and 
Deisenhofer 2001). The binding properties of the individual statins may account for 
their potency. For example, rosuvastatin has the most binding interactions with HMG-
CoA reductase. Clinical trials have suggested that rosuvastatin is the most effective 
statin for reducing LDL cholesterol, followed by atorvastatin, simvastatin then 
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pravastatin. Simvastatin and pravastatin are the most effective statins for increasing 
the percentage of HDL cholesterol, which they increase by an average of 12% 
(Schachter 2005). 
Statins have both hydrophilic and hydrophobic components to their structure. 
Simvastatin, fluvastatin and atorvastatin are highly lipophilic and can readily enter 
cells by directly interacting with the plasma membrane. Rosuvastatin exhibits 
intermediate behaviour, due to a hydrophilic methane sulphonamide group. Pravastatin 
is hydrophilic, as it contains a polar hydroxyl group, and requires selective uptake into 
cells by a sodium-independent organic anion transporter protein-1B1 (OATP1B1). 
This transporter protein is exclusively expressed in the liver and so entry into other 
cells types is limited (Hamelin and Turgeon 1998; Corsini et al. 1999). The most 
important property of statins is their hepatoselectivity given that most endogenous 
cholesterol production takes place in the liver. The hydrophilic statins, pravastatin and 
rosuvastatin, are more hepatoselective than lipophilic statins (Schachter 2005).  
Most of the statins are metabolised initially in the liver, lowering systemic 
bioavailability. These statins are metabolised by the cytochrome P450 (CYP) system, 
most commonly by the highly active CYP3A4 enzyme. In contrast, pravastatin and 
rosuvastatin undergo minimal metabolism due to their hydrophilic structure (Sirtori 
2014). Pravastatin is degraded in the stomach, independently of the CYP enzymes, and 
is excreted by the kidneys and liver (Schachter 2005).  
The bioavailability of statins differs widely. Lovastatin and simvastatin have low 
bioavailability of 5%. Pitavastatin’s bioavailability is much greater at 60%. Pravastatin 
has a bioavailability of 18%. All statins, with the exception of pravastatin, have high 
binding affinity to plasma proteins. Therefore, systemic exposure to unbound, 
pharmacologically active drug is low. Active pravastatin levels in the circulation are 
higher than the other statins but uptake into other tissues is limited, due to its 
hydrophilic structure. The elimination half-life of lovastatin and the semi-synthetic 
statins, pravastatin and simvastatin, range from 1-3 hours. The half-lives of the 
synthetic statins, atorvastatin, fluvastatin, pitavastatin and rosuvastatin, range from 1 
hour for fluvastatin to 19 hours for rosuvastatin (Schachter 2005).   
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Therefore, the differing chemical structures and hydrophobicity of statins can 
influence their potency, as well as their absorbance, distribution, metabolism and their 
excretion from the body. These factors should be considered when selecting a statin 
for therapeutic use.   
1.3.5 Pleiotropic effects of statins 
Over the last decade, clinical trial outcomes have suggested that statins have benefits 
beyond their lipid lowering properties. Statins have been shown to be 
immunomodulatory, anti-inflammatory, anti-proliferative, apoptotic and can reduce 
oxidative stress (Kavalipati et al. 2015). These effects have been widely reviewed 
(Liao and Laufs 2005; Wang et al. 2008; Zhou and Liao 2010; Kavalipati et al. 2015). 
As the lipophilic statins are more likely to enter non-hepatic cells than the hydrophilic 
statins, it could be hypothesised that these statins may have more pleiotropic benefits 
than the hydrophilic statins. However, studies suggest that the hydrophilic statins, such 
as pravastatin, also exert similar pleiotropic effects. Therefore, it has now been 
proposed that these effects may be mediated by HMG-CoA reductase inhibition in the 
liver, which subsequently reduces circulating isoprenoid levels. This hypothesis may 
explain how hydrophilic statins can have beneficial effects in cells that these drugs can 
not directly enter (Zhou and Liao 2010). 
1.3.5.1 Prevention of endothelial dysfunction and oxidative 
stress 
The endothelium, the inner lining of blood vessels, responds to environmental factors 
and maintains haemostatic balance by regulating blood vessel contraction and 
leukocyte trafficking. Endothelial dysfunction is characterised by the increase of 
reactive oxygen species (ROS), which leads to a reduction in the protective molecules, 
endothelial nitric oxide synthase (eNOS) and nitric oxide (NO).  
Statins reduce endothelial dysfunction and oxidative stress in patients with 
hyperlipidaemia and metabolic syndrome (Thallinger et al. 2005; Alber et al. 2007; 
Murrow et al. 2012). Statins have this effect independently of LDL cholesterol 
reduction. This was addressed in patients with chronic heart failure who were 
prescribed simvastatin or ezetimibe, a cholesterol absorption inhibitor. Both treatments 
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lowered LDL cholesterol levels to a similar degree. However, simvastatin treatment 
increased the number of functionally active endothelial progenitor cells and increased 
the activity of the enzyme that catalyses the dismutation of superoxide radicals, which 
was examined as a marker of oxidative stress (Landmesser et al. 2005). In a similar 
comparison study, simvastatin and ezetimibe again lowered LDL cholesterol levels to 
the same extent in patients with coronary artery disease but simvastatin also improved 
vasodilator function (Fichtlscherer et al. 2006).  
The antioxidant effect of statins may be due to the inhibition of the small GTPase Rac. 
Statins can reduce oxidative stress and vascular remodelling in the context of cardiac 
hypertrophy by inhibiting the isoprenylation of Rac (Brown et al. 2006). Atorvastatin 
treatment reduced ROS production in rat aortic vascular smooth muscle cells that had 
been stimulated with angiotensin II, a peptide hormone that causes vasoconstriction. 
The mRNA expression and abundance of the angiotensin receptor was also reduced. 
Atorvastatin inhibited the activity and membrane translocation of Rac1 (Wassmann et 
al. 2001). Simvastatin treatment inhibited angiotensin II-induced rat cardiomyocyte 
hypertrophy, reduced Rac1 activity and lowered the production of the superoxide 
anion, suggesting simvastatin was having an antioxidant effect via Rac1 inhibition. 
This effect was reversed by supplementation with mevalonate and GG-PP but not by 
F-PP or cholesterol (Takemoto et al. 2001). Both pravastatin and atorvastatin inhibited 
Rac1 activity in myocardial explants from patients with chronic heart failure (Maack 
et al. 2003). These studies highlight the importance of statin-induced Rac inhibition 
for reducing oxidative stress. 
Statins regulate eNOS through multiple pathways, for example the Rho/ROCK 
pathway as RhoA negatively regulates eNOS expression and activity. Statins increase 
the stability of eNOS mRNA, by inhibiting Rho geranylgeranylation, which leads to 
increased expression of eNOS (Laufs and Liao 1998). Statins can also regulate eNOS 
through the serine-threonine protein kinase, Akt. Statins activate this protein in 
endothelial cells by upregulating phosphatidylinositol-3 kinase (PI3K) signalling, 
which promotes the phosphorylation of eNOS and also increases angiogenesis 
(Kureishi et al. 2000). The inhibition of the Rho/ROCK pathway also activates the 
PI3/Akt pathway (Wolfrum et al. 2004). Alternatively, statins can promote eNOS 
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activity by reducing the expression of caveolin-1, which is a membrane protein that 
directly binds to eNOS in caveolae and inhibits its activity (Pelat et al. 2003).  
Statins induce the production of heme oxygenase 1 (HO-1), which is a stress response 
protein that is essential for heme catabolism. HO-1 cleaves heme to form biliverdin 
and carbon monoxide. Biliverdin is then converted to the antioxidant, bilirubin. As 
well as having antioxidant effects, HO-1 has anti-inflammatory effects, it can prevent 
the development of atherosclerosis in mice and has been upregulated by statin 
treatment in mouse models of preeclampsia and PTB (Juan et al. 2001; Hinkelmann et 
al. 2010; Leung et al. 2011; Gonzalez et al. 2014; Ramma and Ahmed 2014). 
1.3.5.2 Immunomodulation 
Previous studies have suggested that statins may mediate their anti-inflammatory and 
anti-atherosclerotic effects by inhibiting CCL2 expression, which could consequently 
affect monocyte chemotaxis (Martinez-Gonzalez et al. 2001; Kleemann et al. 2003; 
Veillard et al. 2006). Atorvastatin, simvastatin and fluvastatin suppressed human 
monocyte chemotaxis and these statins also reduced CCL2 expression in human aortic 
endothelial cells by inhibiting JAK/STAT signalling cascades. These effects were both 
blocked by mevalonate and GG-PP but not F-PP, suggesting they were cholesterol-
independent (Jougasaki et al. 2010). Conversely, in animal models of inflammatory 
skin conditions and wound healing, the topical application of simvastatin has been 
shown to reduce inflammation by promoting macrophage infiltration to the site of 
injury (Adami et al. 2012; Asai et al. 2012). This suggests that statins have complex 
effects on immune regulation.  
Simvastatin treatment can inhibit major histocompatibility complex class II (MHC II) 
expression and subsequent T-cell activation. MHC II is upregulated in inflammatory 
conditions such as myocarditis, multiple sclerosis and rheumatoid arthritis. For 
antigens to be presented on cell surfaces, changes in the actin cytoskeleton are required 
to facilitate endocytosis of the antigen, internal processing and presentation of the 
MHC II molecules. Small GTPases control the actin cytoskeleton and statins inhibit 
the isoprenylation of these proteins (Kwak et al. 2000; Kwak et al. 2001). Other small 
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GTPases, Cdc42 and Rac, play a role in dendritic cell antigen presentation to T-cells 
(Nobes and Marsh 2000).  
Statin treatment mediates a shift from Th1 to Th2 phenotype, producing anti-
inflammatory effects. This Th2 bias is characterised by an increase in Th2 cytokines, 
such as IL-4, IL-5 and IL-10, and an inhibition of Th1 cytokine secretion, such as IFN-
γ and TNF (Youssef et al. 2002; Aprahamian et al. 2006). In a mouse model of 
inflammatory arthritis, simvastatin suppressed Th1-related immune responses and 
IFN-γ release from mononuclear cells (Leung et al. 2003). In another study, 
atorvastatin stimulated the differentiation of Th2 cells, reduced immune cell 
infiltration into the central nervous system and inhibited the expression of MHC II in 
mice with autoimmune encephalomyelitis. This work highlights the potential for statin 
treatment for other Th1-mediated autoimmune diseases (Youssef et al. 2002). Th17 
cells have also been identified as an important target of statins when modulating 
immune responses in autoimmune diseases such as multiple sclerosis. Simvastatin had 
a Th17-polarising effect on cytokine secretion from dendritic cells isolated from 
multiple sclerosis patients (Zhang et al. 2013).  
Statins alter circulating Tregs in humans, with simvastatin and pravastatin increasing 
Treg circulation in hyperlipidaemia patients (Mausner-Fainberg et al. 2008). 
Atorvastatin increased the frequency and modulation of Tregs in a mouse model of 
acute allergic asthma, which was associated with reduced immune cell infiltration into 
the lungs and increased IL-10 production (Blanquiceth et al. 2016). Statins have also 
been found to have inflammation-independent immunomodulatory effects as 
lovastatin and atorvastatin increased the frequency of circulating CD4+ FOXP3+ 
Tregs in heathy males (Rodriguez-Perea et al. 2015). Overall, these 
immunomodulation properties aid the anti-inflammatory effects of statins. 
1.3.5.3 Anti-inflammatory properties 
The anti-inflammatory effects of statins were first identified in cases of atherosclerosis 
and cardiovascular disease. Atherosclerosis is an inflammatory process, which is 
characterised by leukocyte recruitment, excessive pro-inflammatory mediators and 
lipid accumulation. Statins have been shown to exert anti-inflammatory effects on the 
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vascular wall in cases of atherosclerosis and the resulting cardiovascular diseases 
(Libby 2002).  
C-reactive protein (CRP) is a non-specific marker of inflammation and is also an 
independent predictor of cardiovascular disease. The PRINCE trial was an important 
development in the recognition of statin-mediated anti-inflammatory effects. This trial 
investigated the effect of pravastatin treatment on plasma levels of CRP. After 24 
weeks of treatment, CRP levels had reduced both in patients with cardiovascular 
disease and in the control subjects who had no history of cardiovascular disease (Albert 
et al. 2001). The JUPITER randomised trial concluded that rosuvastatin treatment 
reduced CRP levels and reduced the overall incidence of major cardiovascular events 
in healthy individuals with elevated CRP but without hypercholesterolemia (Ridker et 
al. 2008). This anti-inflammatory effect was observed in a number of other studies 
performed in subjects with type 2 diabetes, carotid artery plaques and 
hypercholesterolemia (Crisby et al. 2001; Kalela et al. 2001; Solheim et al. 2001; 
Sommeijer et al. 2004). Furthermore, in hypercholesteraemic patients, serum IL-6, IL-
8 and CCL2 were all reduced following 6 weeks of simvastatin treatment (Rezaie-
Majd et al. 2002).  
To investigate the anti-inflammatory effects of statins further, healthy volunteers 
inhaled LPS to induce acute lung inflammation. Pre-treatment with simvastatin 
attenuated LPS-induced TNF, MMP-7, MMP-8, MMP-9 and CRP production in the 
bronchoalveolar lavage fluid of the volunteers. LPS-induced CRP levels were also 
reduced in the plasma of simvastatin-treated subjects. LPS stimulated the nuclear 
translocation of NF-κB in monocyte-derived macrophages, which was inhibited by 
simvastatin pre-treatment (Shyamsundar et al. 2009). 
Arguably, the quintessential example of an excessive innate immune response is 
sepsis. In a cecal ligation and puncture (CLP) mouse model exhibiting polymicrobial 
sepsis, both pre-treatment and post-treatment with statins substantially prolonged 
survival and reduced the adhesion of leukocytes to endothelial cells (Merx et al. 2004; 
Merx et al. 2005). Simvastatin pre-treatment also improved CLP-induced acute kidney 
injury, prevented renal vasculature damage and hypoxia, as well as reducing systemic 
inflammation (Yasuda et al. 2006). Randomised, controlled trials have not found a 
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reduction in pro-inflammatory markers with acute statin treatment of patients with 
sepsis compared to placebo (Kruger et al. 2011; Kruger et al. 2013). However, 
previous statin treatment is associated with lower baseline IL-6 concentration and 
continued statin treatment improves survival rates in patients with sepsis (Kruger et al. 
2013). Previous statin therapy is also associated with a reduced risk of bacterial 
infections and statin users who do develop bacterial infections have a reduced hospital 
stay and a lower mortality rate compared to non-statin users (Nassaji et al. 2015). Statin 
therapy has also been associated with reduced mortality in patients with viral 
infections, most likely because statins reduce their inflammatory response 
(Vandermeer et al. 2012). However, it has been argued that these results reflect bias 
from “healthy user” effects as statin users are less likely to have co-morbidities and 
may practice more healthy behaviours (van den Hoek et al. 2011). Recent meta-
analyses and systematic reviews have reported that the effects of statins on infection 
are still inconclusive (Tralhao et al. 2014; Shrestha et al. 2016). 
A multitude of in vitro studies have investigated the anti-inflammatory effects of 
statins. Simvastatin treatment reduced the synthesis of inflammatory mediators from 
various cell types in culture, such as human umbilical vein endothelial cells, human 
primary macrophages, vascular smooth muscle cells and synoviocytes collected from 
patients with rheumatoid arthritis (Rezaie-Majd et al. 2002; Dichtl et al. 2003; Veillard 
et al. 2006; Xu et al. 2006). Simvastatin lowered the pro-inflammatory cytokine TNF 
and increased IL-10 production from macrophages, as well as significantly reducing 
IκBα degradation and NF-κB translocation in vitro (Leung et al. 2011). Pravastatin 
significantly reduced LPS-stimulated IL-6, IL-8 and GM-CSF protein production in 
human bronchial epithelial cells (Iwata et al. 2012). Pravastatin concentration-
dependently reduced CRP, IL-6 and TNF at the gene and protein level in rat vascular 
smooth muscle cells. Pravastatin also downregulated the release of pro-inflammatory 
mediators, TNF and CCL2, from human monocytes (Grip et al. 2000). 
Statins have differential effects on the inflammatory response. For example, an in vitro 
study assessed the ability of six statins to inhibit LPS-induced NF-κB binding activity 
in human monocytes. All statins reduced the phosphorylation and degradation of IκB 
with cerivastatin being the most potent, followed by atorvastatin, simvastatin, 
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pravastatin, lovastatin then fluvastatin. This should be taken into account when 
selecting a statin with the aim of anti-inflammatory benefits (Hilgendorff et al. 2003).  
Statin administration has also been associated with the induction of pro-resolving lipid 
mediators with strong anti-inflammatory properties, such as 15-epi-lipoxin-A4. 
Atorvastatin increased the production of 15-epi-lipoxin-A4 levels in the rat 
myocardium (Birnbaum et al. 2006). In a mouse model of airway mucosal injury and 
inflammation, lovastatin treatment increased the production of 15-epi-lipoxin-A4 and 
consequently, reduced lung inflammation (Planaguma et al. 2010). Lovastatin and 
simvastatin also stimulated the biosynthesis of 15-epi-lipoxin-A4 during interactions 
between human neutrophils and airway epithelial cells in vitro (Planaguma et al. 2010). 
Although the mechanisms by which statins have anti-inflammatory effects are not fully 
elucidated, they are thought to involve the inhibition of protein isoprenylation in the 
mevalonate pathway (Wang et al. 2008).  
1.3.5.4 Anti-contraction properties 
Recent studies have demonstrated that statins have anti-contractile effects. Most of 
these studies have focused on the cardiovascular system, where statins have been 
shown to reduce the contractile response of vascular smooth muscle cells in vitro 
(Kuzuya et al. 2004; Mraiche et al. 2005; Perez-Guerrero et al. 2005; Nasu et al. 2009; 
Gonzalez et al. 2014). Statins also have a relaxant effect on rat aortic rings (Mraiche 
et al. 2005; Sonmez Uydes-Dogan et al. 2005; Rossoni et al. 2011; Alp Yildirim et al. 
2016; Chen et al. 2016). 
This anti-contractile effect has been reported in other cell types, such as endometriotic 
stromal cells and lung fibroblasts (Nasu et al. 2009; Ra et al. 2011). In addition, organ 
bath studies have reported anti-contractile effects of simvastatin. For instance, pre-
treatment with simvastatin reduced the frequency of spontaneous and C5a-induced 
contraction of human myometrial samples, as well as in myometrial tissue collected 
from simvastatin-treated mice (Gonzalez et al. 2014). Rosuvastatin induced relaxation 
in cardiac veins isolated from calf hearts (Nurullahoglu-Atalik et al. 2015). 
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These properties have been associated with mevalonate-related pathways, more 
specifically, the inhibition of Rho geranylgeranylation and the subsequent inhibition 
of ROCK activation (Mraiche et al. 2005; Sonmez Uydes-Dogan et al. 2005; Nagaoka 
et al. 2007; Alp Yildirim et al. 2016). The anti-contraction effect has also been 
demonstrated further downstream of the Rho/ROCK pathway as statin treatment 
reduces the phosphorylation of MLC, which is crucial to facilitate smooth muscle 
contraction. Zeng et al. (2005) reported that simvastatin inhibited the contraction of 
glomerular endothelial cells by preventing RhoA activation and subsequent MLC 
phosphorylation. Lovastatin treatment prevented endothelial cell motility in vitro due 
to Rho inactivation and actin depolymerisation (Xiao et al. 2012). Similar studies have 
been performed in multiple cell types, which have demonstrated that the mechanism 
by which statins exert their anti-contraction pleiotropic effects is by inhibiting 
Rho/ROCK, thus preventing MLC phosphorylation (Alvarez de Sotomayor et al. 
2001; Mraiche et al. 2005; Kuhlmann et al. 2006; Nagaoka et al. 2007; Kidera et al. 
2010; Wu et al. 2011; Xiao et al. 2012; Alp Yildirim et al. 2016).  
Furthermore, statins can alter Ca2+ flux, which may be another mechanism by which 
statins affect contractility. Simvastatin altered the excitation-contraction coupling of 
rat skeletal muscle fibres by increasing cytosolic Ca2+ levels (Pierno et al. 1999). 
Fluvastatin and atorvastatin impaired the release of Ca2+ from the SR in rat skeletal 
muscle fibres resulting in elevated resting cytosolic Ca2+ concentration, which altered 
Ca2+ homeostasis (Liantonio et al. 2007). One study found that simvastatin impaired 
vascular contractility by modifying the influx of Ca2+ and disturbing RhoA activity 
(Kang et al. 2014). Simvastatin relaxed rat superior mesenteric artery rings in vitro, 
which was associated with the opening of voltage-dependent K+ channels and the 
blocking of extracellular Ca2+ influx (Chen et al. 2016). Simvastatin, atorvastatin, 
fluvastatin and rosuvastatin also had antagonistic effects on voltage-gated Ca2+ 
channels, inhibiting the contraction of gastrointestinal tissue in an organ bath study 
(Ali et al. 2016). 
1.3.5.5 Anti-proliferative and pro-apoptotic properties 
Statins can inhibit cell proliferation and induce cell apoptosis. These pleiotropic affects 
have proved beneficial in the development of cancer therapies. Recently, it was 
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reported that long term statin use is associated with a reduced risk of many 
haematological malignancies (Pradelli et al. 2015). A large scale study assessing the 
relationship between statin use and cancer-related mortality in the Danish population 
found reduced cancer-related mortality with statin use (Nielsen et al. 2012). Statin 
users also have a lower risk of breast cancer recurrence and there is a reduced risk of 
malignancy-related death in post-menopausal women (Sakellakis et al. 2016; Wang et 
al. 2016). Furthermore, statin treatment is associated with reduced cancer-related 
mortality in prostate cancer patients (Raval et al. 2016).  
Statins exert pro-apoptotic, anti-proliferative, anti-inflammatory and 
immunomodulatory effects, which may prevent tumour growth and metastasis (Pisanti 
et al. 2014). Statins have pro-apoptotic effects in cancer cell lines, but some cell lines 
are more sensitive than others. This treatment can affect angiogenesis by 
downregulating vascular endothelial growth factor (VEGF) and preventing endothelial 
cell proliferation (Vallianou et al. 2014). 
Studies have demonstrated anti-proliferative and pro-apoptosis effects in cancer of the 
breast, colon, prostate, lung and liver with statin treatment. These effects were 
attributed to statins inhibiting small GTPases, such as RhoA, and pathways such as 
PI3K/Akt. Anti-invasion and anti-migration effects have been reported in breast, 
prostate, renal and colon cancer. In addition, atorvastatin and lovastatin were 
associated with overcoming drug resistance to chemotherapeutic drugs in lung cancer 
xenograft models (Pisanti et al. 2014).  
To summarise, statins have a number of properties in addition to lowering LDL 
cholesterol concentration. They can treat endothelial dysfunction, they have anti-
oxidative stress properties as well as immunomodulatory, anti-inflammatory and anti-
contraction properties. Furthermore, they have recently been investigated as a 
treatment for a multitude of cancers as a result of their anti-proliferative and pro-
apoptotic properties.  
1.3.6 Statin treatment for obstetric complications 
Of late, animal and human studies have described the use of statins to prevent 
pregnancy complications, such as intrauterine growth restriction (IUGR), 
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antiphospholipid syndrome, recurrent miscarriage, preeclampsia and PTB (Redecha et 
al. 2008; Redecha et al. 2009; Gonzalez et al. 2014; Costantine et al. 2016; Lefkou et 
al. 2016). 
Simvastatin and pravastatin treatment prevented fetal loss and IUGR in a mouse model 
of antiphospholipid-induced pregnancy loss. The expression of tissue factor, a crucial 
mediator in antiphospholipid-induced pregnancy loss, was downregulated on 
neutrophils collected from statin treated mice. Statin treatment also prevented 
neutrophil activation and reduced ROS production, preventing placental oxidative 
damage (Redecha et al. 2008). 
Pravastatin treatment also prevented pregnancy loss in a model of recurrent 
spontaneous miscarriage generated by mating CBA/J and DBA/2 mice. Pravastatin 
prevented fibrin deposition in the placentas of these mice and reduced tissue factor 
expression, which led to reduced plasma levels of the angiogenic molecule soluble 
fms-like tyrosine kinase (sFlt-1) in these mice. This restored placental blood flow and 
prevented oxidative stress by increasing NO levels (Redecha et al. 2009). This CBA/J 
x DBA/2 mouse model has also been suggested as a model of preeclampsia (Ahmed 
2011).   
Preeclampsia is one of the major causes of maternal and neonatal morbidity. Factors 
contributing to this syndrome are thought to include an imbalance of angiogenic 
factors, such as VEGF, placental growth factor (PGF), sFlt-1 and soluble endoglin 
(sENG), resulting in insufficient trophoblast invasion into the uterus and remodelling 
of the spiral arterioles. This causes placental hypoxia, endothelial dysfunction and the 
release of inflammatory mediators and vasoactive factors that induce maternal effects, 
such as hypertension and proteinuria (Costantine et al 2010).  
One study reported that simvastatin reduced VEGF-induced sFlt-1 release from 
normal, term placental villous explants. Simvastatin also reduced VEGF-induced sFlt-
1 release and upregulated HO-1 in human umbilical vein endothelial cells in vitro. This 
suggested a potential role for statins in the treatment of preeclampsia (Cudmore et al. 
2007). Brownfoot et al. (2016) investigated the effect of simvastatin, rosuvastatin and 
pravastatin on sFlt-1 and sENG secretion on primary human umbilical vein endothelial 
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cells, trophoblast cells and preterm preeclamptic placental explants. Simvastatin was 
the most effective inhibitor of sFlt-1 secretion in these three models. All statins 
increased sENG secretion from endothelial cells and upregulated HO-1. This increase 
in sENG is concerning as sENG contributes to the pathogenesis of preeclampsia. 
However, reassuringly, sENG secretion was not increased in the placental explants 
following statin treatment (Brownfoot et al. 2016). 
In a sFlt-1 overexpression mouse model of preeclampsia, pravastatin lowered serum 
sFlt-1 levels and improved vascular function when the carotid arteries of these mice 
were subjected to in vitro reactivity experiments (Costantine et al. 2010). Kumasawa  
et al. (2011) developed a unique model of preeclampsia by transplanting blastocysts 
transduced with a lentiviral vector expressing human sFLT-1 into pseudopregnant 
mice, producing a placenta-specific expression system. This model exhibited 
hypertension, proteinuria and IUGR. Pravastatin ameliorated these preeclampsia-like 
symptoms and induced both placental and non-placental Pgf expression, which may 
have aided the prevention of endothelial dysfunction (Kumasawa et al. 2011). 
Pravastatin treatment also has fetal protective effects in mouse models of 
preeclampsia. The offspring from a sFlt-1 overexpression model displayed poor 
vestibular function, balance and coordination. These side effects were prevented when 
preeclamptic mothers received pravastatin during gestation (Carver et al. 2014). In this 
model, offspring also exhibited delayed growth and pravastatin normalised this 
(McDonnold et al. 2014). 
Two clinical trials have investigated the effect of pravastatin for the prevention and 
treatment of preeclampsia; one trial involved women at high risk of preeclampsia and 
the other trial was assessing women with early onset preeclampsia.  
The first study performed a randomised controlled trial to investigate the safety and 
pharmacokinetics of pravastatin treatment in 20 women; 10 treated with pravastatin 
and 10 treated with placebo. Women at high risk of preeclampsia were treated with 
10mg/day pravastatin between 12 and 16 weeks gestation until delivery. Four subjects 
out of ten in the placebo group developed preeclampsia, whereas none of the ten 
subjects in the pravastatin group developed preeclampsia. The placebo group also had 
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five indicated preterm deliveries compared to only one in the pravastatin group. 
Maternal cholesterol levels were reduced by the treatment but the levels of cholesterol 
in the umbilical cord were unaltered and birthweights were not different between 
groups. No differences in drug side effects or congenital malformations were found 
between the pravastatin and placebo group. Overall, no safety risks were identified 
with this treatment (Costantine et al. 2013; Costantine et al. 2016).  
The second study, a proof of concept trial, investigated the effect of 40mg/day 
pravastatin treatment on early onset preeclampsia when prescribed between 24 and 
31+6 weeks gestation. This trial assessed the ability of pravastatin to restore 
angiogenic balance by measuring adverse biomarkers associated with preeclampsia in 
the maternal circulation, as well as collecting safety data. Recruitment of women for 
this trial is complete. However, the results are still to be reported (Statins to Ameliorate 
early onset Preeclampsia (StAmP); www.controlled-trials.com/ISRCTN23410175). 
Pravastatin treatment also improves pregnancy outcomes in women with anti-
phospholipid syndrome. Eleven women who were receiving conventional 
antithrombotic treatment for antiphospholipid syndrome were prescribed pravastatin 
on the diagnosis of preeclampsia or IUGR. Women treated with both pravastatin and 
antithrombotic treatment exhibited increased placental blood flow and preeclamptic 
features were improved, compared to subjects receiving antithrombotic treatment only. 
The addition of pravastatin treatment resulted in live births that occurred close to term 
in all subjects. Importantly, there were no fetal abnormalities reported (Lefkou et al. 
2016). 
Statins have also demonstrated anti-inflammatory effects in a mouse model of 
systemic maternal infection. When pregnant mice were treated with simvastatin prior 
to an intraperitoneal injection of LPS, Il-1β and Il-6 mRNA expression were reduced 
in the uterus, as well as Il-6 and Tnf in the cervix, compared to LPS only treated mice 
(Basraon et al. 2012). A wide range of LPS-induced inflammatory cytokines were also 
reduced in the maternal serum by the simvastatin treatment. Pravastatin treatment 
reduced LPS-induced Il-1β and Il-6 mRNA expression in the uterus and cervix, 
respectively and serum levels of IL-1β and GM-CSF were also reduced (Basraon et al. 
2012).  
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Pravastatin and simvastatin treatment prevented PTB in a mouse model of ascending 
infection. The authors described a reduction in MMP activity and collagen I content in 
the cervix, indicating that statin treatment prevented cervical remodelling. They also 
reported a reduction in complement-induced contraction of mouse and human 
myometrial strips with simvastatin and pravastatin treatment (Gonzalez et al. 2014). 
However, the total sample size of mice in this study was relatively small, with group 
numbers of 5-7 mice per treatment, and the mechanisms of action of statins were not 
fully elucidated. In addition, the key role of inflammation was not addressed in these 
studies. A similar study using the same PTB model found that statins had 
neuroprotective properties following fetal exposure to LPS. This treatment reportedly 
prevented fetal brain cortical abnormalities, evidenced by a reduction in caspase-3 
staining, and LPS-induced cortical neuron disruption was ameliorated. These effects 
were associated with the Akt/PKB signalling pathway (Pedroni et al. 2014).  
Pravastatin also displayed fetal protective effects in a mouse model of glucocorticoid 
overexposure by treating placental vascular defects. In mice lacking 11β-
hydroxysteroid dehydrogenase type 2 (11β-HSD2), there was a reduction in umbilical 
blood velocity and the fetuses exhibited signs of cardiac dysfunction. Pravastatin 
treatment increased the vascularisation, increased the placental fetal capillary volume 
and improved umbilical cord velocity. These effects resulted in normalised fetal 
weight and improved fetal cardiac function. This suggests that statin treatment may be 
a useful therapeutic for fetal growth restriction as it may improve the development of 
the placental vasculature (Wyrwoll et al. 2016). 
1.3.7 The safety profile of statins  
In general, statins have few serious side effects and are relatively well tolerated. The 
most reported side effect of statin use is myalgia, in which rates vary from 1-10% of 
users. The most serious side effect is rhabdomyolysis, which occurs in less than 0.1% 
of users (Ramkumar et al. 2016). Some statin users report side effects such as muscle 
weakness, muscle pain or aching, stiffness, muscle tenderness, cramps and arthralgia, 
which implies that statins may induce myotoxicity. However, the prevalence of statin-
induced myotoxicity has been debated due to unclear definitions of the condition, 
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clinical reports are hugely variable and large randomised clinical trials are not always 
representative of clinical practice (du Souich et al. 2017).  
The risk factors for statin-induced myopathy are hypothyroidism, drug-drug 
interactions, reduced activity of liver membrane transporters and conditions such as 
mitochondrial damage or increased ROS. Polypharmacy is an issue with statin 
treatment due to a number of therapeutics interacting with the CYP enzyme group. 
Inhibitors of CYP enzymes may lead to an elevation of statin levels, which increases 
the risk of toxicity. Common causes of interactions include gemfibrozil, a fibrate that 
also lowers lipids and interacts with CYP3A4 enzyme, and grapefruit juice, which 
potently inhibits CYP3A4. Conversely, anti-epileptic drugs are inducers of the 
CYP3A4 enzyme, which can reduce statin concentration and therefore, their 
effectiveness. As pravastatin is metabolised independently of the CYP system, it does 
not have many drug interactions (Ramkumar et al. 2016).  
A recent meta-analysis concluded that while high doses of statins reduce the risk of 
cardiovascular disease, they could increase the risk of type 2 diabetes. These 
differential metabolic effects cannot currently be explained and further research must 
be performed to fully understand these additional statin effects (Lim et al. 2014). 
However, the benefits of cardiovascular protection and reduced mortality with statin 
treatment outweigh the risk of developing type 2 diabetes (Castro et al. 2016). 
Overall, statin treatment is considered to be safe for most people. Statins should be 
prescribed with caution to those with multiple co-morbidities. In cases of 
polypharmacy, pravastatin may be the ideal statin as it has fewer drug interactions. 
1.3.7.1 Statin use in pregnancy 
Statins are defined as category X by the FDA for use in pregnancy and are generally 
contraindicated for pregnancy use worldwide. Currently, safety data obtained during 
pregnancy comes from women using statins during the early weeks of an unidentified 
or unplanned pregnancy.  
The FDA categorisation was based on early animal studies that demonstrated 
teratogenic potential with the use of exceptionally high concentrations of statins 
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(Minsker et al. 1983). However, the fetal skeletal abnormalities in these studies have 
been attributed to maternal toxicity-induced nutritional deficiency rather than 
teratogenic effects (Lankas et al. 2004). There are also concerns that statin treatment 
may affect cholesterol biosynthesis in the developing fetus. In addition, the inhibition 
of isoprenoids and other factors involved in intracellular signalling are associated with 
the insulin-like growth factor system. This system is necessary for placental 
development and its disruption could also contribute to adverse outcomes (Forbes et 
al. 2008; Forbes et al. 2015). 
Most teratogenic evidence is associated with the older, more commonly prescribed, 
lipophilic statins lovastatin and simvastatin. There is limited information on the effects 
of pravastatin and the newer statins, rosuvastatin and pitavastatin, in pregnancy 
(Godfrey et al. 2012). 
A retrospective observational study by Edison and Muenke (2004) reported that there 
was an increase in fetal limb defects after simvastatin exposure during the first 
trimester. The authors associated these defects with defective cholesterol metabolism. 
However, these findings have since been criticised and challenged by larger studies, 
which found that there was no greater risk when comparing to population baseline 
levels of fetal malformations (Gibb and Scialli 2005; Petersen et al. 2008; Bateman et 
al. 2015).  
The most recent evidence comes from a well-designed epidemiological study 
performed by Bateman et al. (2015). This study assessed pregnancy and childbirth in 
data collected from a large cohort of 1152 women in the USA between 2000 and 2007. 
They assessed the risk of major congenital malformations, as well as organ specific 
malformations, in the offspring of women who used statins during the first trimester 
of pregnancy. High density propensity scoring was used to control for confounding 
factors, such as maternal medical condition, particularly diabetes, the use of other 
medication, as well as demographic factors. The unadjusted results suggested a slight 
increase in the risk of congenital malformation with first trimester statin use. However, 
this risk disappeared once confounders were taken into account. There was no 
increased risk of organ specific malformations found. This analysis was performed on 
low income women and so cannot be generalised. However, as these women are at 
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greater risk of poor pregnancy outcomes, these results can also be regarded as 
reassuring for those from higher income surroundings (Haramburu et al. 2015). A 
limitation of such a study is that it relies on treatment compliance, as the criteria of 
“statin use” is based only on dispensed prescriptions. There was also no information 
on issues during pregnancy, such as medical terminations and miscarriages, or long 
term effects (Bateman et al. 2015).  
As statins are not prescribed during pregnancy, there is no safety data on their use later 
in gestation when treatments for pregnancy disorders are likely to be given. 
Furthermore, absence of risk is more difficult to prove. Therefore, more safety 
information is required. Pilot trials for pravastatin use in cases of preeclampsia are 
beginning to address this on a small scale, with group numbers of 10-11 women in 
these studies (Costantine et al. 2016; Lefkou et al. 2016). However, it is still too early 
to assess the long term effects of this exposure. Obstetric complications, such as PTB 
and preeclampsia, can result in life-long morbidity as well as maternal and neonatal 
mortality. Therefore, it can be argued that the possible benefits of statin treatment 
outweigh the risks in these instances. 
In conclusion, statins are well-tolerated drugs that potently inhibit the synthesis of 
cholesterol. These drugs also prevent the development of cardiovascular disease. 
Statins vary in their structure and this affects their potency, absorption and metabolism. 
All statins competitively inhibit the HMG-CoA reductase enzyme within the 
mevalonate pathway, inhibiting cholesterol production, as well as the synthesis of 
isoprenoids. This prevents the isoprenylation of small GTPases, which are intracellular 
signalling molecules responsible for cellular processes, such as proliferation, cell 
growth and remodelling of the actin cytoskeleton. Therefore, statins have anti-
inflammatory, immunomodulatory, antioxidant and anti-contraction effects. For this 
reason, statin treatment has been suggested for a range of inflammatory and 
autoimmune diseases and more recently as a cancer therapy. Statins show promise for 
the treatment of pregnancy disorders, such as IUGR, miscarriage, preeclampsia and 
antiphospholipid syndrome. One study has also suggested the use of statins to prevent 
PTB. However, this requires further investigation. Statin use is currently 
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contraindicated in pregnancy but large epidemiological studies have not found a 
teratogenic effect. Further safety investigations are required to confirm these findings.  
1.4 Summary 
This chapter firstly addressed the role of inflammation in labour. Term labour is an 
inflammatory process in which immune cells are primed in the circulation and infiltrate 
the intrauterine tissues. There is an increase in pro-inflammatory mediators, such as 
cytokines, chemokines and prostaglandins, at the maternal-fetal interface. These 
mediators initiate labour by stimulating myometrial contractions, cervical ripening and 
fetal membrane rupture. Uterine stretch and fetal signalling may also play a role in the 
initiation of labour. However, when this inflammatory cascade begins earlier in 
gestation this can lead to the pathological, preterm initiation of the labour process. PTL 
is difficult to predict and current treatments are ineffective at preventing PTB. As PTB 
is the leading cause of mortality in children, treatments must aim to protect the fetus 
from injury and improve neonatal outcome. Although the aetiology of PTL is unclear, 
the majority of cases have been associated with infection and inflammation. Tocolytic 
drugs do not substantially delay delivery and they do not improve the outcome of the 
premature babies. In addition, the efficacy of vaginal progesterone application has 
recently been questioned. Anti-inflammatory agents may be key to the successful 
prevention and treatment of PTL but many of these compounds are only at the early 
stage of testing and are not approved for human use. Drug development is extremely 
expensive and time-consuming and few drugs successfully complete the process. 
Many of these limitations may be overcome by repurposing a drug that is already FDA-
approved. Thus, statin treatment, with its many pleiotropic effects, may be an ideal 
therapeutic for PTL. 
Statins are used to reduce cholesterol levels and prevent cardiovascular disease. By 
inhibiting the mevalonate pathway, statins also inhibit the isoprenylation of small 
GTPases, which are involved in a multitude of cellular functions. The result is that 
statins are capable of regulating the immune system, reducing inflammation and also 
inhibiting the contraction of cells. These properties suggest statins could potentially 
target the underlying causes of PTL as well as inhibiting myometrial contraction. 
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Human studies have already reported the success of statin treatment in cases of 
preeclampsia. Therefore, statin therapy could be a novel approach for treating PTL.  
1.5 Hypothesis and aims 
The work presented in this thesis was based on the hypothesis that statins will prevent 
PTB by reducing inflammation.  
In order to address this hypothesis, the aims of the thesis were as follows: 
 To investigate the effect of statins on inflammation in the reproductive tract in 
vitro  
 To examine the effect of statins on the contractility of the myometrium in a cell 
line 
 To investigate the mechanisms by which statins affect either contractility or 
inflammation in PTL 
 To determine whether statins can delay/prevent PTB or improve neonatal 
outcome in an LPS-induced mouse model of PTB.
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2.1 Myometrial cell culture 
2.1.1 Pregnant human myometrial 1-41 (PHM1-41) cell 
line 
PHM1-41 cells are commercially produced myometrial smooth muscle cells, which 
were isolated from a pregnant, non-labouring woman at 39 weeks gestation. The cells 
were immortalised and selected by resistance to Geneticin (G418) by Monga et al. 
(1996). The cells were originally selected for smooth muscle cell morphology but they 
were not derived by limiting dilution cloning. Therefore, this PHM1-41 myometrial 
cell line may be a polyclonal population of cells. These cells are morphologically and 
phenotypically similar to cultured primary myometrial cells and have previously been 
used for studies investigating gene expression, ion channel activity, oxytocin 
signalling pathways and contraction-associated pathways (Monga et al. 1996; 
Hutchinson et al. 2014; Rajagopal et al. 2015; Makieva et al. 2016). The cell line was 
purchased at passage 12 and used up to passage 22 (PHM1-41 ATCC® CRL-3046™, 
LGC Standards, Teddington, UK). In the experiments outlined in this chapter, the 
PHM1-41 myometrial cells were cultured in 4.5g/L high glucose Dulbecco's Modified 
Eagle Medium (DMEM; BE12-709F, Lonza, Slough, UK) supplemented with 10% 
fetal bovine serum (FBS; Gibco, Life Technologies, Paisley, UK), 1% 
Penicillin/Streptomycin (P/S; Sigma-Aldrich, Poole, UK), 1% L-Glutamine (Sigma-
Aldrich) and 0.1mg/ml G418 sulfate (Geneticin, Gibco, Life Technologies). During 
experiments, G418 sulfate was omitted from the culture medium. Partial serum 
starvation was carried out in 4.5g/L high glucose DMEM supplemented with 5% FBS, 
1% P/S and 1% L-Glutamine. All incubations were carried out at 37°C, in a 
humidified, 5% carbon dioxide (CO2) atmosphere.  
2.1.2 Sub-culturing myometrial cells 
To sub-culture the PHM1-41 myometrial cells, medium was removed and cells were 
washed twice with sterile phosphate buffered saline (PBS; Life Technologies). 
Trypsin-Ethylenediaminetetraacetic acid (EDTA; Lonza) was added to the flask 
(Sarstedt, Nümbrecht, Germany) and incubated for 2-3 minutes, until cells detached. 
Cells were collected in 10% FBS DMEM, with 1% P/S, 1% L-Glutamine and 
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0.1mg/ml G418, to neutralise the trypsin-EDTA and cells were counted using a 
haemocytometer. The cell suspension was centrifuged at 300 x g for 5 minutes. Cells 
were then resuspended in complete culture medium and seeded at 1-3x106 cells/T75 
flask or 2-4x106 cells/T162 flask. Medium was changed every 2 days until the cells 
were confluent.  
2.1.3 Mycoplasma testing 
Before beginning a new set of experiments, the myometrial cells were routinely 
monitored for mycoplasma, using the MycoAlert™ Mycoplasma Detection Kit 
(Lonza). This assay detects the presence of enzymes released from lysed mycoplasma, 
which react with the MycoAlert™ substrate, catalyzing the conversion of adenosine 
diphosphate (ADP) to adenosine triphosphate (ATP). The ATP level is measured 
before and after MycoAlert™ substrate addition. Elevated ATP levels signify the 
presence of mycoplasmal enzymes. Mycoplasma testing was performed by Dr Forbes 
Howie (Specialised Assay Service, University of Edinburgh). 
Cells were seeded at 1.5x105 cells/ml (3x105 cells in 2ml) in 6-well plates and cultured 
in 10% FBS DMEM, omitting P/S and G418, for 48 hours. An aliquot of medium was 
removed and centrifuged at 200 x g for 5 minutes, to remove cell debris and 100µl of 
supernatant was collected for analysis.  The MycoAlert™ reagent was then added in 
an equal volume of 100µl and the samples were incubated for 5 minutes at room 
temperature. The first luminescence reading was then taken on a FLUOstar OPTIMA 
(BMG Labtech, Ortenberg, Germany). Then, 100µl MycoAlert™ substrate was added 
to the sample, followed by a 10 minute incubation at room temperature. The 
luminescence was then read again and the ratio between the two readings was 
calculated. Ratios greater than 1.2 suggested mycoplasma contamination.  
2.2 Treatment preparation 
Pravastatin (P4498; Sigma-Aldrich) was dissolved directly in sterile PBS and stored 
in a stock solution of 5mg/ml at 4°C for up to 1 month. A simvastatin (S6196-25MG; 
Sigma-Aldrich) stock solution was prepared by dissolving 4mg of the drug in 100μl of 
ethanol (EtOH) and 150μl of 0.1N sodium hydroxide (NaOH) and incubated at 50°C 
for 2 hours. The stock solution was adjusted to pH7 with 5N hydrogen chloride (HCl). 
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The volume was made up to 1ml using sterile PBS, which was filter sterilised using a 
0.22µm filter (Millipore, Billerica, MA, USA) and stored at 4°C for up to 1 month. 
Lipopolysaccharide (LPS; E. coli 0111:B4, L3024, Sigma-Aldrich) was reconstituted 
in sterile PBS, aliquoted and stored at -20°C. (±)- Mevalonolactone (M4667; Sigma-
Aldrich) was diluted 1 in 10 in EtOH to produce a stock solution, as required. Farnesyl 
pyrophosphate ammonium salt (F-PP; F6892, Sigma-Aldrich) and Geranylgeranyl 
pyrophosphate ammonium salt (GG-PP; G6025, Sigma-Aldrich) were purchased in 
solutions of 2500µM and 2000µM, respectively, in methanol (CH3OH). Mevalonate, 
F-PP and GG-PP were all stored at -20°C. All treatment dilutions were performed with 
sterile PBS to achieve final treatment concentrations. 
2.3 Pravastatin and simvastatin treatment of 
myometrial cells 
Cells were seeded at 1.5x105 cells/ml (3x105 cells in 2ml) in 6-well plates and then 
partially serum-starved in DMEM containing 5% FBS, 1% P/S and 1% L-Glutamine, 
for 24 hours at 37°C. Cells were stimulated with 100ng/ml LPS and treated in duplicate 
either simultaneously with pravastatin (10µM) or simvastatin (0.1µM, 10µM, 50µM), 
or pre-treated or post-treated with pravastatin/simvastatin (Figure 2.1) and incubated 
for 24 hours at 37°C. Control wells were included with PBS only, LPS (100ng/ml) 






Figure 2.1. Statin and LPS treatments of myometrial cells. Cells received one of three treatment 
regimens, each with a total incubation time of 24 hours. LPS and statins were either co-administered or 
cells were first pre-treated with statins (6 hours) or received statin treatment 6 hours post-LPS 
stimulation. 
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2.4 Myometrial cell image capture 
Images of the cells were captured following 24 hours of co-treatment, pre-treatment 
and post-treatment of statins and LPS, to assess any effects on cell morphology. Image 
capture was performed using a Leitz Labovert microscope with a x10 objective lens 
and a Zeiss AxioCam ICc1 camera. Imaging was performed using Zeiss ZEN (2011) 
software. 
2.5 MTT metabolic activity assay 
Cell metabolic activity was assessed for all treatments by measuring the ability of 
myometrial cells to metabolise 3-(4, 5-dimethylthiazol-2yl)-2, 5-diphenyltetrazolium 
bromide (MTT; Sigma-Aldrich). The metabolism of yellow tetrazolium MTT by living 
cells results in purple formazan, which can be solublised and quantified by a 
spectrophotometer. The cells were seeded at 104 in a 96-well plate and treated with 
pravastatin (1, 10, 100µM), simvastatin (0.1, 1, 10, 25, 50, 100µM), LPS (25, 
100ng/ml), mevalonate (200µM), GG-PP (10µM) or F-PP (10µM) for 24-48 hours, in 
triplicate. MTT solution was applied for the final 4 hours of the 24-48 hour treatments, 
at 37°C. The medium was removed and 100µl acidified isopropanol was added for 20 
minutes, then light absorbance was the measured at 540nm (LabSystems Multiskan 
EX). 
2.6 Collagen gel contraction assay 
2.6.1 Collagen gel preparation  
A collagen gel contraction assay was utilised to assess the effect of simvastatin on the 
contraction of myometrial cells and was performed as previously described by our 
laboratory (Hutchinson et al. 2014). The collagen utilised was a kind gift from Dr Alex 
Henke (Shire Pharmaceuticals, Lexington, MA, USA), which was prepared from rat 
tails, as previously described (Bell et al. 1979). Briefly, frozen rat tails were thawed in 
70% EtOH for 20 minutes. The tendons were then removed, minced and placed in 
dilute acetic acid (250ml/tail) for 48 hours, with gentle agitation, at 4°C. The resulting 
solution was centrifuged at 14, 000 x g for 1 hour. The supernatant was removed and 
this crude collagen solution was refined by the addition of 0.1M NaOH in a 6:1 ratio. 
This neutralised the acetic acid and caused the collagen to precipitate. The mixture was 
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centrifuged at 300 x g for 5 minutes, the supernatant was discarded and an equal 
volume of fresh acetic acid was added to resolubilise the collagen. This solution was 
stored at 4°C until required for the collagen gel contraction assay. Simvastatin 
concentration response experiments used the remainder of this collagen solution. 
Therefore, all other experiments were performed using commercially available Type I 
rat tail collagen (2ml; A1048301, ThermoFisher Scientific, Hemel Hempstead, UK). 
2.6.2 Collagen gel casting and contraction assay 
Myometrial cells were washed twice in PBS and trypsinised, then resuspended in 10% 
FBS DMEM with 1% P/S and 1% L-Glutamine at 1x106 cells/ml. Non-treated 24-well 
plates were utilised, to prevent cell adherence (3738, Costar®, Corning, NY, USA). 
NaOH (0.1M) was prepared in water (H2O), sterile filtered using a 0.22μM filter and 
syringe, and stored at 4°C until required. To seed a full non-treated 24-well plate, 2.4ml 
of the cell suspension was transferred to a fresh, chilled tube on ice and 5.6ml medium 
was added (105 cells/well). To the cells, 1.2ml 0.1M NaOH was added and the cell 
suspension was divided evenly. The following steps were carried out quickly on ice. 
Rat tail collagen (either the crudely extracted or commercially available type I rat tail 
collagen) was added to each tube in a volume of 2ml, pipetting gently to mix, while 
avoiding bubbling, to prevent polymerisation. The collagen cell suspension (500µl) 
was added to a 24-well plate, working vertically, up and down columns for symmetric 
distribution. The collagen gels were allowed to polymerise overnight, incubated at 
37°C. The collagen gels were then partially serum-starved for 2 hours with medium 
containing 5% FBS, 1% P/S and 1% L-Glutamine. The collagen gels were gently 
detached and treatments were added in 6 technical replicates. Treatments included 
simvastatin (0.1, 1, 10, 25, 50, 100μM), LPS (25, 50, 100, 200, 300, 400ng/ml), 
mevalonate (100, 200μM), GG-PP (10, 20, 40μM) and F-PP (10, 20, 40, 80, 100μM). 
The plates were incubated at 37°C and photographed at 0, 24 and 48 hours using a 
Leica MZ6 light microscope/camera (Mayfair, UK) on the ICD and 2x2 colour binning 
settings. Images were captured using Leica Firecam software (v3.4.1). ImageJ 
(National Institutes of Health, Bethesda, MD, USA) was used to measure collagen gel 
area. 
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2.7 In-Cell Western assay 
In-Cell Western analyses (Figure 2.2) were performed to quantify pMLC in 
myometrial cells, as previously described (Hutchinson et al. 2014). In brief, cells were 
seeded at 2x104 cells/well in a volume of 200µl 10% FBS DMEM with 1% P/S and 
1% L-Glutamine in black 96-well, clear base plates (6005225; Perkin Elmer, Waltham, 
MA, USA) and incubated overnight at 37°C. The cells were partially serum starved 
with 5% FBS DMEM containing 1% P/S and 1% L-Glutamine for 2 hours, then 
treatments (Figure 2.2) were applied in triplicate for 48h, at 37°C. Following 
incubation, treatments were removed by inverting the plates and cells were fixed with 
4% formaldehyde (Sigma-Aldrich) for 15 minutes at room temperature. The fixative 
was removed and the cells were washed and permeablised 3 times with 0.1% Triton 
X-100 (BDH Laboratory Supplies, Poole, UK) in PBS for 5 minutes on a rocker at 
room temperature. Plates were blocked with Odyssey® blocking buffer (PBS) (P/N 
927-40000; LI-COR Biosciences, Lincoln, NE, USA) for 1 hour at room temperature. 
Primary antibodies of interest (Table 2.1) were diluted in Odyssey® blocking buffer 
then applied in a volume of 50µl/well, followed by an overnight incubation at 4°C. 
The plates were then washed in 0.5% PBS TWEEN® 20 (PBST), 3 times for 15 
minutes, on a rocker at room temperature. The secondary antibodies (Table 2.1) were 
diluted in Odyssey® blocking buffer and 50µl/well was added for 2 hours at room 
temperature, in the dark. The plates were washed again, as before with PBST, in the 
dark. The Odyssey® CLx Imaging System (LI-COR Biosciences) was used to read the 
plates and measure the signal in each well. The intensity of pMLC fluorescence was 
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Figure 2.2. Schematic representation of the In-Cell Western assay. Cells were treated with 
simvastatin (10µM, 50µM) and supplemented with LPS (25ng/ml), mevalonate (200µM), GG-PP 
(10µM) or F-PP (10µM), then fixed and incubated with primary antibodies for pMLC and α-Tubulin, 







































Table 2.1. Primary and secondary antibodies for In-Cell Western analyses 
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2.8 Mouse model of preterm birth 
2.8.1 Animal studies 
All animal studies were conducted under a UK Home Office licence to Professor J.E. 
Norman (70/8927) in line with the Animal Scientific Procedures Act (1986). To carry 
out procedures, all researchers were required to have a personal licence and maintain 
up-to-date training records on procedures. All new practical work was reviewed with 
the Named Training and Competency Officer (NTCO) and a Named Veterinary 
Surgeon (NVS) prior to commencing any training. Practical training was carried out 
under the supervision of an appropriate trainer until deemed competent to perform the 
procedure unsupervised. All new experiments were reviewed by the NVS before mice 
were ordered from Charles River Laboratories (Margate, UK). The principles of “the 
three Rs”, reduction, replacement and refinement, were adhered to as far as possible. 
Annual Returns of Procedures were completed and sent to the Home Office providing 
details of procedures carried out, the severity of the procedures and the number of 
animals used. 
Animals were acclimatised for 10 days prior to timed-mating, while housed in groups 
of 5 or 6 and provided with food and water. Timed-matings and plug checks were 
carried out by animal house technician, Mike Dodds. Gestational day one (D1) was 
designated when the vaginal plug was found. After procedures were performed, the 
pregnant mice were housed separately and monitored for signs of delivery. 
Temperature (19-23°C) and humidity (~55%) were tightly controlled, with constant 
light/dark cycles (12 hours/12 hours). 
Animals were sacrificed in accordance with Schedule 1 (Animals Scientific 
Procedures Act, 1986). Dams were sacrificed by the inhalation of rising concentrations 
of CO2 into a sealed chamber. Death was confirmed by cervical dislocation, using a 
blunt instrument, or exsanguination, where the blood was drained. Pups were 
sacrificed by cervical dislocation.   
2.8.2 Ultrasound procedure 
The ultrasound procedure was performed by Mr Adrian Thomson (Preclinical 
Ultrasound Facility, University of Edinburgh, PIL: IC1F2EA12), as described by 
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Rinaldi et al. (2015b). On gestational D17, mice were randomly assigned to the 
treatment groups, then anesthetised with inhalation of isoflurane (5% for induction, 
1.5% for maintenance in oxygen) and positioned supine on the ultrasound stage. 
Abdominal hair was first clipped, then removed with depilatory cream. Warm 
ultrasound gel was then applied to the abdomen. Scans were performed with the Vevo 
770 high-frequency ultrasound scanner (FUJIFILM VisualSonics, Inc., Toronto, ON, 
Canada) with a RMV 707B probe (center frequency, 30 MHz). Temperature and heart 














Figure 2.3. Ultrasound-guided intrauterine LPS-induced PTB mouse model. (A) An example of a 
CD1 mouse lying supine on the ultrasound stage, receiving isoflurane through the nose cone, as the 
ultrasound probe guides the intrauterine injection. (B) An ultrasound image showing two amniotic sacs 
and the injection point in the intrauterine space. (C) Contrast agent was injected into the intrauterine 
space, between two amniotic sacs, to show feasibility. Images curtesy of Adrian Thomson or adapted 
from Rinaldi et al. (2015b). 
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2.8.3 LPS dose response trial for the ultrasound-guided 
intrauterine LPS-induced PTB mouse model  
Firstly, ultrasound was used to count the number of viable pups, then used to guide 
injection of LPS (0.3μg, 1μg, 3μg, 10μg, 15μg, 20μg in 25μl PBS; from E. coli 
0111:B4) or PBS (25μl) directly into the uterine lumen, between 2 gestational sacs, 
using a 33-gauge Hamilton syringe (Figure 2.3). Care was taken not to enter the 
amniotic cavity. Mice were kept at 30°C until recovered from surgery, then transferred 
to individual cages to be continuously monitored using individual closed-circuit 
television cameras and a digital video recorder. Time to delivery was recorded as the 
number of hours from the time of intrauterine injection of LPS/PBS to the delivery of 
the first pup. The number of live/dead pups was recorded within 24 hours of their 
delivery. The percentage of live born pups per litter was calculated by dividing the 
number of live pups found within 24 hours of delivery by the number of viable pups 
counted via ultrasound on D17. 
2.8.4 Statin treatment of the LPS-induced PTB mouse 
model 
On gestational D16, mice were restrained by grasping the scruff of the neck between 
the thumb and forefinger, while maintaining a grip on the tail, and given an 
intraperitoneal injection of simvastatin (20µg or 40µg in 200µl PBS), pravastatin 
(10µg in 200µl PBS) or PBS (200µl), using a sterile 0.5ml BD Micro-Fine Ultra™ 
0.3mm x 8mm (30 gauge) pen needle (Oxford, UK). This was performed by 
positioning the needle parallel to the line of the thigh, pushing through the centre of 
the posterior quadrant of the abdomen into the peritoneal cavity. By positioning the 
needle along the line of the leg, this avoids the bladder in the posterior abdomen and 
the liver anteriorly. Penetration was shallow so that only the tip of the needle entered 
the peritoneal cavity. These intraperitoneal injections were performed by Dr Heather 
MacPherson (PIL: I27C06758). Mice were then anaesthetised on D17 of pregnancy 
by the inhalation of isoflurane and ultrasound was used to confirm the number of viable 
fetuses. Following this, ultrasound was utilised to guide injection of LPS (1µg or 20µg 
in 25µl PBS) or PBS (25µl) into the uterus, between 2 gestational sacs.  Two hours 
later, the mice received another intraperitoneal treatment of pravastatin/simvastatin or 
PBS, administered as on D16 (Figure 2.4). Animals were allowed to recover from the 
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anaesthesia and were monitored for signs of labour and delivery of pups. All animals 
were randomly assigned to each group. Cage cameras were used to monitor animals 








Figure 2.4. Statin and LPS treatments for the PTB mouse model. Gestational day one (D1) was 
designated when the vaginal plug was found. On gestational D16, mice received an intraperitoneal 
injection of PBS, pravastatin or simvastatin. D17, either PBS or LPS was administered, as a control or 
to instigate PTB, respectively. This was followed by another intraperitoneal treatment 2 hours later.  
2.8.5 Tissue collection and storage 
In a separate cohort of mice, tissues and fluids were harvested 6 hours after intrauterine 
injection of PBS/LPS (Table 2.2). Dams were sacrificed by the inhalation of CO2, 
followed by exsanguination. Approximately 1ml of maternal blood was taken from the 
vena cava using a 25 gauge needle and 1ml syringe and allowed to clot in a 1.5ml 
Eppendorf for 1-2 hours at room temperature. The blood was then centrifuged at 2000 
x g for 20 minutes and the serum aliquoted and stored at -80°C. Maternal serum was 
also collected from another cohort of mice for liquid chromatography-tandem mass 
spectrometry (LC-MS/MS) analysis. These mice received one intraperitoneal injection 
of either 20µg simvastatin, 40µg simvastatin or PBS on gestational D17. Serum was 
collected 1 hour and 2 hours after treatment. 
Amniotic fluid was collected in a 1.5ml Eppendorf from each gestational sac using a 
pasteur pipette and pooled, resulting in one sample per dam. The amniotic fluid was 
stored on wet ice, then centrifuged at 8000 x g for 10 minutes at 4°C, aliquoted and 
stored at -80°C.  
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As the location of the intrauterine injection site was unknown due to the ultrasound 
procedure, uterus, placenta and fetal membrane samples were collected from both the 
left and right horn of each mouse. When analysing mRNA concentration, the average 
of the right and left horn tissues was taken per mouse. The cervix was cut in half to 
provide one sample for gene expression and one for histology. Fetal heart, lung and 
brain samples were also collected. Fetal plasma was collected in capillary blood 
collection tubes (Microvette® CB 300 µl, K2 EDTA, Sarstedt) and centrifuged at 2000 
x g for 5 minutes. The plasma was stored at -80°C. Samples taken for mRNA 
expression analysis were collected in RNAlater (Sigma-Aldrich). These samples were 
kept at 4°C overnight, then the RNAlater was removed and the samples were stored at 
-80°C until required. Samples for protein analysis were immediately frozen on dry ice, 
then stored at -80°C until required. Samples taken for histology were collected in 
neutral buffered formalin (NBF, Sigma-Aldrich) and then changed to EtOH (70%) 
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2.9 RNA extraction and reverse transcription 
2.9.1 RNA extraction from cells 
Cells were lysed using Buffer RLT (Qiagen Ltd., Maryland, USA) with beta-
mercaptoethanol (β-ME; Sigma-Aldrich) and further homogenised by repeated 
passage through a blunt 20-gauge needle (0.9mm diameter; BD Microlance™) in an 
RNase-free syringe (BD Plastipak™). An RNAeasy mini kit (Qiagen) was used to 
extract total RNA with the solutions supplied. EtOH (70%) was added to the 
homogenised lysate (v/v) and mixed well by pipetting. The sample was added to an 
RNeasy spin column within a 2ml collection tube and centrifuged for 15 seconds at 
8000 x g (10, 000 rpm). Columns were washed with 350μl Buffer RW1 by 
centrifugation for 15 seconds at 8000 x g (10, 000 rpm) to remove carbohydrates and 
proteins. DNase digestion, to eliminate genomic DNA contamination, was performed 
by adding 10μl DNase I stock, in 70μl Buffer RDD (Qiagen), directly onto the spin 
column membrane for each sample and these were then incubated for 15 minutes at 
room temperature. The columns were washed with RW1 as before. This was followed 
by two Buffer RPE washes, to remove salts, at 8000 x g (10, 000 rpm) for 15 seconds 
and 2 minutes, respectively. A further centrifugation was performed for 1 minute at 
full speed to eliminate any possible Buffer RPE carryover.  RNA was eluted from the 
spin column membrane using 30μl RNase-free H2O by centrifuging for 1 minute at 
8000 x g (10, 000 rpm). Extracted RNA was stored at -80°C until required. 
2.9.2 RNA extraction from tissue 
Tissue was lysed in 1ml TRI reagent® (Sigma-Aldrich) with one sterile 5mm stainless 
steel bead (Qiagen) per Eppendorf/sample. The tissue was lysed at 25Hz using a Tissue 
Lyser II (Qiagen), for 3 minutes, twice, with tubes rotated half way through. The 
samples were then incubated for 15 minutes at room temperature, then centrifuged at 
14, 000 x g for 10 minutes at 4°C. The supernatant was transferred to a 2 ml phase-
lock tube (5-PRIME, Hamburg, Germany) and 200µl 1-bromo-3-chloropropane (BCP; 
Sigma-Aldrich) added to each sample. The samples were vigorously shaken for 15 
seconds, incubated for 10 minutes at room temperature, then centrifuged at 14, 000 x 
g for 15 minutes at 4°C. The upper aqueous phase was transferred to a new 2ml 
Eppendorf and 550µl of EtOH (70%) added. The samples were then added to RNeasy 
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mini spin columns and RNA extraction carried out as described in section 2.9.1. The 
extracted RNA was again stored at -80°C until required. 
2.9.3 RNA quantification  
Nucleic acid concentration was quantified by measuring the absorbance of the sample 
at 260nm on a NanoDrop 2000c (ThermoFisher Scientific). RNA absorbs at 260nm, 
while contaminants, such as protein, absorb closer to 280nm. Therefore, the ratio of 
the absorbance at 260nm and 280nm indicated RNA purity. Ratios of 1.8-2.1 were 
considered acceptable. 
2.9.4 Reverse Transcription (RT) – Complementary DNA 
(cDNA) preparation 
Total RNA was reverse transcribed using the High Capacity cDNA Reverse 
Transcription kit (Applied Biosystems, Life Technologies) (Table 2.3). A 2X RT 
mastermix was prepared on ice. This included the following reagents; 10X RT buffer, 
25X deoxyribonucleotide triphosphates (dNTPs), 10X random primers, RNase 
inhibitor, MultiScribe™ RT enzyme and RNA-free H2O. RNA (300ng/µl) was added 
to the mastermix and pipetted gently to mix, then centrifuged at 10, 000 rpm for 30 
seconds to remove any air bubbles. A “no reverse transcriptase” control was included, 
omitting the enzyme, to control for genomic DNA contamination. A “no template” 
control, omitting the RNA, was included to control for general contamination of 
reagents. A G-Storm GS1 Thermal Cycler (G-Storm, Somerset, UK) was set to 
perform the following cycles; 25°C for 10 minutes, 37°C for 120 minutes, 85°C for 5 
minutes, then held at 4°C. Samples were stored at -20°C until required for quantitative 
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Table 2.3. RT reagent mixture 
2.10 Quantitative real time polymerase chain reaction 
(qRT-PCR) 
qRT-PCR was carried out with predesigned gene expression assays from Applied 
Biosystems, to quantify the mRNA expression of specific genes of interest. Details of 
the reagent mixture and target genes are shown in Table 2.4 and Table 2.5, 
respectively. qRT-RCR was performed in a 384-well plate (Applied Biosystems) with 
all samples and controls added in duplicate. A reagent mixture was prepared and 14µl 
was added to each well, together with 1µl of cDNA sample. In addition to the cDNA 
samples, wells containing the following controls were included; “no reverse 
transcriptase”, “no template” and finally an H2O control, replacing cDNA, to 
determine any reagent contamination. Plates were carefully sealed with optical 
adhesive film (MicroAmp®, Applied Biosystems) and then centrifuged at 500 x g for 
1 minute. All qRT-PCR analyses were performed on an Applied Biosystems 7900HT 
instrument set to perform the following cycles; 50°C held for 2 minutes, 95°C held for 
10 minutes, then 95°C for 15 seconds and 60°C for 1 minute, repeated for 40 cycles. 
Target gene expression was normalised for RNA loading using β-actin (ACTB VIC, 
Human: 4326315E, Mouse: 4352341E, Applied Biosystems). Previous studies from 
Reagent Volume (µl) per sample 
for 2X RT mastermix 
10X RT Buffer 2 
25X dNTPs 0.8 
10X Random primers 2 
RNase inhibitor 1 
MultiScribe™ RT enzyme 1 
RNA-free H2O 3.2 
RNA (300ng) 10 
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our laboratory found this endogenous gene to be consistent during late pregnancy in 
the mouse and consistent in the human myometrial cell line (Hutchinson et al. 2014; 
Rinaldi et al. 2014; Rinaldi et al. 2015a; Rinaldi et al. 2015b). The expression in each 
sample was calculated relative to a calibrator sample (vehicle control) using the 2−ΔΔ 
threshold cycle (CT) method of analysis. 
Reagent Volume (µl) per sample for 
TaqMan reagent mixture 
TaqMan Universal Master Mix II 7.5 
Primer/probe or β-actin  0.75 
RNA-free H2O 5.75 
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Gene  Species Code 
IL-6  Human Hs00985639_m1 
IL-8  Human Hs00174103_m1 
IL-10  Human Hs00961622_m1 
IL-13 Human Hs00174379_m1     
Ccl2 Mouse Mm00441242_m1       
Cox-2 Mouse Mm00478374_m1  
Cxcl1 Mouse Mm04207460_m1 
Cxcl2 Mouse Mm00436450_m1 
Cx43 Mouse Mm01179639_s1 
Il-1β Mouse Mm00434228_m1 
Il-6 Mouse Mm00446190_m1 
Il-10 Mouse Mm01288386_m1 
Tlr4 Mouse Mm00445273_m1 
Tnf Mouse Mm00443258_m1 
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2.11 Enzyme-linked immunosorbent assay (ELISA) 
To perform a sandwich ELISA, the plates are first coated with a specific monoclonal 
capture antibody directed against the protein of interest (Figure 2.5). The standards, 
samples and controls are then added to the plate and any protein recognised by the 
monoclonal capture antibody will be bound. Unbound proteins are removed by 
washing and a biotinylated detection antibody is added, which also detects the protein 
of interest that is immobilised by the capture antibody. The enzyme streptavidin-
horseradish peroxidase (HRP) is applied, which binds to the detection antibody. 
Following a further wash to remove unbound antibody-enzyme conjugates, a substrate 
solution of hydrogen peroxide and tetramethylbenzidine (TMB) is added to detect 
peroxidase activity. This induces a colour change which can be measured by 
spectrophotometry. The colour intensity is proportional to the concentration of protein 
present. A standard curve is used to extrapolate protein concentration. The specific 
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Figure 2.5. DuoSet sandwich ELISA protocol. ELISAs were performed following the principles 
described above. Figure edited from: (RnDSystems) 
https://www.rndsystems.com/resources/technical/duoset-elisa-development-systems-assay-principle.  
2.11.1 DuoSet ELISA solution preparation 
Preservatives, required for the dry coat solution, ELISA buffer and substrate buffer, 
were prepared with 2 methylisothiazolone (20%; 2g) and bromonitrodioxane (20%; 
2g) dissolved in a 10ml solution of dimethylsulfoxide (DMSO; 5ml) and 
dimethylformamide (DMF; 5ml) and stored in the dark at room temperature. The dry 
coat solution, applied to plates to immobilise the primary antibody, was prepared by 
adding polyvinyl pyrollidone (2%; 20g), bovine serum albumin (BSA; 0.5%), EDTA 
(5mM; 1.68g), tris base (50mM; 6.05g) and preservatives (0.1%; 1ml). ELISA buffer 
(1x) was prepared by adding Tris base (100mM; 12.11g), sodium chloride (NaCl) 
(0.9%; 9g), EDTA (2mM; 0.744g), BSA (0.2%; 2g), phenol red solution (0.03%; 
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300μl), TWEEN® 20 (0.03%; 300μl) and 1ml preservatives to 800ml deionized water 
(dH2O) and dissolved. The pH was adjusted to 7.2 with 5N HCl and the volume made 
up to 1L. Wash buffer (20x) was prepared by adding NaCl (0.9%; 360g), Tris base 
(10mM; 48.4g), TWEEN® 20 (0.05%; 20ml) to 1.7L dH2O, adjusted to pH 7.5 and 
made up to 2L. This was diluted 1 in 20 in dH2O for use. Substrate buffer was prepared 
by adding sodium acetate anhydrous (100nM; 4.1g) and the above preservatives 
(0.1%; 0.5ml) to 405ml dH2O, adjusting to pH6 using glacial acetic acid before making 
the solution up to 500ml. Solution A, for adding to the substrate buffer, was TMB 
(0.3%; 0.3g) dissolved in 100ml DMF and stored in the dark at room temperature. 
Solution B was prepared by dissolving urea hydrogen peroxide (0.5%; 0.5g) in 100ml 
50mM sodium acetate buffer. Directly before use, 1ml each of solution A and B were 
added to 10ml stock substrate buffer and mixed well. ELISA stop solution (sulfuric 
acid; 2N H2SO4) was prepared by adding 36N concentrated acid into dH2O. 
2.11.2 DuoSet ELISA plate coating 
Mouse anti-human IL-6/IL-8 capture antibodies (Table 2.6; R&D Systems, Inc. 
Abingdon, UK) were reconstituted in sterile PBS, aliquoted and stored at -20°C until 
use. When required, each antibody was diluted in PBS and 100μl was added to each 
well of a 96-well plate. The plate was then sealed and incubated overnight at 4°C. The 
following day, the contents of the plate were removed and the plate blotted. Dry coat 
(100µl) was added to each well and incubated for 1 hour at room temperature. The 
contents were again removed, the plate blotted dry and then incubated for 3-4 hours at 
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Table 2.6. IL-6 and IL-8 DuoSet Human ELISA reagents 
2.11.3 Method for DuoSet human IL-6 and IL-8 ELISA  
Plates were first washed 4 times with wash buffer and blotted dry. A 7-point standard 
curve, diluted in ELISA buffer (IL-6: 600, 300, 150, 75, 37.5, 18.75, 9.375pg/ml, IL-
8: 2000, 1000, 500, 250, 125, 62.5, 31.25pg/ml) was added, with ELISA buffer as a 
zero standard (0pg/ml). Experimental samples (myometrial cell supernatants) were 
diluted as necessary in ELISA buffer and a quality control was added. All standards, 
samples and controls were applied in duplicate. The plate was sealed and incubated 
overnight at 4°C. The following day, the contents were flicked out and the plate 
washed and blotted 4 times. The detection antibody (100μl) diluted in ELISA buffer 
(Table 2.6) was added per well and incubated on a plate shaker for 1 hour at room 
temperature. The contents were then flicked out and the plate washed and blotted 4 
times, as before. DuoSet Streptavidin HRP solution (Table 2.6) was then diluted in 
ELISA buffer and 100μl added to each well. Plates were incubated for 20 minutes at 
room temperature on the plate shaker, protected from direct sunlight. The solution was 
removed and the plate washed 4 times. Finally, 100μl of the substrate solution, 
containing solutions A and B (described in section 2.11.1) was added to each well and 
incubated for 20 minutes at room temperature. Then 50μl 2N H2SO4 stop solution was 
added to quench colour development. The plates were read immediately at 450nm 
using the absorbance mode of Thermomax Microplate Reader (Molecular Devices, 
Sunnyvale, CA, USA) and Softmax® Pro software (v5.0, Molecular Devices). A 
standard curve for each plate was generated and the sample concentrations were 
determined from this curve using the Softmax® Pro software. 
Reagent Dilution Diluent  
Capture antibody 1:120 PBS 
Detection antibody 1:60 ELISA buffer 
Streptavidin HRP  1:40 ELISA buffer 
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2.11.4 Quantikine mouse IL-6 ELISA    
An IL-6 ELISA (M6000B; Quantikine, R&D Systems) was performed using maternal 
serum and amniotic fluid collected from mice. The 96-well plates were purchased pre-
coated with a monoclonal antibody specific for mouse IL-6. The mouse IL-6 positive 
control was reconstituted in 1ml dH2O. The wash buffer was prepared by adding 20ml 
wash buffer concentrate to 500ml dH2O. The substrate solution was prepared by 
combining equal volumes of colour reagents A and B, no more than 15 minutes prior 
to use. The mouse IL-6 standard was reconstituted with Calibrator Diluent RD5T, to 
produce a stock solution of 500pg/ml. The stock solution was then diluted to achieve 
the dilution series; 500, 250, 125, 62.5, 31.3, 15.6, 7.8pg/ml. The Calibrator Diluent, 
RD5T, acted as the zero standard (0pg/ml). 
Following the preparation of the above reagents, 50µl of assay diluent, RD1-14, was 
added to each well, followed by 50µl of the appropriate standard, control, maternal 
serum or amniotic fluid sample. The plate was incubated for 2 hours at room 
temperature and covered with an adhesive strip. The wells were then aspirated, washed 
five times and blotted. The mouse IL-6 conjugate (100µl) was added to each well, an 
adhesive strip applied and the plate was incubated for 2 hours at room temperature. 
The plate was aspirated and washed 5 times. The substrate solution was then prepared 
and 100µl was added per well. The plate was protected from light and incubated for 
30 minutes at room temperature. The stop solution (100µl/well) was added and the 
plate was tapped gently to ensure thorough mixing. The plate was then read within 30 
minutes at 450nm, as described in section 2.11.3. 
2.12 Western blotting 
2.12.1 Protein extraction from tissue   
Tissue was placed in a 2ml Eppendorf tube with one sterile, stainless steel 
homogenising bead (Qiagen). RIPA lysis buffer was purchased in a ready-to-use 
solution containing 150mM NaCl, 1.0% IGEPAL® CA-630, 0.5% sodium 
deoxycholate, 0.1% SDS and 50mM Tris at pH8.0 (R0278; Sigma-Aldrich). On the 
day of the experiment, the lysis buffer was prepared with 10ml RIPA buffer and one 
protease inhibitor tablet (cOmplete™ Protease Inhibitor Cocktail Tablet, 
04693132001, Roche, Basel, Switzerland) and 500-700µl was added per tube 
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depending on tissue size and texture. Samples were homogenised using a Tissue Lyser 
II (Qiagen) at 25Hz for 3 minutes, twice. The samples were then incubated on ice for 
5 minutes and centrifuged at 10, 000 x g for 10 minutes at 4°C. The supernatant was 
aliquoted and stored at -80°C.  
2.12.2 Protein quantification  
The BIO-RAD DC™ protein assay (Bio-Rad Laboratories Ltd, Watford, UK) is a 
colorimetric assay which measures protein concentration. It is a similar reaction to the 
Lowry assay but it is more time-efficient (http://www.bio-rad.com/en-uk/product/dc-
protein-assay). The protein reacts with an alkaline copper tartrate solution and Folin 
reagent. Protein first reacts with the copper in an alkaline solution and then reduces 
the Folin reagent, causing a blue colour to develop. The intensity of colour is 
proportional to the quantity of protein present. The absorbance can be measured at 
650nm. 
A 4 point standard curve (1.37, 0.685, 0.342, 0.171mg/ml) was prepared by performing 
a two-fold dilution using the BIO-RAD DC™ top standard diluted in the protein 
extraction buffer (RIPA buffer, see 2.12.1). The RIPA buffer was used as a blank 
(0mg/ml). Working reagent A was prepared by the addition of 20µl reagent S 
(surfactant solution) in 1ml of reagent A (alkaline copper tartrate solution). Standards 
and samples were added to a 96-well plate, in duplicate, in a volume of 5µl, followed 
by 25µl of working reagent A. Reagent B (200µl, dilute Folin Reagent) was then added 
to each well. The plate was incubated for 15 minutes at room temperature and then 
read using a Thermomax microplate reader at 650nm. If the sample concentration was 
higher than the top standard, the assay was repeated with samples diluted in RIPA 
buffer. 
2.12.3 Fluorescent Western blot  
Fluorescent Western blot was performed to quantify CX43 in the mouse uterus. Protein 
samples were mixed with NuPAGE® LDS Sample Buffer and NuPAGE® Sample 
Reducing Agent (ThermoFisher Scientific) and heated to 70°C for 10 minutes to 
denature the protein (G-Storm GS1 Thermal Cycler). Firstly, Precision Plus Protein™ 
Prestained Standard molecular weight marker (BIO-RAD) was loaded on a 4-12% 
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(1mm, 12 well) Bis-Tris precast NuPAGE® gel in 1X NuPAGE® MOPS running 
buffer (Table 2.7). Denatured protein samples were then loaded (20µg of 
protein/sample) and the gel was run at 180 V for 70 minutes, to separate the proteins. 
The proteins were transferred to Immobilon-FL PVDF membranes (Millipore) in 1X 
transfer buffer, using a wet-transfer system, at 100 V for 90 minutes (Table 2.7). The 
membranes were then blocked with 5% non-fat dry milk in 0.5% TWEEN® 20 tris 
buffered saline (TBST; Life Technologies) to minimise non-specific binding. The 
membrane was then incubated with primary antibodies against CX43 and α-Tubulin, 
diluted in 5% non-fat dry milk in 0.5% TBST, overnight at 4°C (Table 2.8). The 
following day, membranes were washed in TBST for 5 minutes, three times. 
Membranes were then incubated with secondary antibodies (LI-COR Biosciences) 
diluted in 5% non-fat dry milk in 0.5% TBST (Table 2.8) for 2 hours and washed again 
for 5 minutes, repeated 3 times. Membranes were scanned using the LI-COR 
Odyssey® Fc Imaging System. The intensity of each CX43 band (43kDa) was 
normalised to α-Tubulin (50kDa), as a loading control, and then quantified using the 
Odyssey analysis software.  
2.12.4 Chemiluminescent Western blot 
Chemiluminescence was performed to quantify IL-6 (23kDa) in the mouse uterus. 
Western blot was performed as described in section 2.12.3, with minor alterations 
which are outlined as follows. Subsequent to gel separation, the protein (45µg of 
protein/sample) was transferred to Immobilon-P PVDF membranes (Millipore) and 
blocked with 5% BSA (Sigma-Aldrich) in TBST. After primary and secondary 
antibody incubation (Table 2.8), the membranes were incubated with Amersham ECL 
Western blotting detection reagent (GE Healthcare Life Sciences, Marlborough, MA) 
for 30 seconds (α-Tubulin) and 5 minutes (IL-6), then scanned and analysed as 
described in 2.12.3. Recombinant Human IL-6 Protein (21kDa; R&D Systems) was 
included as a positive control. 
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1X NuPAGE® MOPS SDS Running 
Buffer 
50ml 20X NuPAGE® MOPS SDS 
Running Buffer 
950ml dH2O 
10X Transfer Buffer 30g Tris 
144g Glycine 
900ml dH2O  
 
1X Transfer Buffer 100ml 10X transfer buffer 
800ml dH2O 
100ml CH3OH 
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Table 2.8. Primary and secondary antibodies for Western Blot analyses 
2.13 Liquid chromatography tandem-mass 
spectrometry (LC-MS/MS) 
LC-MS/MS involves first separating the sample components by liquid 
chromatography, which occurs as a result of the interactions of the sample with the 
mobile and stationary phases. The components are then introduced to the mass 
spectrometer, which creates and detects charged ions. This technique can provide 
information about the molecular weight, structure, identity and quantity of specific 
sample compounds. In this case, it was used to quantify progesterone in the serum 
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2.13.1 Extraction of progesterone from pregnant mouse 
serum  
The following protocol and analyses were performed by Mr George Just in the Mass 
Spectrometry Core laboratory of the Clinical Research Facility, Edinburgh. 
D9-progesterone (1.5ng; C/D/N Isotopes Inc, Canada) was included as an internal 
standard and was prepared at 1 mg/ml in CH₃OH. To give a 10µg/mL stock internal 
standard solution, 10µl of 1mg/ml internal standard solution was added to a 3.5ml vial 
with 970µl of 10mM ammonium acetate (pH 4.5). Then, 19.98ml of 10mM 
ammonium acetate (pH 4.5) was added to 20µl of each 10µg/ml stock internal standard 
solution to give 20ml of 0.01µg/ml working internal standard solution. Progesterone 
(1mg/ml in CH₃OH) was used to prepare a set of stock standards, as detailed in Table 
2.9. 
For extraction, standards were prepared as outlined in Table 2.10. The liquid was 
evaporated using a flow of oxygen-free nitrogen in a dri-block set to 40°C (Techne, 
Cole Parmer, UK) then 50µl of control plasma or biological serum/amniotic fluid 
sample was added to individual 5ml glass centrifuge tubes. Working internal standard 
solution was added in a volume of 150µl to each sample and standard. The tubes were 
vortexed and the standards were transferred to a 96-well (200µl) Biotage SLE+ plate 
(Biotage, Sweden) for liquid extraction. An Isolute vacuum manifold (Biotage) was 
applied for 15 seconds to initiate loading. Once loaded, samples were incubated for 5 
minutes to completely absorb. Samples were then eluted into a Waters 96-well (2ml) 
collection plate (Manchester, UK) using 1ml of Methyl tertiary butyl ether (MTBE) 
and then once again evaporated to dryness using a flow of oxygen-free nitrogen. 
Precipitate was resuspended in 100µl of water/acetonitrile (50/50, v/v) and 10µl was 
injected for LC-MS/MS quantification. 
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0.01  1 mg/ml 0.97 10 µg/ml 
0.5 10 µg/ml 0.5 5 µg/ml 
0.2 10 µg/ml 0.8 2 µg/ml 
0.1 10 µg/ml 0.9 1 µg/ml 
0.1 5 µg/ml 0.9 0.5 µg/ml 
0.1 2 µg/ml 0.9 0.2 µg/ml 
0.1 1 µg/ml 0.9 0.1 µg/ml 
0.1 0.5 µg/ml 0.9 0.05 µg/ml 
0.1 0.2 µg/ml 0.9 0.02 µg/ml 
0.1 0.1 µg/ml 0.9 0.01 µg/ml 
0.1 0.05 µg/ml 0.9 0.005 µg/ml 
0.1 0.02 µg/ml 0.9 0.002 µg/ml 
0.1 0.01 µg/ml 0.9 0.001 µg/ml 
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Table 2.10. Preparation of standards for extraction 
2.13.2 LC-MS/MS quantification 
Progesterone was measured by LC-MS/MS, using a Sciex QTRAP® 5500 
(Warrington, UK), with a Waters Acquity™ UPLC (Manchester, UK). Mass spectral 
conditions are demonstrated in Table 2.11.  
Analyte separation was performed at 40°C on an Ace® Excel C18 (100x2.1mm, 
1.7µm) column (Advanced Chromatography Technology Ltd, Aberdeen, UK) using a 
gradient solvent system (50:50 of water with 0.1% formic acid and acetonitrile with 
0.1% formic acid) with a gradient run of 6.5 minutes as demonstrated in Table 2.12. 












Progesterone absolute amount 
(ng) 
S0 N/A N/A 0 
S1 0.01 0.001 0.01 
S2 0.01 0.002 0.02 
S3 0.01 0.005 0.05 
S4 0.01 0.01 0.1 
S5 0.01 0.02 0.2 
S6 0.01 0.05 0.5 
S7 0.01 0.1 1 
S8 0.01 0.2 2 
S9 0.01 0.5 5 
S10 0.01 1 10 
S11 0.01 2 20 
S12 0.01 5 50 
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Table 2.11. Mass spectral conditions for analysis of progesterone and the internal standard, D9-Progesterone, utilising positive and negative electrospray. Da 



















Progesterone 314.462 315.0 97.0; 109.0 146 29; 37 10; 18 
D9-Progesterone 323.52 324.1 100.0 151 31 38 
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Table 2.12. Chromatographic conditions (Flow Rate 0.5 ml/min) 
2.14 Statistical analysis 
Data are presented as mean ± standard error of the mean (SEM) and were analysed 
using GraphPad Prism (Version 7; GraphPad Software Inc., San Diego, CA). For cell 
studies, “n” denotes the number of individual experiments performed, with the 
replicate number per experiment indicated in the figure legends. For mouse studies, 
“n” represents the number of individual dams treated. Time to delivery data were 
analysed using Kruskal-Wallis, with Dunn's post hoc test. The percentage data for live 
born pups and collagen gel contraction were analysed by performing an arcsine 
transformation on the proportions, followed by a one-way analysis of variance 
(ANOVA), with either Dunnett’s or Holm-Sidak post hoc test. All gene expression, 
ELISA, In-Cell Western and LC-MS/MS data were square root transformed, if 
necessary, then analysed by one-way ANOVA, followed by Dunnett’s or Tukey’s post 
hoc test. A p value <0.05 was considered statistically significant.
Time  
(minutes) 
Mobile Phase A:  
Water (0.1%  
formic acid, v/v) 
Mobile Phase B; 
Acetonitrile  
(0.1%  formic acid, 
v/v) 
0 50 50 
1 50 50 
4 0 100 
5 0 100 
5.1 50 50 
6.5 50 50 
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Chapter 3: Investigating the effect of statin 
treatment on inflammation in a pregnant human 
myometrial cell line 
3.1 Introduction 
Labour is an inflammatory event, initiated by the shift from a quiescent to a pro-
inflammatory environment. This instigates a three step process, characterised by 
myometrial contractility, cervical ripening and fetal membrane rupture (Romero et al. 
1994; Rinaldi et al. 2011). Leukocytes, such as monocytes and neutrophils, infiltrate 
the myometrium and cervix, stimulating an increase in inflammatory mediators 
including cytokines and chemokines. Pro-inflammatory mediators, such as IL-1β, IL-
6, IL-8 and TNF are all upregulated in these tissues during active labour (Bokstrom et 
al. 1997; Thomson et al. 1999; Osman et al. 2003). If these events occur earlier in 
gestation, they can result in the pathological, preterm initiation of this labour cascade. 
In addition,  inflammatory mediators may reach the fetal circulation, resulting in fetal 
injury (Adams Waldorf and McAdams 2013). 
Approximately 70% of PTBs are spontaneous (Rubens et al. 2014). Intrauterine 
infection is believed to be present in 25-40% of PTBs. However, this is likely to be an 
underestimate, as infections are often sub-clinical and cannot be detected by current 
culturing techniques (Goldenberg et al. 2008). Existing therapies are ineffective at 
preventing PTB and do not treat the underlying causes (Romero et al. 2014). Ideally, 
a treatment for PTL would target the local inflammation, having the dual benefit of 
delaying the labour process and reducing fetal injury. 
Statins are an established treatment for the reduction of LDL cholesterol synthesis and 
subsequently, for the prevention of cardiovascular disease. In addition to lowering 
lipids, statins also exert anti-inflammatory properties (Zhou and Liao 2010). As a 
result, these drugs have been investigated for use in multiple inflammatory conditions 
such as sepsis, rheumatoid arthritis and asthma (Zeki et al. 2013; Dobesh and Olsen 
2014; Das et al. 2015). The anti-inflammatory properties of statins have been widely 
investigated in vitro, mostly in vascular smooth muscle cells, where they have been 
shown to mediate the reduction of IL-6 and IL-8 (Ito et al. 2002a; Ito et al. 2002b). 
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Statins can also inhibit human neutrophil and monocyte chemotaxis, while reducing 
the release of pro-inflammatory mediators such as IL-6, IL-8 and CCL2 (Rezaie-Majd 
et al. 2002; Maher et al. 2009; Jougasaki et al. 2010). 
The pharmacokinetics of statins vary. For example, pravastatin is hydrophilic and 
requires selective uptake by the sodium-independent transporter protein, OATP1B1. 
This transporter protein is exclusively expressed in the liver and so, entry into other 
cells types is limited (Hamelin and Turgeon 1998; Corsini et al. 1999). Simvastatin is 
a lipophilic drug, which readily enters cells by passive diffusion (Schachter 2005).  
As statins have anti-inflammatory properties, they may be an ideal therapeutic to target 
the inflammation associated with PTL. Therefore, the hypothesis of this chapter was 
that statins will reduce LPS-induced inflammation in human myometrial cells.  
3.2 Methods 
3.2.1 Myometrial cell culture and treatment 
Myometrial cells were cultured as described in 2.1. They were seeded at 1.5x105 
cells/ml in 6-well plates and treated with LPS (100ng/ml) and pravastatin (10µM) or 
simvastatin (0.1µM, 10µM, 50µM). For inflammatory mediator analysis, the cells 
were either co-treated with LPS and statins (n=6), pre-treated with statins for 6 hours 
before LPS (pravastatin only n=5, all other treatments n=6) or treated with statins 6 
hours after LPS stimulation (n=6), as outlined in 2.3. All treatments lasted for 24 hours 
and were performed in duplicate. Pravastatin and simvastatin experiments were 
performed simultaneously. Therefore, the same vehicle and LPS treatment data were 
utilised for both pravastatin and simvastatin analyses. For clarity, the results are 
displayed separately for each statin, with the control group data represented in each 
graph.  
3.2.2 Myometrial cell image capture 
Images of myometrial cells were captured following 24 hours of co-treatment, pre-
treatment and post-treatment with statins and LPS, to assess any effects on cell 
morphology, as described in 2.4. Treatments were performed in duplicate and images 
were captured from 3 individual experiments (n=3).  
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3.2.3 MTT metabolic activity assay  
The metabolic activity of the myometrial cells was assessed as a measurement of cell 
viability, following statin and LPS treatment. This was performed using an MTT assay, 
as detailed in 2.5. The co-, pre- and post-treatments were performed in triplicate for 24 
hours (n=6). 
3.2.4 qRT-PCR 
The mRNA expression of the inflammatory markers IL-6, IL-8, IL-10 and IL-13 were 
assessed by qRT-PCR analysis, following 24 hour statin and LPS treatment, as 
described in 2.10. The mRNA expression of these genes of interest was normalised to 
the endogenous control gene, β-actin, within each individual sample. Samples were 
then compared to the vehicle control group (PBS) using the 2−ΔΔ CT method of 
analysis, as detailed in 2.10. The results are presented as fold change relative to the 
vehicle control group. 
3.2.5 ELISA 
ELISAs were performed with myometrial cell supernatants to quantify the levels of 
IL-6 and IL-8 secreted by these cells during treatment with statins and LPS. Details of 
the assays are explained in 2.11.3. The supernatants were collected following 24 hour 
incubation with statin and LPS treatments, at the same time as cells were harvested for 
qRT-PCR analyses. 
3.2.6 Statistical analysis 
Data are presented as mean ± SEM and were analysed using GraphPad Prism. In these 
studies, “n” denotes the number of individual experiments performed, with the 
replicate number per experiment indicated in the figure legends. Where data were not 
normally distributed, they were square root transformed prior to analysis. Gene 
expression (CT values) and ELISA data were analysed by one-way ANOVA, followed 
by Dunnett’s post-hoc test. A p value <0.05 was considered statistically significant. 
The effect of statin treatment on preterm labour 
Chapter 3: Investigating the effect of statin treatment on inflammation in a pregnant 
human myometrial cell line  96 
3.3 Results 
3.3.1 The effect of statin treatment on the morphology of 
human myometrial cells  
Myometrial cells are smooth muscle cells, which have a fibroblast-like, elongated, 
spindle-shaped morphology. To investigate whether statin treatment may affect the 
morphology of these cells, they were treated with pravastatin or simvastatin, with and 
without LPS stimulation. The myometrial cells were either co-treated with LPS and 
pravastatin/simvastatin, pre-treated with pravastatin/simvastatin or treated with 
pravastatin/simvastatin post-LPS stimulation. Images were captured after the cells 
were incubated for 24 hours with the treatments.  
3.3.1.1 The effect of pravastatin treatment on myometrial cell 
morphology 
When cells were treated with 10µM pravastatin, there was no noticeable difference in 
their morphology (Figure 3.1). LPS alone did not appear to have an effect on the shape 
of these cells. Additionally, there was no apparent effect of treating with both 
pravastatin and LPS. These results did not vary between the co-, pre- and post-
treatment group. 
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Figure 3.1. Myometrial cell morphology following pravastatin and LPS treatment. Representative images show myometrial cells which were either co-treated with 
pravastatin and LPS, pre-treated with pravastatin for 6 hours before LPS or given pravastatin 6 hours post-LPS stimulation. All incubations lasted for 24 hours. Spindle-
shaped myometrial smooth muscle cells are shown in the vehicle control images (arrows). n=3 (in duplicate), vehicle (PBS) and LPS data shared for 
pravastatin/simvastatin experiments. Scale bar shows 50µm. Arrows indicate examples of normal myometrial cell morphology. All images were taken with a x10 
objective lens.  
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3.3.1.2 The effect of simvastatin treatment on myometrial cell 
morphology 
When the myometrial cells were treated with 10µM simvastatin alone, the cells 
appeared marginally more elongated (Figure 3.2). When the myometrial cells were 
treated with 0.1µM simvastatin and LPS, there was no effect on cell morphology, when 
compared to the cells treated with vehicle. However, when the cells were treated with 
LPS and either 10µM or 50µM simvastatin, they again looked slightly more elongated. 
This possible morphology change was visible in the co-, pre- and post-treatment 
groups. However, this was not quantified.  
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Figure 3.2. Myometrial cell morphology following simvastatin and LPS treatment. Representative images show myometrial cells which were either co-treated with 
simvastatin and LPS, pre-treated with simvastatin for 6 hours before LPS or given simvastatin 6 hours post-LPS stimulation. All incubations lasted for 24 hours. 
Myometrial smooth muscle cells are spindle-shaped, as evidenced in the vehicle control images (arrows). However, when given 10µM simvastatin treatment, in each 
treatment regimen, the cells became slightly thinner (arrowheads). Treatments were performed in duplicate (n=3), vehicle (PBS) and LPS images shared for 
pravastatin/simvastatin experiments. Scale bar shows 50µm. Arrows indicate examples of normal myometrial cell morphology. Arrowheads indicate more elongated 
myometrial cells. All images were taken with a x10 objective lens.  
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3.3.2 The effect of statin treatment on the metabolic 
activity of a human myometrial cell line 
MTT assays were performed to investigate the effect of pravastatin, simvastatin and 
LPS treatment on cell metabolic activity. This was undertaken to give a preliminary 
indication of the functionality and viability of the myometrial cells following 
treatment. The myometrial cells were either co-, pre- or post-treated with 
pravastatin/simvastatin and/or LPS for 24 hours. The metabolic activity per treatment 
was made relative to the mean metabolic activity of the vehicle control (PBS). 
Myometrial cell metabolic activity was unaffected by concentrations of up to 100µM 
of pravastatin (Figure 3.3) and simvastatin (Figure 3.4), after treatment for 24 hours. 
The inclusion of LPS had no additional effect on cell metabolism, irrespective of 
whether the cells received, co-, pre- or post-LPS statin treatment. 
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Figure 3.3. Myometrial cell metabolic activity following pravastatin and LPS treatment (24 
hours). (A-F) Myometrial cell metabolic activity was unaffected by 24 hours of up to 100µM 
pravastatin and LPS (100mg/ml) co-, pre- and post-treatment. n=6 (in triplicate), vehicle (veh; PBS) 




The effect of statin treatment on preterm labour 
Chapter 3: Investigating the effect of statin treatment on inflammation in a pregnant 













Figure 3.4. Myometrial cell metabolic activity following simvastatin and LPS treatment (24 
hours). (A-F) Myometrial cell metabolic activity was unaffected by up to 100µM simvastatin and LPS 
(100ng/ml) co-, pre- and post-treatment for 24 hours. n=6 (in triplicate), vehicle (veh; PBS) group 
shared for simvastatin only (sim) and simvastatin + LPS, mean ± SEM. 
 
3.3.3 The effect of statin treatment on inflammatory 
mediator mRNA expression and protein production 
in myometrial cells stimulated with LPS 
To establish the effect of pravastatin and simvastatin treatment on the expression of 
inflammatory mediators in myometrial cells, mRNA expression and protein secretion 
of the pro-inflammatory mediators IL-6 and IL-8, were determined by qRT-PCR and 
ELISA, respectively. In addition, the mRNA expression of anti-inflammatory 
cytokines, IL-10 and IL-13, was also investigated. LPS-stimulated myometrial cells 
were either co-, pre- or post-treated with pravastatin/simvastatin for 24 hours.  
The effect of statin treatment on preterm labour 
Chapter 3: Investigating the effect of statin treatment on inflammation in a pregnant 
human myometrial cell line  103 
3.3.3.1 The effect of pravastatin on pro-inflammatory mediator 
expression and protein secretion in myometrial cells 
LPS upregulated concentrations of IL-6 mRNA 6.7 fold in the co-treatment group 
(p<0.0001 vs vehicle), which was validated at the protein level (mean 2207 ± 489pg/ml 
vs vehicle mean 88.3 ± 18pg/ml; p<0.0001; Figures 3.5A, 3.6A). LPS also increased 
IL-6 mRNA and IL-6 protein in comparison to pravastatin treatment alone (p<0.0001). 
Co-treatment with pravastatin did not affect these LPS-stimulated levels of IL-6 
mRNA or IL-6 protein. IL-8 expression was robustly upregulated 50.2 fold by LPS 
(p<0.0001 vs vehicle), as was IL-8 secretion from the myometrial cells (mean 4704 ± 
893pg/ml vs vehicle mean 81.3 ± 23pg/ml; p<0.0001; Figures 3.5B, 3.6B). The same 
effect was observed in comparison to pravastatin treatment alone (p<0.0001). 
However, co-treatment with pravastatin and LPS did not alter IL-8 expression or IL-8 
protein levels compared with LPS alone. 
In the pre-treatment group, LPS stimulated IL-6 to increase 11.5 fold (p<0.0001 vs 
vehicle) and the IL-6 protein levels were increased (mean 2417 ± 715pg/ml vs vehicle 
mean 78.9 ± 16pg/ml; p<0.0001; Figures 3.5C, 3.6C). These levels were also 
significantly increased in comparison to pravastatin treatment alone (p<0.0001). Pre-
treatment with pravastatin before LPS did not impact on IL-6 mRNA or IL-6 secretion. 
LPS induced an 87.6 fold increase in IL-8 expression (p<0.0001 vs vehicle), which 
was confirmed by an increase in IL-8 production by the myometrial cells (mean 6689 
± 1502pg/ml vs vehicle mean 105.4 ± 42pg/ml; p<0.0001; Figures 3.5D, 3.6D). Again, 
these levels were also significantly increased compared to pravastatin only treatment 
(p<0.0001). However, pravastatin pre-treatment did not alter the levels of IL-8 mRNA 
or IL-8 protein compared with LPS only. 
In the post-treatment group, IL-6 expression increased 7.3 fold with LPS stimulation 
(p<0.0001 vs vehicle) and IL-6 protein also increased (mean 2678 ± 528pg/ml vs 
vehicle mean 138.3 ± 32pg/ml; p<0.0001; Figures 3.5E, 3.6E). These levels were 
significantly higher compared to pravastatin treatment alone (p<0.0001) but 
pravastatin treatment post-LPS stimulation did not affect IL-6 RNA or IL-6 protein 
secretion. LPS stimulated a 51.5 fold increase in IL-8 expression (p<0.0001 vs vehicle) 
and robustly increased IL-8 protein secretion from the myometrial cells (mean 6161 ± 
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902pg/ml vs vehicle mean 164.1 ± 31pg/ml; p<0.0001; Figures 3.5F, 3.6F). This 
increase in IL-8 gene and protein production was also significantly higher than 
pravastatin alone (p<0.0001). Again, post-treatment with pravastatin after LPS did not 
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Figure 3.5. The effect of pravastatin treatment on pro-inflammatory mRNA expression in human 
myometrial cells following LPS stimulation (24 hours). Co-, pre- and post-treatment regimens with 
pravastatin and LPS in human myometrial cells. (A-F) LPS increased the expression of IL-6 and IL-8 
from myometrial cells. This upregulation was unaltered by the co-, pre- or post-treatment with 
pravastatin. n=5-6 (in duplicate), vehicle (PBS) and LPS data shared for pravastatin/simvastatin 
experiments, ****p<0.0001, mean fold change ± SEM, one-way ANOVA with Dunnett’s post hoc test. 
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Figure 3.6. The effect of pravastatin treatment on pro-inflammatory mediator secretion from 
LPS-stimulated human myometrial cells (24 hours). Co-, pre- and post-treatment regimens with 
pravastatin and LPS in human myometrial cells. (A-F) LPS increased the secretion of IL-6 and IL-8 
from myometrial cells. This increase was unaltered by the co-, pre- or post-treatment with pravastatin. 
n=5-6 (in duplicate), vehicle (PBS) and LPS data shared for pravastatin/simvastatin experiments, 
****p<0.0001, mean ± SEM, one-way ANOVA with Dunnett’s post hoc test. 
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3.3.3.2 The effect of pravastatin on anti-inflammatory gene 
expression in myometrial cells 
Pravastatin treatment did not alter the pro-inflammatory mediators, IL-6 and IL-8, so 
the effect of pravastatin treatment on the anti-inflammatory genes, IL-10 and IL-13 
was then investigated. LPS administration did not significantly alter IL-10 or IL-13 
expression following any treatment regimen. Similarly, pravastatin treatment did not 
alter the expression of these anti-inflammatory genes in the co-, pre- or post-treatment 
















The effect of statin treatment on preterm labour 
Chapter 3: Investigating the effect of statin treatment on inflammation in a pregnant 




















Figure 3.7. The effect of pravastatin treatment on anti-inflammatory gene expression in human 
myometrial cells (24 hours). Co-, pre- and post-treatment regimens with pravastatin and LPS in human 
myometrial cells. IL-10 and IL-13 expression were unaffected by pravastatin or LPS treatment. n=5-6 
(in duplicate), vehicle and LPS data shared for pravastatin/simvastatin experiments, mean fold change 
± SEM. 
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3.3.3.3 The effect of simvastatin on pro-inflammatory mediator 
mRNA expression and protein production in myometrial 
cells 
Given the lack of effect of pravastatin on LPS-induced inflammatory mediator 
expression, an alternative statin, simvastatin, was investigated. In the co-treatment 
group, LPS alone stimulated upregulation of IL-6 expression, in comparison to vehicle 
and simvastatin only treated cells (p<0.0001; Figure 3.8A). This was validated by a 
significant increase in the secretion of IL-6 into the cell supernatant, in comparison to 
the vehicle group, as described in 3.3.3.1, and the simvastatin only group (p<0.0001; 
Figure 3.9A). When cells were co-treated with 50µM simvastatin and LPS, the IL-6 
fold change was significantly lower compared to LPS alone (2.4 fold vs 6.7 fold, 
p<0.0001) and IL-6 secretion was also significantly reduced, compared to when LPS 
was given alone (mean 617.3 ± 163pg/ml vs LPS mean 2207 ± 489pg/ml; p=0.0015). 
LPS stimulation increased IL-8 mRNA expression and IL-8 protein production 
robustly, in comparison to the vehicle and simvastatin only groups (p<0.0001; Figures 
3.8B, 3.9B). IL-8 mRNA was lower when the cells were co-treated with 50µM 
simvastatin and LPS, compared to LPS alone (30.3 fold vs 50.2 fold, p=0.0312). IL-8 
protein expression was also lower with 50µM simvastatin and LPS co-treatment, 
compared to LPS alone (2295 ± 266pg/ml vs LPS mean 4704 ± 893pg/ml; p=0.0207). 
Interestingly, co-treatment with 10µM simvastatin and LPS upregulated IL-8 mRNA 
expression (p=0.0243 vs LPS) but this was not observed at the protein level. 
In the pre-treatment group, again LPS stimulated a significant increase in IL-6 
(p<0.0001) and IL-6 protein secretion was significantly increased by LPS, compared 
to vehicle and simvastatin only treated cells (p=0.0001, p<0.0001, respectively; 
Figures 3.8C, 3.9C). When the cells were pre-treated with 50µM simvastatin prior to 
LPS stimulation, IL-6 mRNA expression was significantly lower, when compared to 
LPS alone (5.5 fold vs 11.5 fold, p=0.0007). Although simvastatin pre-treatment 
showed a trend to reduce IL-6 at the protein level, this was not statistically significant. 
LPS also increased IL-8 mRNA expression (p<0.0001) and IL-8 secretion from the 
myometrial cells, in comparison to the vehicle and simvastatin only treated cells 
(p<0.0017; Figures 3.8D, 3.9D). Pre-treatment with simvastatin did not alter IL-8 
mRNA or IL-8 protein production, compared to the LPS group. 
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In the post-treatment group, LPS induced IL-6 upregulation, compared to the vehicle 
and simvastatin only treated cells (p<0.0001; Figures 3.8E, 3.9E). This was also 
observed at the protein level for IL-6 (p=0.0004). When the myometrial cells were first 
stimulated with LPS, then post-treated with 50µM simvastatin, IL-6 mRNA was lower, 
compared to LPS stimulation alone (2.8 fold vs 7.3 fold, p=0.0003). Although, IL-6 
secretion was not significantly reduced. LPS stimulated a large increase in IL-8 
expression and IL-8 secretion, compared to vehicle and simvastatin only treated cells 
(p<0.0001; Figures 3.8F, 3.9F). When cells received 50µM simvastatin post-LPS 
treatment, IL-8 mRNA levels were significantly reduced (30.0 fold vs 51.4 fold, 
p=0.041) and IL-8 secretion was significantly lowered, in comparison to LPS 
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Figure 3.8. The effect of simvastatin treatment on pro-inflammatory mRNA expression in LPS-
stimulated human myometrial cells (24 hours). Co-, pre- and post-treatment regimens with 
simvastatin and LPS in human myometrial cells. (A-F) LPS robustly upregulated IL-6 and IL-8 
expression in human myometrial cells. (A, B) Co-treatment with LPS + 50µM simvastatin 
downregulated IL-6 and IL-8. (C, D) Pre-treatment with 50µM simvastatin downregulated IL-6 but not 
IL-8 expression. (E, F) Post-LPS treatment with 50µM simvastatin downregulated IL-6 and IL-8 
expression. n=6 (in duplicate), vehicle (PBS) and LPS data shared for pravastatin/simvastatin 
experiments, *p<0.05, ***p<0.001, ****p<0.0001, mean fold change ± SEM, one-way ANOVA with 




The effect of statin treatment on preterm labour 
Chapter 3: Investigating the effect of statin treatment on inflammation in a pregnant 
human myometrial cell line  112 
 
Figure 3.9. The effect of simvastatin on pro-inflammatory mediator secretion in LPS-stimulated 
human myometrial cells (24 hours). (A-F) LPS treatment increased IL-6 and IL-8 secretion from 
human myometrial cells. (A, B) Co-treatment with LPS + 50µM simvastatin reduced IL-6 and IL-8 
secretion. (C, D) Pre-treatment with simvastatin did not affect LPS-induced IL-6 or IL-8 secretion at 24 
hours. (E-F) Post-LPS treatment with 50µM simvastatin reduced IL-8 but not IL-6 levels. n=6 (in 
duplicate), vehicle (PBS) and LPS data shared for pravastatin/simvastatin experiments, *p<0.05, 
**p<0.01, ***p<0.001, ****p<0.0001, mean ± SEM, one-way ANOVA with Dunnett’s post hoc test. 
3.3.3.4 The effect of simvastatin on anti-inflammatory cytokine 
mRNA expression in myometrial cells 
In the co-treatment group, 10µM simvastatin alone significantly upregulated IL-10 
expression in the myometrial cells, compared to cells treated only with LPS (5.7 fold 
vs 2.2 fold LPS, p=0.0003; Figure 3.10A). Co-treatment with 10µM and 50µM 
simvastatin and LPS also upregulated IL-10 expression (7.3 fold, p<0.0001; 5.7 fold, 
p=0.0003 vs LPS, respectively). This co-treatment effect was also observed with IL-
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13 mRNA expression, where there was a 1.8 fold upregulation of IL-13 mRNA 
concentration by 10µM simvastatin alone (p=0.0008 vs LPS; Figure 3.10B). 
Additionally, co-treatment with LPS and 10µM simvastatin upregulated IL-13 1.5 fold 
(p=0.0064) and 50µM simvastatin upregulated the gene 1.7 fold (p=0.0021), which 
was significantly elevated in comparison to LPS treatment alone. 
When the myometrial cells were pre-treated with 10µM and 50µM simvastatin before 
LPS stimulation, IL-10 was significantly upregulated (7.3 fold, p=0.0165; 7.1 fold 
p=0.0027 vs LPS, respectively; Figure 3.10C). There was a modest 1.7 fold 
upregulation of IL-13 expression by 10µM simvastatin alone (p=0.0235 vs LPS; 
Figure 3.10D). IL-13 was also increased by 10µM and 50µM simvastatin pre-treatment 
(1.7 fold, p=0.0172; 1.9 fold, p=0.0031 vs LPS, respectively). 
Treatment with 10µM simvastatin post-LPS stimulation upregulated IL-10 expression 
4.5 fold (p=0.0018 vs LPS) but IL-13 was unaltered by post-treatment with simvastatin 
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Figure 3.10. The effect of simvastatin treatment on anti-inflammatory mRNA expression alone 
and in combination with LPS stimulation of human myometrial cells at 24 hours. (A, B) 
Simvastatin treatment alone significantly upregulated IL-10 and IL-13 expression. Co-treatment with 
LPS and 10µM and 50µM simvastatin also upregulated IL-10 and IL-13 expression. (C) Pre-treatment 
with 10µM and 50µM simvastatin upregulated IL-10 expression. (D) Simvastatin alone and pre-
treatment with 10µM and 50µM simvastatin before LPS stimulation upregulated IL-13 expression. (E) 
Post-LPS treatment with 10µM simvastatin upregulated IL-10. (F) IL-13 levels were unaltered by post-
LPS treatment with simvastatin. n=6 (in duplicate), vehicle (PBS) and LPS data shared for 
pravastatin/simvastatin experiments, *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001, mean fold 
change ± SEM, one-way ANOVA with Dunnett’s post hoc test. 
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3.4 Discussion 
3.4.1 The effect of statin treatment on myometrial cell 
morphology  
3.4.1.1 Pravastatin 
Pravastatin is a commonly used statin, as it has limited side effects (del Sol and 
Nanayakkara 2008). This drug is hydrophilic and requires selective uptake by a 
specific transporter protein, which is exclusively expressed in the liver. Therefore, 
pravastatin is highly hepatoselective (Ziegler and Hummelsiep 1993; Hatanaka 2000).  
In these experiments, 10µM pravastatin did not affect myometrial cell morphology. 
The inclusion of LPS did not have any additional effect on the cell shape. This was 
true for co-, pre- and post-treatment groups. The cells, by appearance, seemed healthy, 
implying that the treatment was not having an adverse effect. However, the appearance 
alone cannot be relied upon for assessing cell function. 
These results are in agreement with multiple studies which found that, even at high 
concentrations, pravastatin did not alter the morphology of cells such as aortic smooth 
muscle cells, mesenchymal stem cells and various cancer cell lines (Lee et al. 2004; 
Martinet et al. 2008; Menter et al. 2011). However, pravastatin was found to have a 
pronounced effect on hepatocyte morphology, due to its facilitated uptake into these 
cells (Menter et al. 2011). It has been proposed, that while most lipophilic statins do 
affect the morphology of certain cells, the reason pravastatin does not is because the 
drug does not gain entry into the cells (Menter et al. 2011). It is highly possible that 
these myometrial cells do not express the transporter protein required for pravastatin 
to enter the cell. 
The myometrial cells could be treated with higher concentrations of pravastatin to 
further confirm that this treatment does not have an effect on cell morphology. 
However, this effect may be due to pravastatin not actually being taken up by the cells. 
As no one else has investigated statin treatment on these myometrial cells, it is 
unknown if they possess the transporters required, particularly as they are 
immortalised cells, which may not function and contain exactly the same machinery 
as they would in vivo. 
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3.4.1.2 Simvastatin  
As a lipophilic drug, simvastatin readily diffuses across cell membranes and alters a 
variety of genes, namely in the mevalonate pathway, affecting cell cycle progression, 
DNA replication, apoptosis and cytoskeleton signalling (Gbelcova et al. 2017).  
In this study, simvastatin treatment may have had a concentration-dependent effect on 
cell morphology. There was no effect using 0.1µM simvastatin but at concentrations 
of 10µM and 50µM, cell morphology appeared marginally altered, as evidenced by 
the cells becoming slightly more elongated. However, there did not appear to be an 
additive effect of LPS treatment. Although changes in cell shape are not ideal, as it 
suggests the drug is affecting the regulation of the cell in some way, these possible 
changes were only slight and were not quantified. Furthermore, morphology alone 
does not give an indication of functionality. 
It has been well documented that simvastatin is capable of altering the morphology of 
cells. Simvastatin induced morphology changes in human endometriotic stromal cells 
at concentrations equivalent to those used in this chapter, as well as inhibiting 
proliferation and preventing the contraction of these cells (Nasu et al. 2009). Another 
study on endometrial stromal cells also reported a disruption in the cytoskeleton of 
cells, as a result of simvastatin treatment. F-actin fibres became disorganised and 
disassembled after 24 hours of 10µM simvastatin treatment, which was believed to 
have been caused by the inhibition of isoprenylation within the mevalonate pathway 
(Sokalska et al. 2010). 
One study investigated the effect of simvastatin on both normal and cancer cell lines. 
Simvastatin caused morphology changes in prostate and colon cancer cells, where the 
mitochondria redistributed to the cellular processes. In a pancreatic cancer cell line, 
cellular processes began to extend just 1 hour after treatment with 10µM simvastatin. 
In hepatocytes, simvastatin disrupted caveolae, small lipid rafts associated with actin 
filaments, causing cytoplasmic process extension, resulting in morphology changes. 
Again, these changes to the cytoskeleton were attributed to the inhibition of 
isoprenylation (Menter et al. 2011). In contrast, 10µM simvastatin did not alter the 
morphology of rabbit aorta smooth muscle cells. However, when these cells were 
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treated with a high concentration of simvastatin (100µM), they began to detach, 
changing from elongated to globular, spherical cells (Martinet et al. 2008). 
This experiment could be repeated and quantified at different concentrations, to 
determine if there is any true morphology change and to give an indication of the 
concentration at which an effect is first observed. Further experiments could also be 
performed to investigate the location or distribution of cytoskeletal proteins. 
3.4.2 The effect of statin treatment on myometrial cell 
metabolic activity 
3.4.2.1 Pravastatin 
When assessing cell metabolic activity as a measure of cell viability, there was no 
effect of pravastatin treatment up to concentrations of 100µM, both alone and in 
combination was LPS treatment. This implies that pravastatin treatment is not 
negatively affecting the activity of the myometrial cells at 24 hours.  
Many other studies looking at a variety of cell types, such as macrophages, smooth 
muscle cells and multiple cancer cell lines, also found that pravastatin did not affect 
cell viability (Guijarro et al. 1999; Sindermann et al. 2000; Martinet et al. 2008; Menter 
et al. 2011). However, as mentioned previously, these studies highlighted the 
possibility that pravastatin is perhaps too hydrophilic to enter into these cells. 
3.4.2.2 Simvastatin  
Simvastatin did not affect myometrial cell metabolic activity at concentrations up to 
100µM. There was also no effect of adding LPS treatment, in the co-, pre- and post-
treatment groups, at 24 hours. This suggests that simvastatin treatment does not affect 
the viability of the myometrial cells at the concentrations used in the experiments 
outlined in this chapter, which is reassuring.  
There is varying evidence regarding the effect of simvastatin on cell viability, which 
appears to be cell-dependent (Morikawa et al., 2004). For example, simvastatin 
induced concentration-dependent cell death in ovarian, endometrial and cervical 
cancer cell lines but with limited or no cytotoxic effect on normal cells (Kato et al., 
2010). Menter et al. (2011) found that simvastatin was more effective at inducing cell 
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death in poorly differentiated cancer cells, than those which were well differentiated. 
Interestingly, these effects were observed using lower concentrations of simvastatin 
than were used in the experiments within this chapter. Another study found that, while 
30µM simvastatin treatment lowered the cell viability of the J774A.1 macrophage cell 
line, primary mouse peritoneal macrophages and rabbit aortic smooth muscle cells 
were virtually unaffected (Croons et al., 2010). In addition, 50µM simvastatin had no 
effect on human macrophage cell viability at 24 hours, which agrees with the results 
in this chapter (Tuomisto et al., 2008). Therefore, it appears that simvastatin can affect 
cell viability but mostly in cancer cells, where this effect can be considered beneficial.  
Other than cell type, other explanations for this differing effect of simvastatin propose 
that cell culture environment could play a role. For instance, sub-confluent cells were 
found to be less sensitive to simvastatin treatment, compared to cells seeded at a low 
density (Sindermann et al., 2000). Reduction in cell viability was also more common 
when cells were cultured in medium containing low serum concentration, which is a 
common procedure to synchronise the growth phase of the cells for experimentation, 
forcing them to enter the quiescent G0/G1 phase (Croons et al., 2010). The 
experiments in this chapter were performed on sub-confluent cells, which were 
partially serum-starved by reducing the serum concentration from 10% (v/v) to 5% 
(v/v) FBS in DMEM. Other studies perform serum starvation at levels as low as 0.05% 
(Pirkmajer and Chibalin, 2011). However, previous experimentation in our laboratory 
found that these myometrial cells require a degree of serum at all times in order to 
remain healthy and function consistently.  
The focus of these experiments was to assess the viability of the cells, to ensure they 
were alive and metabolically active at different statin concentrations, which was 
confirmed. However, further experiments could be performed to assess the function of 
the cells in more detail, such as looking at proliferation, caspase activity or DNA 
fragmentation. 
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3.4.3 The effect of statin treatment on inflammation in a 
human myometrial cell line 
3.4.3.1 Pravastatin 
Pravastatin treatment did not affect the mRNA or protein encoded by either pro-
inflammatory mediators, IL-6 or IL-8, or the mRNA expression of anti-inflammatory 
mediators, IL-10 or IL-13, in the co-, pre- or post-treatments of LPS-stimulated human 
myometrial cells.  
This is surprising, as there is extensive evidence from human studies that pravastatin 
can reduce inflammation. A key study addressing the anti-inflammatory effect of 
statins was the PRINCE trial. This trial assessed the effect of pravastatin on the plasma 
levels of the inflammatory biomarker, CRP. Pravastatin lowered CRP levels in 
subjects with cardiovascular disease, as well as in the subjects with no history of 
cardiovascular disease, after 24 weeks. This effect was independent of LDL 
cholesterol levels (Albert et al. 2001). Pravastatin also reduced the plasma levels of 
CRP in a small cohort of patients with type 2 diabetes (Sommeijer et al. 2004). As well 
as lowering inflammation in patients with carotid artery plaques and men with 
hypercholesterolemia (Crisby et al. 2001; Kalela et al. 2001; Solheim et al. 2001). 
Evidence of the anti-inflammatory effect of pravastatin is also available from a wealth 
of in vitro studies. For instance, pravastatin significantly reduced LPS-stimulated IL-
6, IL-8 and GM-CSF protein production in human bronchial epithelial cells (Iwata et 
al. 2012). Pravastatin concentration-dependently reduced CRP, IL-6 and TNF at the 
gene and protein level in rat vascular smooth muscle cells. However, this affect was 
only observed at pravastatin concentrations above 30µM (Guo et al. 2012; Lu et al. 
2015). Pravastatin downregulated the release of pro-inflammatory mediators, TNF and 
CCL2 but not IL-6, from human monocytes but only at very high concentrations of 
100µM and 500µM (Grip et al. 2000).   
The choice of pravastatin concentration (10µM) was made initially as it is one of the 
most commonly selected concentrations used for investigating the pleiotropic effects 
of statins in vitro, albeit higher than therapeutically relevant concentrations 
(Bjorkhem-Bergman et al. 2011; Iwata et al. 2012; Chang et al. 2014; Statt et al. 2015). 
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Nevertheless, in this instance there was no effect of pravastatin treatment on LPS-
induced inflammation in myometrial cells. An important point to consider is that in 
vitro conditions are not wholly representative of the in vivo environment. For example, 
there are animal and human studies that suggest pravastatin could improve pregnancy 
outcomes in women with anti-phospholipid syndrome (Redecha et al. 2008; Lefkou et 
al. 2016). However, in a human trophoblast cell line, pravastatin treatment did not 
reduce inflammation or inhibit anti-phospholipid antibody-mediated changes (Odiari 
et al. 2012).  
The experiments in this chapter could be repeated with a higher concentration of 
pravastatin but it is likely that the concentration would need to be increased 
substantially in order to see any affect. The presence of transport protein, OATP1B1, 
which facilitates pravastatin uptake, could be investigated in these cells. As discussed 
in the previous sections, the hydrophilic nature and hepatoselectivity of pravastatin 
prevents it from acting on many cell types, particularly in vitro, when only one cell 
type is present. Therefore, it is possible that pravastatin may still have anti-
inflammatory properties on the myometrium in vivo, which is worth investigating. 
3.4.3.2 Simvastatin  
Simvastatin treatment significantly reduced the mRNA expression and protein 
production of IL-6 and IL-8, when cells were stimulated with LPS. Specifically, the 
higher concentration of simvastatin (50µM) significantly reduced these mediators at 
both the gene and protein level, when cells were co-treated with simvastatin and LPS. 
Pre-treatment with 50µM simvastatin significantly reduced IL-6 mRNA expression 
but this didn’t reach significance at the protein level and there was no effect of pre-
treatment with simvastatin on IL-8 gene or protein expression. This was interesting, as 
the pre-treatment group was incubated with LPS for the least amount of time (18 
hours), while simvastatin was present for the whole 24 hours. However, there was also 
a lot of variation between individual experiments, which may have prevented statistical 
significance. Higher passage number, for example, could have affected the 
responsiveness of these cells, as all other variables remained constant. Following 6 
hours of LPS stimulation, post-treatment with 50µM simvastatin significantly reduced 
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IL-6 gene expression, as well as IL-8 gene expression and IL-8 secretion from the 
myometrial cells. 
Interestingly, simvastatin alone was capable of increasing the expression of IL-10 and 
IL-13, both of which are classed as anti-inflammatory genes. This increase in 
expression was seen during co-treatment experiments, when the cells were exposed to 
statins for the full 24 hour incubation. Simvastatin alone increased IL-13 but not IL-10 
in the pre-treatment group. Again, the variation between samples of the simvastatin 
only group may explain why IL-10 was not significantly increased in comparison to 
the LPS group. There was no effect of simvastatin alone on IL-10 and IL-13 in the 
post-treatment group. This may be because simvastatin was only present for 18 hours 
of the incubation, as the cells were being stimulated with LPS for the first 6 hours of 
the 24 hour incubation. IL-10 gene expression was significantly upregulated after post-
LPS treatment with 10µM simvastatin but there was no significant effect on IL-13 
expression. Ideally, it would helpful to have protein data for the anti-inflammatory 
cytokines, to see whether this reinforces the changes observed at the gene level. 
Unfortunately, as IL-10 is expressed in very low levels, the protein was undetectable 
by our ELISA assay. Presumably IL-13, which is expressed at even lower levels, would 
be difficult to measure other than perhaps by an especially sensitive assay. 
These anti-inflammatory properties of simvastatin have been widely investigated in 
human and animal studies, as well as in vitro (Schonbeck and Libby 2004; Jain and 
Ridker 2005; Loppnow et al. 2011). For example, in hypercholesteraemic patients, 
serum IL-6, IL-8 and CCL2 were reduced following 6 weeks of simvastatin treatment 
(Rezaie-Majd et al. 2002). In mice, simvastatin significantly reduced the mRNA 
expression of Il-1β and Il-6 in the uterus of a pregnant mouse that had received LPS 
(Basraon et al. 2012). Treatment with simvastatin has also resulted in reduced 
synthesis of inflammatory mediators from various cells types in culture, such as human 
umbilical vein endothelial cells, primary human macrophages, vascular smooth muscle 
cells and even synoviocytes obtained from patients with rheumatoid arthritis (Rezaie-
Majd et al. 2002; Dichtl et al. 2003; Veillard et al. 2006; Xu et al. 2006). In one study, 
simvastatin lowered the pro-inflammatory cytokine, TNF and increased IL-10 
production from RAW264.7 macrophages, at 10µM and 30µM respectively, as well 
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as significantly reducing IκBα degradation and NF-κB translocation (Leung et al. 
2011). As a future experiment, it would be interesting to investigate whether 
simvastatin treatment is affecting the transcription factor, NF-κB, in these myometrial 
cells. 
The rationale for performing co-, pre- and post-treatments was to aid better 
understanding of the potential clinical application of statin treatment; whether it be 
used as a preventative measure for high risk patients or given at the onset of PTL. Co-
treatment with simvastatin had greater anti-inflammatory effects than either the pre-
treatment or post-treatment. However, this may not be a clinically relevant treatment 
regimen. Pre-treatment induced a greater increase in anti-inflammatory genes and 
post-treatment showed a greater reduction in the pro-inflammatory mediators. It is 
important to note that variation within the groups perhaps prevented the trends 
achieving statistical significance and also the slightly shorter incubation time with 
simvastatin for the post-treatment group, may have affected the results. In a similar 
study, simvastatin was shown to reduce the secretion of a range of pro-inflammatory 
cytokines from LPS-stimulated human fetal membranes. In this study, pre-treatment 
with simvastatin 6 hours before LPS stimulation appeared more effective at reducing 
inflammatory cytokine release and soluble cytokine receptors than co-treatment or 
post-treatment. Co-treatment was the least effective method, as it did not significantly 
reduce IL-1β, IL-6 or TNF secretion, compared to the LPS group (Basraon et al. 2015). 
Further experimentation is required to tease out the most effective statin treatment 
protocol for reducing inflammation. 
The anti-inflammatory effects described in some of the above studies were achieved 
by lower concentrations of simvastatin than the experiments presented in this chapter. 
For the current experiments, concentrations of simvastatin were chosen based on 
previous studies which describe therapeutic concentrations (0.1µM), a common mid-
range concentration used in cell culture (10µM) and a higher concentration (50µM) 
(Lilja et al. 1998; Dichtl et al. 2003; Leung et al. 2003; Bjorkhem-Bergman et al. 2011; 
Chang et al. 2014; Basraon et al. 2015). It is possible that responsiveness to simvastatin 
therapy may be influenced by the specific cell type. Interestingly, in these myometrial 
cells, simvastatin only reduced pro-inflammatory mediators at 50µM but 10µM 
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simvastatin was sufficient to increase the expression of anti-inflammatory genes. It 
would be informative to treat the myometrial cells with lower concentrations of 
simvastatin to gain a better understanding of the specific concentrations required to 
see an effect. Importantly, despite these higher concentrations, the metabolic activity 
of the cells was not compromised by 50µM simvastatin. 
In summary, pravastatin treatment did not affect myometrial cell morphology or cell 
metabolic activity. Pravastatin treatment also did not alter the expression of 
inflammatory mediators, following LPS stimulation. However, it is likely that the 
myometrial cells do not possess the transporter protein that pravastatin requires for cell 
entry. Simvastatin may have induced some slight morphology changes in the 
myometrial cells but cell metabolic activity was unaffected. In contrast to pravastatin, 
simvastatin treatment was capable of reducing LPS-induced inflammation, by both 
lowering the expression of pro-inflammatory mediators and increasing the expression 
of anti-inflammatory mediators.
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Chapter 4: Determining the effect of simvastatin 
treatment on human myometrial cell 
contraction and the mechanisms contributing 
to this effect 
4.1 Introduction 
Myometrial contractions are key to the labour process, as the uterus switches from 
quiescent to active (Romero et al. 1994). These contractions are mainly regulated by 
calcium flux (Figure 4.1). Briefly, a substantial increase in intracellular Ca2+ 
concentration activates calmodulin, a Ca2+-dependent protein found in the cytoplasm. 
Calmodulin can bind four Ca2+ ions. This complex subsequently activates MLCK, 
leading to the cross-bridging of actin and myosin and a prominent increase in the 
phosphorylation of MLC. This action determines the amplitude and duration of the 
contraction (Haeberle et al. 1985; Csabina et al. 1986; Word et al. 1993). The small 
GTPase, RhoA, is a major regulator of calcium sensitisation within cells. It acts 
through its effector, ROCK, to inactivate the enzyme, MLCP, potentiating the 
contractile effects of elevated intracellular Ca2+ (Uehata et al. 1997; Hartshorne et al. 
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Figure 4.1. The molecular pathways in smooth muscle contraction. Intracellular Ca2+ concentration 
increases through Ca2+ influx into the cells or by Ca2+ release from intracellular stores, such as the SR. 
The Ca2+/calmodulin complex forms and activates MLCK. MLCK phosphorylates MLC (20kDa), 
causing smooth muscle contraction. MLCP dephosphorylates MLC to induce relaxation. RhoA-GTP 
activates ROCK, which can inhibit the actions of MLCP directly or by protein phosphatase 1 regulatory 
subunit 14A (CPI-17) phosphorylation. ROCK may also phosphorylate MLC directly, similarly to 
MLCK. ROCK: Rho-kinase. MLC: Myosin light chain. MLCP: Myosin light chain phosphatase. 
MLCK: Myosin light chain kinase. SR: sarcoplasmic reticulum Adapted from de Godoy & Rattan 
(2011). 
There is growing evidence to suggest that statins have anti-contractile actions. For 
example, they reduce the contractile response of vascular smooth muscle cells and 
endometriotic stromal cells (Kuzuya et al. 2004; Mraiche et al. 2005; Perez-Guerrero 
et al. 2005; Nasu et al. 2009; Gonzalez et al. 2014). 
Statins exert their effects by targeting the mevalonate pathway, a key metabolic 
pathway, important in multiple cellular processes (Buhaescu and Izzedine 2007). 
Statins competitively inhibit HMG-CoA reductase (Figure 4.2). This enzyme catalyses 
the conversion of HMG-CoA to mevalonate, an early rate-limiting step in cholesterol 
synthesis. Mevalonate is then converted to sterol isoprenoids, as well as non-sterol 
isoprenoids, of which F-PP and GG-PP are components. These intermediate 
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metabolites play important roles in the post-translational modification of proteins 
involved in intracellular signalling, cell growth, gene expression, protein glycosylation 
and cytoskeletal assembly (Buhaescu and Izzedine 2007). F-PP is the last product of 
the isoprenoid metabolic pathway with the potential to be incorporated into either 
sterol or non-sterol end products (Bradfute and Simoni 1994). Isoprenylation of GG-
PP is crucial for the activation of small GTPases, such as Rho, Rac and Cdc42. Many 
studies have proposed that the mechanism by which statins exert their anti-contraction 
effect is by inhibiting RhoA, which has an important role in the regulation of the actin 
cytoskeleton. Inhibiting the prenylation of RhoA prevents the downstream 
phosphorylation of MLC (Alvarez de Sotomayor et al. 2001; Mraiche et al. 2005; 
Kuhlmann et al. 2006; Nagaoka et al. 2007; Kidera et al. 2010; Wu et al. 2011; Xiao 









Figure 4.2. The mevalonate pathway. Statins inhibit HMG-CoA reductase from catalysing the 
conversion of HMG-CoA to mevalonate. This inhibits the production of cholesterol, as well as non-
sterol isoprenoid components, such as F-PP and GG-PP, which are important for post-translational 
protein modification. 
Chapter 3 demonstrated that simvastatin could reduce LPS-induced inflammation in 
human myometrial cells. Therefore, these results suggested that simvastatin treatment 
could reduce the pro-inflammatory environment associated with PTL initiation. As 
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myometrial contraction is a key process in term labour and PTL, and the tocolytic 
drugs currently available are ineffective, this chapter investigated whether simvastatin 
could inhibit myometrial contractile response. The hypothesis was that simvastatin 
will prevent myometrial cell contraction in vitro. The aim of this chapter was to 
investigate the effect of simvastatin on the contractile ability of a human myometrial 
cell line. Furthermore, mevalonate, GG-PP and F-PP were supplemented to 
simvastatin treatments to decipher a mechanism of action. 
4.2 Methods 
4.2.1 MTT metabolic activity assay  
Analysis of myometrial cell metabolic activity was performed using an MTT assay, as 
detailed in 2.5. Myometrial cells were treated with simvastatin (10, 50µM) and 
supplemented with LPS (25ng/ml), mevalonate (200µM), GG-PP (10µM) or F-PP 
(10µM), in triplicate. Cells were incubated with treatments for 48 hours (n=4). 
4.2.2 Collagen gel contraction assay 
Simvastatin concentration response experiments were performed using collagen, 
which was extracted from rat tails, as described in 2.6.1. All other experiments were 
performed using commercially purchased rat tail collagen. Collagen gel contraction 
assays were performed by embedding myometrial cells in rat tail collagen and seeding 
non-treated 24-well plates at 105 cells/well, as described in 2.6.2. The gels were 
allowed to polymerise overnight and were then detached and treated with simvastatin 
(10, 50µM), in the presence or absence of LPS (25ng/ml), mevalonate (200µM), GG-
PP (10µM) or F-PP (10µM). The plates were incubated at 37°C and photographed at 
0, 24 and 48 hours using a Leica MZ6 light microscope/camera. Treatments were 
added in 6 technical replicates. For treatment concentration selection, n=1-6: 
simvastatin (0.1-100µM), LPS (25-400ng/ml), mevalonate (100, 200µM), GG-PP (10-
40µM) or F-PP (10-100µM). For final experiments, n=6-11. Results are presented as 
a percentage of the vehicle mean gel size at baseline (0 hours or 24 hours, experiment 
dependent). 
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4.2.3 In-Cell Western 
In-Cell Western analyses were performed to quantify pMLC in myometrial cells. Cells 
were seeded at 2x104 cells/well, in black, clear base 96-well plates, as outlined in 2.7. 
Cells were treated in triplicate with simvastatin (10, 50µM) and supplemented with 
LPS (25ng/ml), mevalonate (200µM), GG-PP (10µM) or F-PP (10µM). The 
treatments were removed after 48 hours and the cells were fixed in formaldehyde, 
incubated with primary antibodies for pMLC and α-Tubulin, followed by secondary 
LI-COR antibodies and then fluorescence was read on the Odyssey® CLx Imaging 
System (n=5). Results are presented as intensity ratios of α-Tubulin:pMLC, within the 
same well. 
4.2.4 Statistical analysis 
Data are presented as mean ± SEM and were analysed using GraphPad Prism. In these 
studies, “n” denotes the number of individual experiments performed, with the 
replicate number per experiment indicated in the figure legends. The percentage data 
for collagen gel contraction were analysed by performing an arcsine transformation on 
the proportions, followed by a one-way ANOVA, with either Dunnett’s or Holm-Sidak 
post hoc test. In-Cell Western data were analysed by one-way ANOVA, followed by 
Dunnett’s post hoc test. 
4.3 Results 
4.3.1 The effect of simvastatin, LPS, mevalonate, GG-PP 
and F-PP treatments on myometrial cell metabolic 
activity  
As discussed in Chapter 3, simvastatin and LPS treatment did not affect the 
metabolism of the myometrial cells at 24 hours. In this chapter, treatment incubations 
for the collagen gel assay and the In-Cell Western assay lasted 48 hours. Therefore, 
MTT assays were performed to investigate the effect simvastatin and LPS have on the 
cells after 48 hours. In addition, MTT assays were carried out for the metabolites of 
the mevalonate pathway, mevalonate, GG-PP and F-PP, which the cells were 
supplemented with to investigate a mechanism of action. 
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Following 48 hours of treatment, 10µM and 50µM simvastatin did not affect 
myometrial cell metabolic activity (Figure 4.3). This was also true for LPS treatment 
alone (25ng/ml) and when the cells were co-treated with LPS and 10µM and 50µM 
simvastatin (Figure 4.3A). Furthermore, mevalonate (200µM), GG-PP (10µM) and F-
PP (10µM) did not affect cell metabolic activity, when given alone or in combination 
















Figure 4.3. Metabolic activity of myometrial cells when treated with simvastatin, LPS, 
mevalonate, GG-PP or F-PP for 48 hours. (A-D) Simvastatin (10, 50µM) treatment did not alter 
myometrial cell metabolic activity. (A) LPS, (B) mevalonate, (C) GG-PP or (D) F-PP did not affect 
myometrial cell metabolic activity when given alone or with simvastatin treatment. n=4 (in triplicate), 
vehicle (veh): (A) PBS, (B) EtOH diluted in PBS, (C, D) CH3OH diluted in PBS, mean ± SEM.  
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4.3.2 The influence of simvastatin treatment on 
myometrial cell contractility, alone and with LPS 
stimulation 
4.3.2.1 The effect of simvastatin on the basal contraction of 
myometrial cells  
Experiments were performed to establish the effect of simvastatin on myometrial cell 
contractility over a range of concentrations. The myometrial cells were embedded in 
collagen gel and the gel sizes were analysed at 24 and 48 hours.  
As these are smooth muscle cells, the vehicle (PBS) treated gels established a basal 
contraction, causing the gel size to reduce over time (Figure 4.4). Following 24 hours 
of 10µM simvastatin treatment, the mean gel size was significantly larger than the 
vehicle mean gel size, suggesting that contraction was attenuated (mean gel size 117.5 
± 3.4% vs vehicle mean 100 ± 3.1%, p=0.0068). Simvastatin, at concentrations of 
25µM and 50µM, also prevented contraction at 24 hours (115.2 ± 3.7%, p=0.023 and 
118.3 ± 4.3%, p=0.004, respectively). 
At 48 hours, the mean size of the vehicle gel had reduced to 85.6 ± 4.8% of the mean 
gel size at 24 hours, displaying further basal contraction (Figure 4.4B). When the cells 
were treated with 10µM simvastatin, the mean gel size was again significantly larger 
than the vehicle (114.6 ± 3.1%, p=0.0003). The mean gel sizes were also significantly 
larger than the vehicle when they were treated with 25µM simvastatin (116.8 ± 2.5%, 
p<0.0001), 50µM simvastatin (119.9 ± 3.5%, p<0.0001) and 100µM simvastatin 
(110.1 ± 5.7%, p=0.0104). There was no significant difference between the vehicle 
and gels treated with 0.1µM or 1µM simvastatin after 48 hours. Simvastatin 
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Figure 4.4. The effect of simvastatin treatment on basal myometrial cell contraction. (A) At 24 
hours, when gels were treated with 10, 25 and 50µM simvastatin, the mean gel size was significantly 
larger than the vehicle. (B) After 48 hours, gels treated with 10, 25, 50 and 100µM simvastatin were 
significantly larger in size than the vehicle. n=3-8 (4-6 replicates), vehicle = PBS, *p<0.05, **p<0.01, 
***p<0.001, ****p<0.0001, mean ± SEM, one-way ANOVA with Dunnett’s post hoc test. 
4.3.2.2 The effect of LPS stimulation on myometrial cell 
contraction  
Firstly, a concentration response experiment was performed to determine whether LPS 
could induce further contractions over the vehicle. Secondly, the anti-contractile effect 
of simvastatin within an LPS-induced inflammatory environment was investigated. 
Gels were analysed at 0, 24 and 48 hours. 
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4.3.2.2.1 LPS concentration response 
An LPS concentration response experiment was performed to investigate the effect of 
LPS on the contraction of the myometrial cells. After 24 hours, contraction was evident 
in the vehicle (PBS) group by the reduction of the mean gel size to 61.4 ± 2.6% of its 
original size at 0 hours (Figure 4.5B). However, concentrations of LPS from 25-
400ng/ml did not significantly increase (or decrease) the contraction of the gels, as 
they were similar in size to the vehicle gels.  
By 48 hours, the vehicle mean gel size had reduced to 45.6 ± 2.7% of its original size 
(Figure 4.5C). Again, there was no significant effect of LPS on the gel size, compared 
to the vehicle. However, there was a slight trend appearing, as the gel sizes from 
treatments with 25, 50 and 100ng/ml LPS looked marginally reduced. The largest 
difference in gel size was with 25ng/ml LPS, where the mean gel size was 8% smaller 
than the vehicle (p=0.1679). Although there was no statistical difference, this 
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Figure 4.5. The effect of LPS on myometrial cell contraction. (A-C) LPS concentrations from 25-
400ng/ml did not significantly induce further contraction of the myometrial cells, when compared to 
the vehicle mean gel size. (C) However, a trend to reduce mean gel size was observed for the lower 
concentrations, particularly 25ng/ml. n=5-11 (4-6 replicates), vehicle = PBS, mean ± SEM. 
 
4.3.2.2.2 The effect of LPS and simvastatin on myometrial cell 
contraction 
The basal contraction of the myometrial cells was evident within 24 hours, as the mean 
gel size reduced to 59.8 ± 1.9% of the baseline gel size (Figure 4.6A-C). Gels treated 
with 10µM simvastatin were 16.6% larger than the mean vehicle size (69.7 ± 3.1%, 
p=0.0059). Gels treated with 50µM simvastatin were also significantly larger than the 
vehicle (67.5 ± 2.0%, p=0.027). LPS treatment caused the mean gel size to reduce to 
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54.2 ± 1.8%, making it 10.3% smaller than the vehicle (p=0.0293). Even in the 
presence of LPS, 10µM simvastatin attenuated the contractile ability of the cells, as 
the mean gel size was 17.4% larger than the vehicle (70.2 ± 1.8%, p=0.0059). This 
was also observed with 50µM simvastatin, where the mean gel size was 70.3 ± 1.7%, 
17.6% larger than the vehicle (p=0.0059).  
After 48 hours, the mean vehicle gel size had further reduced to 43.4 ± 1.6% of its 
original size (Figure 4.6A, D). When gels were treated with 10µM simvastatin alone, 
the mean gel size was 64.4 ± 2.3%, 48.4% larger than the vehicle (p<0.0001). 
Following treatment with 50µM simvastatin, gel sizes were 54.8% larger than the 
vehicle (67.2 ± 2.0%, p<0.0001). The LPS treated gels were still significantly smaller 
than the vehicle gels (37.8 ± 1.6%, p=0.0247). When the gels were treated with both 
10µM simvastatin and LPS, the simvastatin treatment once again inhibited the 
contraction of the gels, as they were 52.1% larger than the vehicle (66.0 ± 2.4%, 
p<0.0001). This was also observed following 50µM simvastatin and LPS treatment, 
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Figure 4.6. The effect of simvastatin treatment on basal and LPS-induced myometrial cell 
contraction. (A) Representative gel images showing gel size at 0, 24 and 48 hours. (B-D) Vehicle gel 
size reduced over time. This contraction was attenuated by simvastatin treatment (10, 50µM). LPS 
treatment (25ng/ml) caused further reduction in gel size, compared to the vehicle. Simvastatin treatment 
(10, 50µM) inhibited the contraction of the gels, even in the presence of LPS. n=5-10 (4-6 replicates), 
vehicle (veh) = PBS, *p<0.05, **p<0.01, ****p<0.0001, mean ± SEM, one-way ANOVA with Holm-
Sidak post hoc test. 
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4.3.3 The effect of mevalonate, GG-PP and F-PP 
supplementation on simvastatin-induced 
contractile attenuation 
4.3.3.1 Mevalonate 
The mevalonate pathway is the main target of statins. By inhibiting HMG-CoA 
reductase, statins prevent the reduction of HMG-CoA to mevalonate by nicotinamide 
adenine dinucleotide phosphate (NADPH) (Friesen and Rodwell 2004). By 
supplementing simvastatin-treated gels with mevalonate, any reversal of the impact of 
simvastatin would imply that these anti-contractile actions were as a result of inhibiting 
the mevalonate pathway, rather than an alternative pathway. 
4.3.3.1.1 Mevalonate concentration response 
Firstly, preliminary experiments were carried out to choose a concentration of 
mevalonate (n=2). Both 100µM and 200µM mevalonate are widely used in the 
literature (Qi et al. 2013; Alarcon and Marikawa 2016). In these concentration 
response experiments, both concentrations appeared to abolish the effect of 10µM 
simvastatin (Figure 4.7). For use in the following experiments, 200µM mevalonate 
was chosen, as it appeared to inhibit 10µM simvastatin marginally more and it was 
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Figure 4.7. Selection of mevalonate concentration. (A-C) Mevalonate at 100µM and 200µM showed 
a trend to reduce the anti-contractile effect of simvastatin (10µM), allowing the gel size to decrease. (C) 
Mean gel size after simvastatin and 200µM mevalonate appeared marginally more similar to the vehicle 
gel size at 48 hours. n=2-4 (4-6 replicates), vehicle (veh) = EtOH diluted in PBS, mean ± SEM. 
4.3.3.1.2 The effect of mevalonate on the anti-contractile action 
of simvastatin  
After 24 hours, vehicle gels had reduced to a mean size of 55.7 ± 1.4% (Figure 4.8A-
C). When the gels were treated with 10µM and 50µM simvastatin, the mean gel sizes 
were 20.8% and 17.2% larger than the vehicle (67.3 ± 2.2%, p<0.0001; 65.3 ± 0.7%, 
p=0.0021, respectively). Mevalonate treatment alone allowed the gels to contract and 
the mean gel size reduced to 55.2 ± 1.4%, similar to the vehicle. When gels were 
treated with either 10µM or 50µM simvastatin and mevalonate, the gels reduced in 
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size, abolishing the anti-contractile effect of simvastatin (mean gel sizes 58.2 ± 2.4% 
and 56.1 ± 0.9%, respectively). 
Following 48 hours of treatment, the vehicle mean gel size had reduced further to 39.6 
± 1.2% of its original size (Figure 4.8A, D). Simvastatin (10µM, 50µM) treated gels 
were both 60.1% larger than the vehicle mean (63.4 ± 1.7% and 63.4 ± 1.9%, 
p<0.0001). Again, when gels were treated with 10µM and 50µM simvastatin and 
supplemented with mevalonate, gel sizes reduced, inhibiting the anti-contractile action 
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Figure 4.8. The effect of mevalonate supplementation on the anti-contractile effect of simvastatin 
on myometrial cells. (A) Representative gel images at 0, 24 and 48 hours. (B-D) Vehicle gels reduced 
in size over time. Simvastatin treatment (10, 50µM) attenuated this contraction, resulting in significantly 
larger gel sizes. When gels received simvastatin and mevalonate (200µM), the effect of simvastatin was 
inhibited and the gel size reduced. n=5-11 (4-6 replicates), vehicle (veh) = EtOH diluted in PBS, 
**p<0.01, ****p<0.0001, mean ± SEM, one-way ANOVA with Dunnett’s post hoc test. 
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4.3.3.2 GG-PP 
GG-PP is an intermediate metabolite of the mevalonate pathway, which is key to the 
post-translational modifications of small GTPases, such as Rho, Rac and Cdc42 
(Nurenberg and Volmer 2012).  
4.3.3.2.1 GG-PP concentration response 
A preliminary concentration response experiment was carried out to choose a 
concentration of GG-PP (n=1). The most commonly used concentration cited in the 
literature is 10µM (Qi et al. 2013; Alarcon and Marikawa 2016). This appeared to 













Figure 4.9. Selection of GG-PP concentration. (A, B) GG-PP appeared to inhibit simvastatin action 
at 10, 20 and 40µM. n=1 (4-6 replicates), vehicle (veh) = CH3OH diluted in PBS. 
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4.3.3.2.2 The effect of GG-PP on the anti-contractile action of 
simvastatin  
At 24 hours, the vehicle mean gel size had reduced to 50.9 ± 1.6%, compared to the 
mean gel size at 0 hours, showing basal contraction of the cells (Figure 4.10A-C). 
Treating the gels with 10µM simvastatin resulted in gels 16.5% larger than the vehicle 
mean (59.3 ± 3.6%, p=0.0483). This affect was also observed with 50µM simvastatin, 
where the gels were 20.6% larger than the vehicle (61.4 ± 2.9%, p=0.0107). GG-PP 
treatment alone did not affect the contraction of the gels, which were a similar size to 
the vehicle (52.5 ± 1.7%). However, when the gels received 10µM and 50µM 
simvastatin and GG-PP, the gels contracted, abolishing the effect of simvastatin (mean 
gel sizes 48.1 ± 2.0% and 49.8 ± 3.4%, respectively). 
The same effects were observed at 48 hours (Figure 4.10A, D). The vehicle mean gel 
size reduced to 36.0 ± 1.6% and simvastatin (10, 50µM) alone resulted in larger gel 
sizes (10µM: 50.3 ± 3.6%, p=0.0027; 50µM: 63.1 ± 3.3%, p<0.0001). When gels 
received 10µM and 50µM simvastatin and GG-PP, the gel sizes reduced and were 
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Figure 4.10. The effect of GG-PP supplementation on the anti-contractile effect of simvastatin. 
(A) Representative gel images at 0, 24 and 48 hours. (B-D) Vehicle gels reduced in size over time. 
Simvastatin treatment (10, 50µM) attenuated this reduction, resulting in significantly larger gel sizes. 
When gels received simvastatin and GG-PP (10µM), the gel size reduced and the effect of simvastatin 
was inhibited. n=5-10 (4-6 replicates), vehicle (veh) = CH3OH diluted in PBS, *p<0.05, **p<0.01, 
****p<0.0001, mean ± SEM, one-way ANOVA with Dunnett’s post hoc test. 
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4.3.3.3 F-PP 
F-PP is another metabolite of the mevalonate pathway, which branches out into a sterol 
pathway, for products such as cholesterol, and a non-sterol pathway, for the post-
translational modifications of small GTPases, such as Ras (Nurenberg and Volmer 
2012).  
4.3.3.3.1 F-PP concentration response 
A preliminary concentration response was carried out to choose a concentration of F-
PP (n=1). The most commonly used concentration in the literature is 10µM (Qi et al. 
2013; Alarcon and Marikawa 2016). Concentrations up to 100µM were tested (Figure 
4.11). However, none of these affected the anti-contractile effect of simvastatin and 
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Figure 4.11. Selection of F-PP concentration. (A, B) F-PP did not appear to affect simvastatin action 
at 10, 20, 40, 80 or 100µM. n=1 (4-6 replicates), vehicle (veh) = CH3OH diluted in PBS.  
4.3.3.3.2 The effect of F-PP on the anti-contractile action of 
simvastatin 
After 24 hours, the mean vehicle gel size had reduced to 50.8 ± 1.2% of the baseline 
size (Figure 4.12A-C). Simvastatin, at both 10µM and 50µM, attenuated the 
contraction of the gels with sizes of 58.1 ± 2.5% and 62.0 ± 2.1% (p=0.032 and 
p=0.0005 vs vehicle, respectively). F-PP alone did not affect the basal contraction of 
the gels, as they reduced to 50.5 ± 1.2%, similar in size to the vehicle. When gels were 
treated with 10µM simvastatin and F-PP, they were 19.1% larger than the vehicle gels 
(60.5 ± 3.3%, p=0.0024). This was also observed with 50µM simvastatin and F-PP, 
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where the mean gel size was 26.8% larger than the vehicle (64.1 ± 1.4%, p<0.0001), 
showing that simvastatin was still having an anti-contractile affect. 
Following 48 hours of incubation, the vehicle mean gel size reduced further to 33.9 ± 
0.9% of its original size (Figure 4.12A, D). Treatment with 10µM and 50µM 
simvastatin still attenuated gel contraction, resulting in significantly larger gels than 
the vehicle (50.1 ± 4.1%, p=0.0001 and 58.2 ± 1.9%, p<0.0001, respectively). When 
gels received 10µM simvastatin and F-PP, the gel size was 50.5 ± 4.7%, 50.0% larger 
than the mean vehicle gel size (p<0.0001). Furthermore, 50µM simvastatin and F-PP 
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Figure 4.12. The effect of F-PP supplementation on simvastatin’s anti-contractile effect. (A) 
Representative gel images at 0, 24 and 48 hours. (B-D) Vehicle gels reduced in size over time. 
Simvastatin treatment (10, 50µM) attenuated this reduction, resulting in significantly larger gel sizes. 
When gels received simvastatin and F-PP (10µM), gel contraction was still inhibited, as the gel sizes 
remained significantly larger than the vehicle. n=5-10 (4-6 replicates), vehicle (veh) = CH3OH diluted 
in PBS, *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001, mean ± SEM, one-way ANOVA with 
Dunnett’s post hoc test. 
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4.3.4 The influence of simvastatin, LPS and the 
mevalonate pathway metabolites on the 
phosphorylation of MLC in myometrial cells 
Smooth muscle contraction is mediated by the phosphorylation of MLC via MLCK 
and/or ROCK (Schaafsma et al. 2008). The In-Cell Western technique was utilised to 
investigate the effect simvastatin has on pMLC levels.  
Simvastatin treatment significantly reduced pMLC levels, both alone (10µM 
p=0.0112, 50µM p<0.0001 vs vehicle) and in the presence of inflammatory stimulation 
with LPS (10µM p=0.0493, 50µM p<0.0001 vs vehicle; Figure 4.13, Figure 4.14A). 
LPS alone did not affect the expression of pMLC (p=0.7905). Once again, when the 
simvastatin treated cells received either mevalonate or GG-PP supplementation, the 
effect of simvastatin was abolished and the pMLC levels were akin to the vehicle 
treated cells (Figure 14.3, Figure 14.4B, C). When the simvastatin treated cells were 
supplemented with F-PP, pMLC levels were significantly reduced compared to the 
vehicle (10µM p=0.0452, 50µM p=0.0008; Figure 14.3, Figure 14.4D). Thus, F-PP 
addition did not abolish the pMLC lowering effect of simvastatin. Complementing the 
results of the collagen gel contraction assay, mevalonate and GG-PP, but not F-PP, 
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Figure 4.13. Levels of pMLC following simvastatin treatment (48 hours). This In-Cell Western 
representative image shows that 10µM and 50µM simvastatin concentration-dependently reduced 
pMLC (green) levels in myometrial cells. When 200µM mevalonate and 10µM GG-PP were added, 
pMLC levels were restored and the well appeared more green. However, 10µM F-PP did not affect 
pMLC levels, as α-Tubulin (red) is more dominant in these wells, as observed in the simvastatin-treated 
wells. n=5 (in triplicate).  
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Figure 4.14. The effect of supplementation with LPS, mevalonate, GG-PP and F-PP on pMLC 
levels (48 hours). Signal intensity ratios (α-Tubulin:pMLC) (A) Simvastatin (10, 50µM) significantly 
lowered levels of pMLC, alone and in the presence of LPS. LPS did not affect pMLC levels. (B, C) 
Mevalonate (200µM) and GG-PP (10µM) rescued pMLC levels when given with simvastatin. (D) F-
PP did not affect pMLC levels, when cells received simvastatin treatment. n=5 (in triplicate), vehicle 
(veh): (A) PBS, (B) EtOH diluted in PBS, (C, D) CH3OH diluted in PBS, *p<0.05, **p<0.01, 
***p<0.001, ****p<0.0001, mean ± SEM, one-way ANOVA with Dunnett’s post hoc test. 
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4.4 Discussion 
4.4.1 Simvastatin attenuates the basal contraction of 
human myometrial cells 
In the collagen gel assay, the gels exerted basal contraction, due to the contractile 
ability of the smooth muscle cells, as previously described (Hutchinson et al. 2014; 
Makieva et al. 2016). This led to the gel area reducing, which was evident after 24 
hours in all experiments. Simvastatin treatment was able to lessen the contraction, 
resulting in significantly larger gel sizes, when comparing to the vehicle. This effect 
was shown at both 24 hours and 48 hours of treatment with simvastatin.  
The anti-contractile effect of simvastatin has been previously described at similar 
concentrations as used in this chapter. Simvastatin reduced the contraction of human 
lung fibroblasts embedded in collagen gels, both alone and in the presence of TNF, IL-
1β and neutrophil elastase (Ra et al. 2011). Simvastatin treatment also inhibited 
vascular contraction in rat aortic rings (Mraiche et al. 2005; Rossoni et al. 2011; Chen 
et al. 2016). In addition, organ bath studies have reported anti-contractile effects of 
simvastatin. For instance, simvastatin reduced the frequency of spontaneous and C5a-
induced contraction in human myometrial samples pre-treated with simvastatin, as 
well as in myometrial tissue collected from simvastatin-treated mice (Gonzalez et al. 
2014). 
The simvastatin concentration response experiments were performed with collagen, 
which was crudely extracted from rat tails within the laboratory. However, 
commercially obtained collagen was used for all further experiments. This did not 
seem to limit the experiment, as the ability of simvastatin to attenuate contraction was 
unaffected by this change in material.  
In the simvastatin concentration response experiments, there did not appear to be a 
concentration-dependent effect. Simvastatin had no effect on contraction at 0.1µM or 
1µM but inhibited contraction at concentrations of 10µM and above, with little 
difference between 10, 25 and 50µM. The highest concentration of 100 µM 
simvastatin, only reduced contraction at 48 hours. For consistency, 10µM and 50µM 
simvastatin were chosen for further experimentation, so comparisons could be drawn 
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with the results outlined in Chapter 3. Interestingly, in these experiments, both 10µM 
and 50µM simvastatin consistently attenuated contraction, with no obvious difference 
in response between concentrations, whereas in Chapter 3 the anti-inflammatory 
properties of 50µM simvastatin were superior to those of the 10µM concentration.  
Simvastatin may affect the shape of cells, as discussed in Chapter 3. This may have 
affected the contractile ability of the myometrial cells. In a study examining the effect 
of simvastatin on endometriotic stromal cell contraction, simvastatin inhibited 
collagen gel contraction and also altered the morphology of the cells. The collagen 
gels were fixed following contraction analysis and observed by laser scanning 
microscopy. Untreated, dendritic-shaped cells adhered to collagen fibres and 
contracted to form a dense, tissue-like structure. In contrast, the cells that received 
simvastatin had become rounded and did not readily adhere to the collagen fibres 
(Nasu et al. 2009).  
It would have been ideal to use primary myometrial cells or tissue to perform these 
investigations, as an immortalised myometrial cell line may be less representative of 
the myometrium in vivo. However, these resources are limited. It would also have been 
informative to perform organ bath studies with human myometrial strips. However, 
these experiments are not only demanding of human samples, but are unable to 
determine long term effects, as contractions in an organ bath are unreliable after 24 
hours. They are also less suitable for teasing out which particular element of the 
pathway is targeted by a drug. Other studies have previously shown that simvastatin 
inhibits the frequency of myometrial contractions, but intensity was not formally 
quantified (Gonzalez et al. 2014).  
4.4.2 Simvastatin attenuates LPS-induced contraction of 
human myometrial cells 
Labour is an inflammatory process, which requires the influx of leukocytes into the 
myometrium and an increase in the production of inflammatory mediators, to stimulate 
contractions. In addition, it is thought that infection is the cause of 25-40% of PTBs 
(Goldenberg et al. 2008). Therefore, LPS was added to the collagen gel assay to model 
this. LPS was shown to stimulate the gels to contract even further. This makes the 
collagen assay a highly relevant myometrial contraction assay system. Remarkably, 
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simvastatin was able to attenuate contraction even in the presence of LPS. This is an 
interesting and important finding as, by stopping myometrial contractions within an 
inflammatory environment, simvastatin could be a useful therapeutic for PTL. A 
previous study from our laboratory also found that LPS was capable of inducing these 
myometrial cells to contract more than the vehicle treated cells (Hutchinson et al. 
2014). Although, these experiments utilised a different serotype of LPS.  
In the LPS concentration response experiment, none of the concentrations significantly 
reduced the gel size in comparison to the vehicle. Although, the lower concentrations 
appeared to slightly reduce the mean gel size. Perhaps the variation and multiple 
groups within the analysis prevented statistical significance, as 25µg LPS did 
significantly reduce the gel size in later experiments. It was surprising that higher 
concentrations of LPS did not affect the contraction of the cells. It would be interesting 
to lower the concentration of LPS, to see if this would induce more contraction. A 
possible explanation for the difficulty in inducing increased contraction is that the gels 
already reduced greatly in size due to the basal contraction of the cells. By 48 hours, 
the gels were very small. It is likely that they were so densely packed, that they could 
not reduce much more in size.  
4.4.3 Mevalonate and GG-PP but not F-PP, abolish the 
anti-contractile effect of simvastatin 
Statins are inhibitors of the mevalonate pathway. Mevalonate is the first metabolite of 
which production is inhibited when statins competitively inhibit HMG-CoA reductase. 
In the collagen assay experiments, mevalonate supplementation reversed the anti-
contractile effects of simvastatin. This implies that simvastatin is, in fact, affecting the 
contraction of the myometrial cells by targeting the mevalonate pathway, rather than 
an alternative pathway. 
Isoprenoid pyrophosphates, F-PP and GG-PP, are branching points in the mevalonate 
pathway. F-PP further branches out into a sterol pathway, to produce cholesterol for 
instance, and a non-sterol pathway, for the post-translational modifications of proteins. 
Small GTPases are isoprenylated by covalent attachment to F-PP, for Ras, or GG-PP, 
for Rho, Rac and Cdc42 (Nurenberg and Volmer 2012). In the contraction assay, GG-
PP abolished the anti-contractile actions of simvastatin. This suggests that the anti-
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contractile effect of simvastatin was via the inhibition of geranylgeranylation of small 
GTPases. In contrast, F-PP supplementation did not reverse the effects of simvastatin. 
This implies that these pleiotropic effects were independent of both cholesterol and 
farnesylated protein inhibition.  
Although F-PP is the precursor to GG-PP, F-PP failed to reverse simvastatin effects. 
To produce GG-PP, both F-PP and I-PP must be present (Nurenberg and Volmer 
2012). When F-PP alone is added back into a statin treatment experiment, I-PP is not 
present, thus GG-PP cannot be produced in this artificial setting. This explains how 
the differential effects of these intermediates can be identified in vitro. It can be 
hypothesised that by supplementing simvastatin experiments with both F-PP and I-PP, 
G-PP may be produced and the actions of simvastatin could be reversed. This 
experiment could be performed in the future. 
The results of these mechanism studies confirmed and extend those in the literature. 
Mraiche et al. (2005) reported that simvastatin induced relaxation in vascular smooth 
muscle cells by preventing Rho geranylgeranylation (Mraiche et al. 2005). Similar 
studies also attributed simvastatin-induced vasodilation of endothelial cells and the 
relaxation of vascular smooth muscle cells to the inhibition of the mevalonate/ROCK 
pathway (Alvarez de Sotomayor et al. 2001; Nagaoka et al. 2007). 
This mechanism has also been observed with other statins. For example, fluvastatin 
reduced the contraction of rat myofibres. These effects were reversed by GG-PP but 
not F-PP and mimicked by a specific geranylgeranyl transferase inhibitor (GGTI-289) 
(Tanaka et al. 2010). A study investigating endothelial junction integrity found that 
atorvastatin prevented the translocation of Rho to the endothelial cell membrane. This 
resulted in cytoskeletal rearrangement, which was due to the inhibition of 
geranylgeranylation and not farnesylation (Xiao et al. 2013). 
In contrast to these findings, which have utilised drugs renowned for their cholesterol-
lowering properties, one study suggested that high levels of cholesterol may reduce 
uterine activity. The addition of cholesterol to myometrial strips dissected from 
pregnant rats reduced the frequency and amplitude of contractions (Smith et al. 2005). 
The authors suggest that this may explain the difficulties obese/dyslipidaemic women 
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can have when labouring and how low cholesterol levels may lead to conditions such 
as PTB. However, there has been little evidence since to support these claims. 
Cholesterol levels could be investigated in the myometrial cells following simvastatin 
treatment. However, it is unlikely that cholesterol is impacting the results described in 
this chapter, as the anti-contractile effects appear to be as a result of the GG-PP branch 
of the pathway, not cholesterol precursor, F-PP. 
4.4.4 The effect of simvastatin treatment on pMLC levels 
In order to investigate the anti-contractile mechanism of simvastatin further, the effect 
this statin has on pMLC levels was assessed. The Rho/ROCK pathway has long been 
associated with smooth muscle contraction. Rho binds to ROCK following 
geranylgeranylation, conversion of GDP to GTP and membrane anchoring (Matsui et 
al. 1996). Activated ROCK can interfere with MLCK, MLCP or phosphorylate MLC 
directly at the Ser-19 site (Schaafsma et al. 2008). This facilitates the actin activation 
of myosin ATPase, leading to actin-myosin contraction (Somlyo and Somlyo 1994; 
Amano et al. 1996; Samizo et al. 1999).   
In this chapter, the effect of simvastatin on the abundance of pMLC was investigated 
by an In-Cell Western assay. Unsurprisingly, levels of pMLC were highest in the 
basally contracting vehicle groups. Simvastatin treatment concentration-dependently 
reduced the phosphorylation of MLC, validating its anti-contractile effect at a 
molecular level. Again, mevalonate and GG-PP, but not F-PP, abolished the effects of 
simvastatin. This suggests that simvastatin attenuated myometrial cell contraction by 
inhibiting the isoprenylation of Rho by GG-PP, preventing the activation of ROCK, 
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Figure 4.15. Simvastatin reduces myometrial cell contraction by inhibiting the Rho/ROCK 
pathway via the attenuation of GG-PP production. Mevalonate and GG-PP, but not F-PP, 
supplementation abolished the anti-contractile effects of simvastatin. By attenuating the production of 
GG-PP, simvastatin inhibited the geranylgeranylation of Rho. Thus, simvastatin indirectly prevented 
the phosphorylation of MLC by ROCK, which subsequently inhibited actin fibre contraction. ROCK: 
Rho-kinase. MLC: Myosin light chain. MLCP: Myosin light chain phosphatase.  
Many studies are in agreement regarding simvastatin-induced attenuation of pMLC 
levels. During an investigation of proliferative vitreoretinal diseases, simvastatin 
inhibited the contraction of bovine hyalocytes embedded in collagen gel by reducing 
the phosphorylation of MLC (Kawahara et al. 2008). Simvastatin also reduced pMLC 
levels and RhoA activity in a bovine aortic endothelial cell line (Lampi et al, 2016). 
As matrix stiffness increased, RhoA activity increased. Interestingly, simvastatin 
reduced levels of active RhoA but total RhoA expression was unaffected. The authors 
also utilised Traction Force Microscopy and found that simvastatin reduced the 
contractile force of the endothelial cells, as well as altering endothelial cell focal 
adhesions and cell cytoskeletal organisation, resulting in more elongated cells (Lampi 
et al, 2016). Zeng et al. (2005) reported that simvastatin inhibited the contraction of 
glomerular endothelial cells, by preventing RhoA activation and subsequent MLC 
phosphorylation. Similar studies, in multiple cell types, have also proposed that the 
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mechanism by which statins exert their anti-contraction, pleiotropic effects is by 
inhibiting Rho/ROCK and subsequently, preventing MLC phosphorylation (Alvarez 
de Sotomayor et al. 2001; Mraiche et al. 2005; Kuhlmann et al. 2006; Nagaoka et al. 
2007; Kidera et al. 2010; Wu et al. 2011; Xiao et al. 2012; Alp Yildirim et al. 2016). 
Other statins, such as lovastatin and atorvastatin, have also been shown to inhibit 
contractility and reduce pMLC levels (Wu et al, 2011; Xiao et al, 2012). 
The importance of ROCK-mediated MLC phosphorylation for myometrial 
contractility has been previously been identified (Moran et al. 2002; Hudson et al. 
2012). The Rho/ROCK pathway is believed to be an important tocolytic target, when 
there have been so few novel therapies is recent decades (Mitchell et al. 2013). For 
instance, ROCK inhibitors have been demonstrated to prolong gestation in PTB mouse 
models (Tahara et al. 2005; Goupil et al. 2010). 
Furthermore, studies have also found that simvastatin can affect Ca2+ flux, which may 
be another anti-contractile mechanism. One study found that simvastatin impaired 
vascular contractility by altering the influx of Ca2+ and disturbing RhoA activity, 
leading to structural remodelling (Kang et al. 2014). Simvastatin relaxed rat superior 
mesenteric artery rings in vitro, which was associated with the opening of voltage-
dependent K+ channels and the blocking of extracellular Ca2+ influx (Chen et al. 2016). 
Simvastatin also had antagonistic effects on voltage-gated calcium channels, inhibiting 
the contraction of gastrointestinal tissue, in an organ bath study (Ali et al. 2016). It 
would be interesting to assess the effect of simvastatin treatment on Ca2+ flux in the 
myometrial cells. If Ca2+ flux was inhibited, this could provide an additional 
explanation for the downstream effect on MLC phosphorylation. This could be 
performed using a colorimetric assay to measure [Ca2+]i changes. 
The next step in deciphering the pathway in full would be to add inhibitors of farnesyl 
transferase (FTI) and geranylgeranyl transferase (GGTI) to the collagen contraction 
assay. These enzymes catalyse the isoprenylation of small GTPases. GGTI should 
mimic the effect of simvastatin, inhibiting contraction and FTI would not affect the 
cell basal contraction, to confirm the findings of this chapter. As the hypothesis is that 
simvastatin inhibits myometrial cell contraction by inhibiting the Rho/ROCK 
pathway, the next experiment could be to quantify RhoA. An experiment was 
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attempted to immunoprecipitate active RhoA in myometrial cells. However, active 
RhoA is very lowly expressed. It was difficult to quantify in vehicle treated cells and, 
as simvastatin is hypothesised to inhibit RhoA, a large number of cells would be 
required to conclusively state that RhoA had been reduced. However, other studies 
have successfully addressed the effect of statins on RhoA. For example, performing a 
colorimetric RhoA assay or assessing the effect of statins on the translocation of RhoA 
(Xiao et al. 2013; Lampi et al. 2016). These experiments could be performed in the 
future. Additionally, a previous study from our laboratory showed that ROCK 
inhibitors can prevent the contraction of myometrial cells. Therefore, this experiment 
was not repeated, as it would merely mimic the effect of simvastatin (Hutchinson et 
al. 2014).  
A possible limitation in the design of these experiments is that concentration response 
experiments for GG-PP and F-PP were only performed once, or twice for mevalonate. 
As there are a multitude of studies that have performed similar experiments in the 
literature and the concentrations used are consistent, these experiments were 
performed briefly, in the interest of time and conserving materials. The myometrial 
cells are slow growing and can only be used up to passage 22 (purchased at passage 
12) and the contraction assays require a lot of collagen to form gels solid enough to set 
and detach from the wells. When F-PP did not affect myometrial contraction at the 
concentration cited in the literature, the concentrations were increased to confirm that 
F-PP did not reverse the effect of simvastatin, rather than the concentration being 
incorrect. It would be ideal to repeat this experiment at least three individual times but 
this would require many more cells, collagen and a large volume of F-PP to reach such 
high concentrations. Given that 10µM F-PP is most commonly used and there was no 
effect up to 100µM, the evidence from one concentration response experiment was 
considered relatively convincing in this case.  
In summary, simvastatin attenuated the contraction of human myometrial cells and 
lowered pMLC levels in these cells, both alone and in the presence of LPS. These 
effects were reversed by the addition of mevalonate and GG-PP but not by F-PP. This 
suggests that the mechanism by which simvastatin reduced myometrial contractions 
was via inhibition of the Rho/ROCK pathway.
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Chapter 5: Investigating the effect of statin 
treatment on an LPS-induced mouse model of 
PTB 
5.1 Introduction 
PTL is defined as labour before 37 completed weeks of gestation (WHO 1977). 
Despite considerable medical advances, PTB occurs in 5-18% of pregnancies annually 
and importantly, it is the leading cause of mortality in children under 5 years 
(Blencowe et al. 2012; Harrison and Goldenberg 2015).  
Treatments targeting PTL are limited and have focused on tocolytic therapies, such as 
NSAIDs, COX-2 selective inhibitors, calcium channel blockers and oxytocin receptor 
inhibitors, which attempt to impede myometrial contractions. Delaying birth allows 
for corticosteroids to be administered for fetal lung development. However, these 
tocolytic treatments are largely ineffective at substantially delaying PTB and fail to 
improve the outcome of the premature neonates (Haas et al. 2012; Haas et al. 2014). 
Above all, these treatments do not target the underlying cause of the PTL and there is 
no benefit of prolonging a pregnancy if the in utero environment is adverse for the 
fetus (Haas et al. 2012). 
PTB is most commonly associated with infection/inflammation (Romero et al. 2014). 
Inflammation initiates labour by stimulating myometrial contractions, fetal membrane 
rupture and cervical ripening (Rinaldi et al. 2011). For this reason, anti-inflammatory 
treatments are now being considered for delaying PTB and reducing fetal injury. For 
example, non-specific NF-κB inhibitors, TLR4 antagonists, TNF biologics and novel 
CSAIDs have all been investigated (Holmgren et al. 2008; Li et al. 2010; Stinson et al. 
2014; Ng et al. 2015). Progesterone administration is commonly used to maintain 
pregnancy and reduce inflammation. However, there is conflicting evidence regarding 
the benefits of this treatment for reducing the rates of PTB and improving neonatal 
outcome (da Fonseca et al. 2003; Fonseca et al. 2007; Hassan et al. 2011; Dodd et al. 
2013; Norman et al. 2016). The demand for an effective therapy prompted the 
investigation of statin treatment due to the increasingly documented pleiotropic 
properties associated with these drugs. 
The effect of statin treatment on preterm labour 
Chapter 5: Investigating the effect of statin treatment on an LPS-induced mouse model 
of PTB  159 
Statins are reported to reduce inflammation and have anti-contractile effects (Kuzuya 
et al. 2004; Mraiche et al. 2005; Perez-Guerrero et al. 2005; Nasu et al. 2009; Zhou 
and Liao 2010; Gonzalez et al. 2014). Recently, statins have been suggested for the 
prevention and treatment of pregnancy disorders, such as preeclampsia and anti-
phospholipid syndrome (Kumasawa et al. 2011; Lefkou et al. 2016).  
Chapter 3 and Chapter 4 described the anti-inflammatory and anti-contraction effects 
of simvastatin on human myometrial cells, respectively. These are beneficial attributes 
for a PTL therapeutic. Pravastatin did not have anti-inflammatory effects on the LPS-
induced myometrial cells. A possible explanation for this was that this statin could not 
enter these cells as it necessitates specific transporter uptake. Consequently, 
pravastatin was not included in the myometrial cell contraction experiments performed 
in Chapter 4. However, this statin may still have beneficial effects in vivo. Therefore, 
it was hypothesised that statin treatment will prevent PTB in an LPS-induced mouse 
model. The aim of this chapter was to investigate the effect of pravastatin and 
simvastatin treatment on an intrauterine LPS-induced PTB mouse model. Furthermore, 
to assess the effect of this treatment on maternal inflammation.  
5.2 Methods 
5.2.1 Ultrasound-guided LPS-induced mouse model of 
PTB 
Mice received an intrauterine injection of LPS (0.3-20µg) or PBS on gestational D17, 
under ultrasound guidance, as described in 2.8.2 (Rinaldi et al. 2015b). For statin 
experiments, mice received an intraperitoneal injection of pravastatin (10µg) or 
simvastatin (20µg or 40µg) on D16 and again 2 hours after intrauterine injection of 
LPS/PBS, as explained in 2.8.4. The mice were monitored by CCTV for signs of 
delivery. Time to delivery and the percentage of live born pups were recorded, as 
detailed in 2.8.3. The “n” numbers for individual experiments are outlined in the figure 
legends. 
5.2.2 Tissue collection 
In a separate cohort of pregnant mice, maternal serum, amniotic fluid, uterus and 
placenta samples were collected 6 hours after intrauterine injection of LPS/PBS, as 
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outlined in 2.8.5. Tissue was collected from mice receiving PBS (n=6), 20µg 
simvastatin (n=6), 40µg simvastatin (n=6), 1µg LPS (n=6), 20µg simvastatin and LPS 
(n=6) and 40µg simvastatin and LPS (n=6).  
Maternal serum was also collected from a separate cohort of mice for LC-MS/MS 
analysis. These mice received one intraperitoneal injection of either 20µg simvastatin, 
40µg simvastatin or PBS on D17. Serum was collected 1 hour (n=6) or 2 hours (n=3) 
after treatment to assess the acute effect of treatment on progesterone concentration, 
as simvastatin has a half-life of 2 hours (Schachter 2005). 
5.2.3 qRT-PCR 
The mRNA expression of multiple genes in the mouse uterus and placenta were 
assessed by qRT-PCR analysis, as described in 2.10. Uterus and placenta samples were 
collected from both the right and left horns, 6 hours after intrauterine injection of 
LPS/PBS. In the uterus, inflammatory markers Tnf, Il-1β, Il-6, Il-10, Cxcl1, Cxcl2, 
Ccl2 and Tlr4 were investigated, as well as contraction-associated genes Cx43 and 
Cox-2 (n=6). In the placenta, Tnf, Il-1β and Il-10 were investigated (n=6). 
The mRNA expression of these genes of interest was normalised to the endogenous 
control gene, β-actin, within each individual sample. Samples were then compared to 
the PBS control group using the 2−ΔΔ CT method of analysis, as detailed in 2.10. The 
results are presented as fold change relative to the PBS control group. 
5.2.4 ELISA 
An ELISA was performed to quantify the concentration of IL-6 in the maternal serum 
(n=3-6) and in pooled amniotic fluid samples (n=5-6), which were collected from dams 
6 hours after intrauterine injection with LPS/PBS. Details of the assay are explained 
in 2.11.4.  
5.2.5 Western blot 
Western blot analyses were performed to detect and quantify IL-6 and CX43 in the 
mouse uterus, collected from the PTB mouse model on D17. Samples were collected 
6 hours after intrauterine injection of LPS/PBS. Protein was extracted from uterus 
samples collected from the right horn of the uterus of each mouse and performed as 
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described in 2.12.1. Western blot was carried out as described in 2.12.3 and 2.12.4. 
CX43 was detected using fluorescence (n=6). Due to low levels, IL-6 was amplified 
using an HRP enzyme and detected using chemiluminescence (n=6). The intensity of 
each band was normalised to loading control, α-Tubulin, then quantified using the 
Odyssey analysis software. 
5.2.6 LC-MS/MS 
LC-MS/MS was performed in the Mass Spectrometry Core laboratory to quantify 
progesterone in the mouse maternal serum, as outlined in 2.13. This analysis was 
carried out in two cohorts of mice. The first cohort were mice that received one 
intraperitoneal injection of 20µg or 40µg simvastatin or PBS on D17; samples were 
collected 1 hour and 2 hours later, to assess the acute impact of treatment. The second 
cohort of mice were those in the PTB model studies, treated with 20µg or 40µg 
simvastatin on D16 and LPS/PBS on D17, followed by a second intraperitoneal 
injection of 20µg or 40µg simvastatin 2 hours later. Samples were then collected 4 
hours later. If the compounds were below the level of detection, they were assigned 
the lowest detection value of 0.05ng.  
5.2.7 Statistical analysis 
Data are presented as mean ± SEM and were analysed using GraphPad Prism. In these 
studies, “n” represents the number of individual dams treated. Time to delivery data 
were mainly analysed using Kruskal-Wallis, with Dunn's post hoc test, as data were 
not normally distributed and could not be transformed. LPS dose response time to 
delivery data successfully underwent logarithmic transformation, which was then 
followed by one way ANOVA analysis, with Dunnett’s post hoc test. The percentage 
data for live born pups were analysed by performing an arcsine transformation on the 
proportions, followed by a one-way ANOVA, with Dunnett’s post hoc test. All gene 
expression (CT values), ELISA, Western blot and LC-MS/MS data were square root 
transformed to achieve normal distribution (if necessary), then analysed by one-way 
ANOVA, followed by Dunnett’s or Tukey’s post hoc test. A p value <0.05 was 
considered statistically significant. 
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5.3 Results 
5.3.1 The effect of statin treatment on an LPS-induced 
mouse model of PTB 
The laparotomy procedure is widely performed to administer bacterial products, such 
as LPS, into the uterus to model intrauterine infection-induced PTB in mice. However, 
due to the invasive nature of this surgery, researchers within our laboratory developed 
a novel, less invasive model using ultrasound to guide the intrauterine injection 
(Rinaldi et al. 2015b). This model was used for the following experiments. 
5.3.1.1 Time to delivery 
Time to delivery was calculated as the time from intrauterine injection of 20µg 
LPS/PBS to the delivery of the first pup. Term was defined as ≥45 hours after 
intrauterine injection of 20µg LPS/PBS. When mice were treated with PBS, 
pravastatin or simvastatin alone, the mice all delivered at term (59.5 ± 2.0 hours; 61.3 
± 2.1 hours; 61.5 ± 3.1 hours, respectively; Figure 5.1). When mice received an 
intrauterine injection of 20µg LPS, they delivered much earlier (28.1 ± 10 hours), with 
5 out of 6 mice delivering preterm. However, given the small group size, this was not 
statistically significant. As the data were not normally distributed, a Kruskal-Wallis 
test was performed, which is less powerful than a one-way ANOVA. When mice were 
given 10µg pravastatin on D16 and 2 hours after 20µg LPS, the mean delivery time 
was 27.1 ± 9.3 hours. Interestingly, 1 of the 5 mice delivered at term following this 
treatment. When mice were treated with 20µg simvastatin on D16 and 2 hours after 
20µg LPS, all of the mice delivered preterm, with a mean delivery time of 18.0 ± 1.3 
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Figure 5.1. Time to delivery. Mice received PBS, pravastatin or simvastatin on D16, then intrauterine 
20µg LPS/PBS on D17, followed by another PBS, pravastatin or simvastatin treatment 2 hours later. 
Time to delivery was calculated as the time from intrauterine injection of 20µg LPS/PBS on D17 until 
the delivery of the first pup. When mice were given intrauterine PBS, they delivered at term (~60 hours 
after PBS). When mice received intrauterine 20µg LPS, they delivered preterm (~24 hours after LPS), 
irrespective of statin treatment. Although, only the mean time to delivery of the simvastatin and LPS 
group was found to be significantly reduced compared to the PBS group. n=5-6, *p<0.05, mean ± SEM, 
Kruskal-Wallis with Dunn's post hoc test. 
5.3.1.2 Percentage of live born pups 
The percentage of live born pups was calculated by dividing the number of live pups 
found in the cage by the number of viable fetuses counted via ultrasound on D17, with 
an individual data point representing each dam/litter (Figure 5.2). 
In the PBS control group, the mean percentage of pups born alive was 91.1 ± 5.7%. In 
line with expectations based on time to delivery, pup survival was also similar after 
administration of pravastatin or simvastatin with intrauterine PBS treatment (95.8 ± 
2.6%, 82.6 ± 12.4%, respectively). When pups were delivered preterm by the mice that 
received an intrauterine injection of 20µg LPS, the mean percentage of live born pups 
was significantly lower (12.5 ± 12.5%, p<0.0001). This effect on the pup survival was 
also observed when mice were given pravastatin or simvastatin after injection of 20µg 
LPS (20%, p=0.0075; 0%, p<0.0001, respectively). 
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Figure 5.2. Percentage of live born pups. The percentage of live born pups per litter was calculated 
by dividing the number of live pups delivered by the number of viable fetuses counted using ultrasound 
on D17. When mice received intrauterine PBS, with either PBS, pravastatin or simvastatin treatment, 
there was a high percentage of live born pups. However, 20µg LPS administration significantly reduced 
the percentage of pups born alive, irrespective of whether the mice received pravastatin or simvastatin 
treatment. n=5-6, **p<0.01, ****p<0.0001, mean ± SEM, one-way ANOVA with Dunnett’s post hoc 
test.  
5.3.2 Ultrasound-guided LPS dose response experiment 
to induce PTB in mice  
In previous studies using the laparotomy model to perform intrauterine injections, 
20µg LPS was required to induce PTB (Rinaldi et al. 2014). This concentration was 
also sufficient to induce PTB in the ultrasound model (Rinaldi et al. 2015b). However, 
as a dose response experiment had not previously been carried out, the impact of 0.3-
20µg LPS on PTB was investigated.  
5.3.2.1 Time to delivery  
The mean time to delivery in the PBS control group was 61.2 ± 3.4 hours (Figure 5.3). 
When an intrauterine injection of 0.3µg LPS was given, only 1 out of 4 mice delivered 
preterm (mean delivery time 56.6 ± 8.3 hours). When the mice received 1µg LPS, all 
mice delivered preterm (23.7 ± 0.6 hours, p=0.014 vs PBS). Following an intrauterine 
injection of 3µg LPS, 3 out of 4 mice delivered preterm. However, there was no 
significant difference compared to the PBS group (32.5 ± 11.2 hours, p=0.0577). When 
the mice were given 10µg LPS, all dams delivered preterm (20.9 ± 0.4 hours, p=0.0049 
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vs PBS). With 15µg LPS, all mice delivered preterm (22.2 ± 0.5 hours, p=0.0168 vs 
PBS). Finally, when mice received 20µg LPS, 6 out of 7 mice delivered preterm (24.8 
± 8.7 hours, p=0.0004 vs PBS). It was notable that even at the higher doses of LPS, 
there were some mice where delivery was not preterm, a result that was replicated in 









Figure 5.3. Time to delivery. Mice received intrauterine PBS or LPS (0.3-20µg) to induce PTB. 0.3µg 
LPS did not cause PTB. However, concentrations of 1, 10, 15 and 20µg significantly reduced the time 
from intrauterine injection to the delivery of the first pup, inducing PTB, compared to the PBS group. 
PBS and 20µg LPS data were collected previously by Dr Sara Rinaldi, n=3-7, *p<0.05, **p<0.01, 
***p<0.001, mean ± SEM, one-way ANOVA with Dunnett’s post hoc test. 
5.3.2.2 Percentage of live born pups 
In the PBS group, the mean percentage of live born pups from each litter was 90.5 ± 
4.8% (Figure 5.4). The mean percentage of pups born alive after 0.3µg LPS was 68.8 
± 23.1%, which was not significantly different compared to the PBS group. When the 
mice received 1µg LPS, none of the pups from the 4 litters survived birth (0%, 
p=0.0004 vs PBS). Following an intrauterine treatment of 3µg LPS, the mean 
percentage of live born pups was 25 ± 25%, which was significantly lower than the 
PBS group (p=0.0122). The percentage of live born pups was also reduced in the 
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groups that received 10µg LPS (7.1 ± 7.1%, p=0.004), 15µg LPS (4.8 ± 4.8%, 









Figure 5.4. Percentage of live born pups. A dose response experiment was performed using 0.3-20µg 
LPS. When mice were given 0.3µg LPS, the percentage of live born pups was not significantly different 
from the PBS group. However, when mice received 1-20µg LPS, the percentage of pups born alive was 
significantly reduced compared to the PBS group. PBS and 20µg LPS data were collected previously 
by Dr Sara Rinaldi, n=3-7, *p<0.05, **p<0.01, ***p<0.001, mean ± SEM, one-way ANOVA with 
Dunnett’s post hoc test.  
5.3.2.3 Inflammatory mRNA expression in the mouse uterus 
It was established that lowering the concentration of LPS to 1µg was still sufficient to 
cause PTB. To further explore the impact of LPS on inflammatory mechanisms 
implicated in PTB, the effects of 20µg and 1µg LPS on Cxcl1, a homologue of human 
IL-8, and Il-6 expression were compared. 
When mice received 20µg LPS, there was a robust upregulation of Cxcl1 mRNA in 
the whole uterus, including both endometrium and myometrium, which increased 
366.9 fold, when comparing to the PBS group (p<0.0001; Figure 5.5A). Lowering the 
concentration of LPS to 1µg also stimulated a significant upregulation of Cxcl1 
compared to the PBS group (27.4 fold, p<0.0001) but the relative expression of Cxcl1 
was significantly lower than in the 20µg LPS group (p=0.0004). 
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This pattern was also observed when investigating Il-6 expression (Figure 5.5B). At 
the higher dose of 20µg LPS, there was a large increase in Il-6 expression in the uterus 
(312.9 fold, p<0.0001 vs PBS). Again, 1µg LPS increased Il-6 expression compared 
to PBS (18.8 fold, p=0.0003) but this was significantly lower when compared to the 







Figure 5.5. Uterine inflammatory gene expression. (A) When mice received 1µg and 20µg LPS, 
Cxcl1 was significantly upregulated in the uterus, compared to the PBS group. By lowering the 
concentration of LPS from 20µg to 1µg, Cxcl1 expression was significantly reduced. (B) Il-6 expression 
was also significantly increased with LPS administration, compared to the PBS group. The upregulation 
of Il-6 was significantly lower with 1µg LPS, compared to 20µg LPS. PBS and 20µg LPS samples were 
provided by Dr Sara Rinaldi. n=3-6, ***p<0.001, ****p<0.0001, mean ± SEM, one-way ANOVA with 
Tukey’s post hoc test. 
5.3.3 The effect of statin treatment on a refined LPS-
induced model of PTB 
Following the dose response studies, experiments were repeated to establish whether 
pravastatin or simvastatin treatments could delay PTB or improve the percentage of 
live born pups. In these studies, PTB was induced using a 1µg LPS dose in the 
intrauterine infection mouse model rather than the dose of 20µg LPS. For clarity, 
pravastatin and simvastatin results are displayed separately. As some pravastatin and 
simvastatin experiments were performed simultaneously, PBS and LPS controls were 
frequently shared. Thus, some control data will appear on both pravastatin and 
simvastatin graphs. 
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5.3.3.1 Pravastatin  
Mice were treated with an intraperitoneal injection of pravastatin (10µg) or PBS on 
D16, followed by ultrasound-guided injection of 1µg LPS or PBS on D17 and another 
pravastatin or PBS treatment 2 hours later. Time to delivery and the percentage of live 
born pups were recorded.   
5.3.3.1.1 Time to delivery 
Mice given only PBS had a mean delivery time of 61.8 ± 1.8 hours (Figure 5.6). Mice 
that received pravastatin and intrauterine PBS had a similar mean time to delivery of 
61.3 ± 2.1 hours. In the LPS group, 8 out of the 9 mice delivered preterm, with a mean 
time to delivery of 25.3 ± 4.4 hours after intrauterine injection (88.9% PTB, p=0.0039 
vs PBS; p=0.0364 vs pravastatin + PBS). When mice received LPS and pravastatin 
treatment, PTB was prevented in 2 of the 8 mice (75% PTB). The mean delivery time 
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Figure 5.6. Time to delivery. Mice were treated with PBS or pravastatin on D16, followed by 1µg 
LPS/PBS on D17 and another PBS or pravastatin treatment 2 hours later. (A, B) When mice were given 
intrauterine PBS, they delivered at term (0% PTB). When mice received intrauterine LPS, time from 
intrauterine injection to delivery was significantly reduced, compared to the PBS only and pravastatin 
control groups and the PTB rate was 88.9%. When pravastatin and LPS were given, PTB was prevented 
in 2 of the 8 mice, with a PTB rate of 75%. There was no significant difference between this group and 
the PBS group or LPS group. PBS and LPS control data shared for pravastatin/simvastatin experiments, 
n=6-9, *p<0.05, **p<0.01, mean ± SEM, Kruskal-Wallis with Dunn's post hoc test. 
5.3.3.1.2 Percentage of live born pups 
In the PBS group, 88.5 ± 6.2% of pups were born alive (Figure 5.7). When mice were 
treated with pravastatin and intrauterine PBS, the mean percentage of live born pups 
was 95.8 ± 2.6%. With LPS treatment, this percentage was greatly reduced to 11.1 ± 
11.1% (p<0.0001 vs PBS). When mice received pravastatin and LPS, the mean 
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Figure 5.7. Percentage of live born pups. Treatment with 1µg LPS significantly reduced the 
percentage of pups born alive. This percentage was also significantly reduced when mice received 
pravastatin and LPS, compared to the PBS group. PBS and LPS control data shared for 
pravastatin/simvastatin experiments, n=6-9, ****p<0.0001, mean ± SEM, one-way ANOVA with 
Dunnett’s post hoc test.  
5.3.3.2 Simvastatin 
The effect of 20µg simvastatin on 1µg LPS-induced PTB and pup survival was 
investigated. The increased concentration of 40µg simvastatin was also included in 
these studies. 
5.3.3.2.1 Time to delivery 
In the PBS group, all mice delivered at term (61.8 ± 1.4 hours; Figure 5.8). When mice 
received 20µg simvastatin and intrauterine PBS, the mean delivery time was 59.1 ± 
2.2 hours and with 40µg simvastatin and PBS, this was 51.7 ± 4.1 hours. When mice 
were given 1µg LPS, 14 out of 18 mice delivered preterm (77.8% PTB), with a mean 
delivery time of 30.6 ± 4.3 hours, which was significantly earlier than the PBS group 
(p=0.0033). When mice received 20µg simvastatin and intrauterine LPS, 8 out of 16 
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mice delivered at term, reducing PTB to 50% (Figure 5.8B). The mean delivery time 
was 46.9 ± 6.5 hours, which was not statistically significant compared to the PBS or 
LPS groups. Of the 10 mice given 40µg simvastatin and LPS, 6 mice delivered at term 













Figure 5.8. Time to delivery. Mice were treated with PBS or simvastatin (20µg or 40µg) on D16, 
followed by 1µg LPS on D17 and another PBS or simvastatin (20µg or 40µg) treatment 2 hours later. 
(A-B) When mice received intrauterine PBS, they delivered at term, with one exception when given 
40µg simvastatin and PBS. In the LPS group, PTB was induced 77.8% of the time and time to delivery 
was significantly reduced, compared to the PBS group. When mice received 20µg simvastatin and LPS, 
PTB rate was reduced to 50% and the time to delivery was no longer significantly different when 
compared to the PBS group. In the 40µg simvastatin and LPS group, PTB was further reduced to 40% 
and the mean time to delivery was not significantly different to the PBS group. PBS and LPS control 
data was shared for pravastatin/simvastatin experiments, n=9-18, **p<0.01, mean ± SEM, Kruskal-
Wallis with Dunn's post hoc test. 
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5.3.3.2.2 Percentage of live born pups 
The percentage of pups born alive was similar when mice received intrauterine PBS 
with intraperitoneal treatments of PBS, 20µg and 40µg simvastatin (90.6 ± 5.2%, 88.3 
± 7.6% and 76.1 ± 10.1%, respectively; Figure 5.9). There was a significant reduction 
in the LPS group, where the mean percentage of pups surviving birth was only 21.4 ± 
9.8% (p<0.0001 vs PBS). There was also a significant reduction in live born pups when 
mice received 20µg simvastatin and LPS (40.4 ± 10.2%, p=0.0016 vs PBS). However, 
there was no significant reduction in pup survival when mice were given 40µg 








Figure 5.9. Percentage of live born pups. In the LPS group, the mean percentage of pups born alive 
was significantly reduced to 21.4%, compared to the PBS group. When mice received 20µg simvastatin 
and LPS, the percentage was also significantly lower than the PBS group. However, when mice were 
treated with 40µg simvastatin and LPS, the percentage of live born pups was higher, at 56.7%, which 
was not significantly different to the PBS group. PBS and LPS control data shared for 
pravastatin/simvastatin experiments, n=9-18, **p<0.01, ****p<0.0001, mean ± SEM, one-way 
ANOVA with Dunnett’s post hoc test. 
5.3.3.2.3 IL-6 concentration in the maternal serum and amniotic 
fluid 
The effect of simvastatin administration on circulating IL-6 concentrations was 
investigated in the maternal serum of dams (Figure 5.10A). Treatment with 1µg LPS 
significantly increased the concentration of IL-6 in maternal serum, when compared 
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to the PBS group, (4067 ± 1168pg/ml vs PBS mean 7.6 ± 2.8pg/ml, p<0.0001), 20µg 
simvastatin and PBS (5.9 ± 1.1pg/ml, p<0.0001) and the 40µg simvastatin and PBS 
group (12.4 ± 4.7pg/ml, p<0.0001). When mice were given 20µg simvastatin and LPS, 
mean IL-6 concentration lowered to 2857 ± 883.3pg/ml but this was not significantly 
lower than the LPS group. However, IL-6 concentration was significantly reduced 
when mice received 40µg simvastatin and LPS (1201 ± 535.8pg/ml, p=0.0213 vs 
LPS). 
IL-6 was also measured in the amniotic fluid of these mice (Figure 5.10B). In contrast 
to the results in the maternal serum, none of the treatments had a significant impact on 












Figure 5.10. IL-6 concentration in the maternal serum and amniotic fluid. (A) 1µg LPS robustly 
increased IL-6 concentration in the maternal serum. This was significantly reduced when mice received 
40µg simvastatin and LPS. (B) IL-6 concentration in the amniotic fluid was unchanged by LPS or 
simvastatin treatment. n=3-6, *p<0.05, ****p<0.0001, mean ± SEM, one-way ANOVA with Dunnett’s 
post hoc test. 
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5.3.3.2.4 mRNA concentrations in the uterus 
As simvastatin treatment prevented PTB, as well as lowering the circulating 
concentration of IL-6, uterine inflammatory gene expression was then investigated.  
Firstly, inflammatory cytokine mRNA expression was determined (Figure 5.11). 
Intrauterine LPS (1µg) administration upregulated Tnf expression 6.1 fold in the 
uterus, compared to PBS treated mice (p=0.0059; Figure 5.11A). This upregulation 
was also significant in comparison to PBS control mice receiving 20µg simvastatin 
(p=0.0017) and 40µg simvastatin (p=0.0031) treatment. However, neither 20µg nor 
40µg simvastatin treatment affected these levels when given with LPS.  
This pattern was also observed with Il-1β expression, where LPS upregulated the 
expression 16.3 fold, which was significantly elevated compared to the groups that 
received intrauterine PBS; PBS (p=0.0002), 20µg simvastatin (p<0.0001) and 40µg 
simvastatin (p<0.0001; Figure 5.11B). However, when mice were treated with 20µg 
or 40µg simvastatin and LPS, there was no effect on Il-1β expression compared to the 
LPS group. 
LPS significantly elevated Il-6 expression 24.7 fold, compared to the PBS group 
(p=0.0005; Figure 5.11C). This elevation was also significant when compared to the 
simvastatin control groups (p<0.0001). Interestingly, when mice were given LPS and 
40µg simvastatin, Il-6 expression was 8.9 fold, which was significantly lower in 
comparison to the LPS group (p=0.0095).  
LPS upregulated Il-10 expression in the uterus compared to the PBS group (6.7 fold, 
p=0.0366), 20µg simvastatin (p=0.0269) and the 40µg simvastatin control groups 
(p=0.0397; Figure 5.11D). When 40µg simvastatin and LPS were given, Il-10 
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Figure 5.11. Inflammatory cytokine mRNA expression in the uterus. (A) Tnf was upregulated in the 
mice treated with 1µg LPS alone but this was not changed by simvastatin treatment. (B) Il-β was 
upregulated by LPS but these expression levels were unaffected by simvastatin treatment. (C) LPS 
increased the expression of Il-6. These levels were significantly reduced in the 40µg simvastatin and 
LPS group. (D) Il-10 expression was increased by LPS and reduced by 40µg simvastatin. n=6, *p<0.05, 
**p<0.01, ***p<0.001, ****p<0.0001, mean fold change ± SEM, one-way ANOVA with Dunnett’s 
post hoc test. 
In addition to cytokines, the effect of these treatments on a selection of chemokines 
was investigated in the same uterus samples (Figure 5.12). For instance, 1µg LPS 
upregulated Cxcl1 expression 22.7 fold (p=0.0005 vs PBS; Figure 5.12A). This mRNA 
expression was also upregulated in comparison to the 20µg simvastatin (p=0.0002) 
and 40µg simvastatin (p=0.001) control groups. Interestingly, treatment of LPS 
stimulated mice with 40µg simvastatin resulted in a significantly lower concentration 
of Cxcl1 compared with LPS alone (14.9 fold, p=0.0464 vs LPS).  
This anti-inflammatory effect of simvastatin was not observed for Cxcl2, although LPS 
alone robustly upregulated this gene 39.0 fold, which was significant in comparison to 
the PBS control groups; PBS (p<0.0001), 20µg simvastatin (p<0.0001) and 40µg 
simvastatin (p<0.0001; Figure 5.12B). 
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LPS administration significantly increased the amount of Ccl2 mRNA, a monocyte 
chemoattractant, 14.4 fold compared to the controls (PBS p=0.0002, 20µg simvastatin 
p<0.0001, 40µg simvastatin, p<0.0001; Figure 5.12C). When mice were treated with 
40µg simvastatin in addition to LPS, the fold change was 5.8 fold, which was 















Figure 5.12. Inflammatory chemokine mRNA expression in the uterus. (A) Cxcl1 was increased by 
1µg LPS and this was significantly reduced by 40µg simvastatin. (B) Cxcl2 was upregulated by 1µg 
LPS but these mRNA expression levels were unaffected by simvastatin treatment. (C) 1µg LPS 
increased the expression of Ccl2. These expression levels were significantly reduced in the 40µg 
simvastatin and LPS group. n=6, *p<0.05, ***p<0.001, ****p<0.0001, mean fold change ± SEM, one-
way ANOVA with Dunnett’s post hoc test. 
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As TLR4, an innate immune recognition receptor, has been found to play a role in 
LPS-induced PTB, the expression of the Tlr4 gene was also investigated (Elovitz et al. 
2003; Li et al. 2010). However, neither LPS nor the addition of simvastatin altered 






Figure 5.13. Tlr4 mRNA expression in the uterus. Tlr4 expression was unaltered by 1µg LPS or 
simvastatin treatment. n=6, mean fold change ± SEM. 
Messenger RNAs encoded by genes associated with uterine contraction were also 
investigated (Figure 5.14). LPS administration did not significantly alter the 
concentration of Cx43, a gap junction gene, in comparison to any of the control groups, 
although there was a trend for increase in the LPS group. Treatment of mice 
administered LPS with 40µg simvastatin significantly lowered Cx43 concentration 
compared to the LPS group (0.86 fold vs 1.7 fold, p=0.0143; Figure 5.14A). The 
expression of Cox-2, a gene involved in prostaglandin synthesis, was also investigated 
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Figure 5.14. Contraction-associated mRNA expression in the uterus. (A) Cx43 was not significantly 
upregulated by 1µg LPS but the mRNA expression was significantly reduced by 40µg simvastatin and 
LPS. (B) Cox-2 expression was unaltered by LPS or simvastatin treatment. n=6, *p<0.05, mean fold 
change ± SEM, one-way ANOVA with Dunnett’s post hoc test. 
5.3.3.2.5 Protein production in the uterus 
As 40µg simvastatin treatment attenuated the LPS-induced upregulation of a number 
of genes, an inflammatory gene, Il-6, and a contraction-associated gene, Cx43, were 
investigated at the protein level. However, the production of IL-6 and CX43 was 












The effect of statin treatment on preterm labour 
Chapter 5: Investigating the effect of statin treatment on an LPS-induced mouse model 

















Figure 5.15. IL-6 protein production in the uterus. (A) Representative chemiluminescent image. (B) 
IL-6 concentration was not altered by LPS or simvastatin treatment in the uterus 6 hours after 
intrauterine PBS/LPS administration. Recombinant human IL-6 protein was included as a positive 
control. Representative image was stitched together, as α-Tubulin and IL-6 protein required different 
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Figure 5.16. CX43 protein production in the uterus. (A) Representative fluorescent image. (B) 
Neither LPS nor simvastatin impacted on CX43 protein concentration 6 hours after intrauterine 
PBS/LPS administration. n=6, mean ± SEM. 
5.3.3.2.6 mRNA concentration in the placenta 
Inflammatory mRNA expression of Tnf, Il-1β and Il-10 was also investigated in the 
placenta (Figure 5.17). LPS alone did not upregulate any of these genes. However, 
when mice were treated with 40µg simvastatin in addition to LPS, the relative 
concentrations of mRNA encoded by these genes were all significantly lower than in 
the LPS group; Tnf (p=0.0153), Il-1β (p=0.0374) and Il-10 (p=0.028).  
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Figure 5.17. Inflammatory cytokine mRNA expression in the placenta. (A-C) Tnf, Il-1β and Il-10 
expression were all significantly reduced in the 40µg simvastatin and LPS group, compared to the LPS 
group. n=6, *p<0.05, mean fold change ± SEM, one-way ANOVA with Dunnett’s post hoc test. 
5.3.3.2.7 The acute effect of simvastatin treatment on 
progesterone concentration in the maternal serum of 
D17 pregnant mice 
Progesterone plays a crucial role in the maintenance of pregnancy (Csapo and Wiest 
1969). As statins inhibit the production of cholesterol, which is the precursor for all 
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steroid hormones, this may affect the synthesis of progesterone (Cornforth and Popjak 
1958). Therefore, progesterone concentrations were investigated in D17 pregnant mice 
in samples that were collected 1 hour and 2 hours after the intraperitoneal 
administration of simvastatin, to establish if simvastatin altered the production of this 
hormone.  
After 1 hour, mean serum progesterone concentration was 45.0 ± 7.9ng/ml in the PBS 
treated mice (Figure 5.18). There was no significant difference between the 
progesterone concentration of the PBS group and the mice that received 20µg 
simvastatin (38.5 ± 1.9ng/ml) or 40µg simvastatin (40.6 ± 3.6ng/ml).  
After 2 hours, the PBS group had a mean serum progesterone concentration of 29.6 ± 
7.8ng/ml. Again, the simvastatin treatment did not alter the progesterone concentration 
in comparison to the PBS group; 20µg simvastatin (43.9 ± 0.7ng/ml), 40µg simvastatin 







Figure 5.18. Progesterone concentration in the D17 pregnant mouse following simvastatin 
treatment. Progesterone concentrations were unaffected by simvastatin treatment (20µg, 40µg), 1 hour 
and 2 hours after administration. 
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5.3.3.2.8 The effect of simvastatin treatment on maternal serum 
progesterone concentration in an LPS-induced mouse 
model of PTB 
Progesterone concentration was measured in the LPS-induced mouse model of PTB to 
determine the effect of LPS and simvastatin treatment. These samples were collected 
6 hours after PBS/LPS intrauterine administration. In the PBS group, mean serum 
progesterone concentration was 67.9 ± 5.8ng/ml (Figure 5.19). This was similar for 
the 20µg simvastatin (49.5 ± 3.4ng/ml) and 40µg simvastatin control groups (59.1 ± 
6.5ng/ml), showing again that simvastatin treatment alone does not affect progesterone 
concentration. However, when mice received LPS, the mean serum progesterone 
concentration dropped to 10.2 ± 1.8ng/ml (p<0.0001 vs PBS). Simvastatin treatment 
appeared to have a dose-dependent effect on LPS-reduced serum progesterone 
concentration. When mice were treated with 20µg simvastatin and LPS, serum 
concentration of progesterone was slightly higher than in the LPS group but 
significantly lower compared to the PBS group (16.2 ± 8.8ng/ml, p=0.0001). 
Following treatment with 40µg simvastatin and LPS, mean serum progesterone 
concentration was slightly higher again at 32.7 ± 10.3ng/ml, although still significantly 
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Figure 5.19. Progesterone concentration in the maternal serum of a simvastatin-treated mouse 
model of PTB. LPS significantly reduced progesterone concentration. These levels were also reduced 
in mice that received simvastatin (20µg, 40µg) and LPS treatment. n=4-6, **p<0.01, ***p<0.001, 
****p<0.0001, mean ± SEM, one-way ANOVA with Dunnett’s post hoc test. 
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5.4 Discussion 
In this chapter, the impact of statins was explored in a mouse model where PTB was 
induced by intrauterine LPS administration under ultrasound guidance. The two statins 
chosen for this in vivo study were simvastatin and pravastatin. It was demonstrated in 
Chapter 3 and Chapter 4 that simvastatin reduced LPS-induced inflammation in human 
myometrial cells and attenuated both basal and LPS-induced myometrial cell 
contraction. These results suggest that simvastatin may be an effective treatment for 
PTL. Therefore, this hypothesis was investigated in a mouse model of PTB. Although 
pravastatin treatment did not reduce LPS-induced inflammation in the myometrial 
cells, this drug has been widely used to treat pregnancy disorders in animal models 
and more recently, in humans (Girardi 2009; Redecha et al. 2009; Costantine et al. 
2013; Gonzalez et al. 2014; Costantine et al. 2016). Therefore, pravastatin treatment 
was included in this chapter, to assess its effect in vivo. 
5.4.1 Refining the ultrasound-guided LPS-induced mouse 
model of PTB 
While previous studies from our group and others have administered 10-20µg of the 
0111:B4 LPS serotype into the uterus to induce PTB, the low rate of pup survival and 
concerns that the LPS might be overwhelming the immune system prompted us to 
perform dose response experiments (Elovitz et al. 2003; Rinaldi et al. 2014; Migale et 
al. 2015; Rinaldi et al. 2015a; Edey et al. 2016). The novel findings of this study 
included the observation that, while 0.3µg LPS did not consistently cause PTB in these 
mice, any dose of LPS greater than or equal to 1µg was sufficient to induce PTB in the 
majority of dams. However, PTB was still associated with the delivery of dead pups, 
even at reduced doses of LPS.  
To compare the inflammatory differences between the 20µg and 1µg concentrations 
of LPS, pro-inflammatory genes, Cxcl1 and Il-6, were investigated in the uterus. By 
lowering the dose of LPS to 1µg, this substantially lowered the mRNA concentration 
of these genes compared to the 20µg dose, while still causing some elevation of the 
genes compared to PBS. This is ideal, as inflammation is required to initiate the labour 
process but it should not be overpowering.  
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The results from this dose response experiment allowed our PTB mouse model to be 
refined. This also improved the clinical relevance of the model as, in humans, many 
cases of intrauterine infection are sub-clinical. Therefore, by lowering the dose of LPS 
as much as possible, the model became more similar to the human condition. However, 
clinically, the majority of babies born prematurely are born alive, so having 100% 
mortality at birth is a slight limitation of the model, as it does not fit the human 
paradigm. Nevertheless, the pravastatin and simvastatin experiments were repeated, to 
establish if these treatments would impact gestational length or the survival of the 
pups, at this lower dose of LPS. 
5.4.2 Statin treatment in a refined LPS-induced mouse 
model of PTB 
5.4.2.1 Pravastatin 
Pravastatin treatment prevented PTB in 2 out of 8 mice that had received LPS. 
However, LPS was not 100% effective, as one mouse in the LPS group delivered at 
term. Therefore, too much cannot be read into this result. The pups from the preterm 
deliveries in the pravastatin and LPS group were not born alive. This suggests that 
pravastatin did not have any additional fetal protective effects when the pups were 
delivered preterm. 
These results contradict the findings of Gonzalez et al. (2014) who reported that 
pravastatin prevented PTB in their intravaginal mouse model. However, the sample 
size in their study was smaller than the experiments performed in this chapter and the 
effect of pravastatin treatment on pup survival was not reported. In addition to the 
differential route of LPS administration, Gonzalez et al. (2014) treated their mice with 
a less severe serotype of LPS (O55:B5) (Migale et al. 2015).  
Pravastatin is the most commonly investigated statin for use in other pregnancy 
disorders. For example, pravastatin treatment has been extensively researched for the 
prevention and treatment of preeclampsia (Kumasawa et al. 2011; Carver et al. 2014; 
McDonnold et al. 2014; Ramma and Ahmed 2014). Two clinical trials have 
investigated the effect of pravastatin; one in women at high risk of preeclampsia and 
another in women with early onset preeclampsia. In high risk women, maternal 
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cholesterol levels were reduced by pravastatin treatment but the concentration of 
cholesterol in the umbilical cord was unaltered and the birthweights were not different 
between groups. No safety risks were identified with this treatment (Costantine et al. 
2013; Costantine et al. 2016). The other trial investigated the effect of 40mg/day 
pravastatin treatment on early onset preeclampsia (StAmP; 23410175). However, the 
results are still to be reported.  
In addition, pravastatin treatment has been found to improve pregnancy outcomes in 
women with anti-phospholipid syndrome, when taken from the diagnosis of 
preeclampsia or IUGR. Pravastatin increased placental blood flow, subsequently 
easing the complications associated with preeclampsia. Importantly, there were no 
fetal abnormalities reported (Lefkou et al. 2016). Pravastatin was also shown to protect 
against IUGR in a mouse model of glucocorticoid overexposure (Wyrwoll et al. 2016). 
Pravastatin, a first generation statin, is one of the least potent statins and it was not 
believed to cross the placenta, as it necessitates specific transporter uptake into cells 
(Kapur and Musunuru 2008). However, more recently, two small ex vivo placental 
perfusion studies reported the transplacental transfer of pravastatin, although limited 
and slow (Nanovskaya et al. 2013; Zarek et al. 2013). One study found that the transfer 
of pravastatin was higher in the fetal-maternal direction, suggesting that efflux 
transporters may be responsible for reducing the transfer of pravastatin across the 
placenta (Nanovskaya et al. 2013). 
As pravastatin is reportedly effective in other obstetric complications, it warrants 
further investigation for PTB prevention. In future studies, the dose of pravastatin 
could be increased to establish if this could prevent PTB or improve neonatal outcome. 
The 10µg dose given in these experiments is equivalent to a human therapeutic dose 
of 20mg, which is relatively low (Kumasawa et al. 2011). Additionally, the timing of 
the treatment could be optimised. 
5.4.2.2 Simvastatin 
In the simvastatin studies, when LPS-stimulated mice were treated with 20µg or 40µg 
simvastatin, a higher number of pregnancies progressed to term and the mean time 
until delivery was no longer significantly different to the PBS group. However, there 
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was not a significant difference between these groups and the LPS group. Due to the 
non-normal distribution of the time to delivery data, the non-parametric Kruskal-
Wallis statistical analysis was performed. This test has less power than a one-way 
ANOVA. Ideally, simvastatin treatment would significantly prolong gestation in 
comparison to the LPS group but power calculations revealed that too many mice 
would be required for there to be a statistical difference. Despite the lack of statistical 
significance, simvastatin is rather convincingly having an effect on the rate of PTB in 
this mouse model. Future experiments should focus on establishing the mechanisms 
involved and optimising the treatment protocol for this to be effectively translated to 
humans.  
Interestingly, an “all or nothing” effect was observed, where the simvastatin treatment 
either prevented PTB or the mice delivered preterm. This suggests that there was a 
threshold that simvastatin had to overcome in order to prevent PTB. One possible 
hypothesis for this “all or nothing” effect is the sex of the fetuses. Male sex is an 
independent risk factor for adverse pregnancy outcome, including PTB (Di Renzo et 
al. 2007; Ferrero et al. 2016). It has been suggested that this could be due to the larger 
size and birthweight of males. Furthermore, factors associated with male sex may 
predispose to infection-mediated PTB (MacGillivray and Davey 1985; McGregor et 
al. 1992). For instance, low concentration of IL-1 receptor antagonist was reported in 
the amniotic fluid of premature males (Bry et al. 1995). Alternatively, this 
phenomenon could be linked to sex hormone differences (Cooperstock and Campbell 
1996). However, the mechanism behind this is not fully understood and it is unknown 
if this would impact on mouse models of PTB. It could be speculated that the sex of 
the pups could have influenced whether simvastatin was able to rescue the pregnancy. 
For example, a high proportion of male fetuses in a litter could increase the threshold 
that simvastatin would need to overcome in order to prevent PTB. The sex of the pups 
was not recorded in this study but future experiments could address this hypothesis. 
The effect of simvastatin on PTB has been assessed in a similar study. Gonzalez et al. 
(2014) reported that 20µg simvastatin prevented PTB in an intravaginal mouse model. 
The experiments in this chapter were performed with a larger cohort and also included 
information on the survival of the pups immediately after delivery, as well as 
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addressing the effect of simvastatin on maternal inflammation. The key difference 
between these studies is the model used. The most common route of intrauterine 
infection is believed to be ascension from the vagina and cervix. However, this is not 
well understood and opinions differ on the route of infection. It is also possible that 
there could be a haematogenous dissemination of infection, microorganisms could be 
introduced during an invasive procedure or originate in the fallopian tubes (Bastek et 
al. 2011). Previous attempts to establish an intravaginal mouse model of PTB in our 
laboratory have failed (Rinaldi et al. 2015b). Although the route of infection in our 
model may not mirror the in vivo situation entirely, by delivering the LPS directly into 
the uterus, we can be assured that intrauterine infection is induced, making this a 
clinically relevant model. Furthermore, myometrial transcriptomic studies reported 
that intrauterine LPS-induced PTB in the mouse closely resembles human labour 
(Migale et al. 2016). 
In comparison to pravastatin, fewer studies have investigated the effect of simvastatin 
in other pregnancy disorders. Simvastatin treatment inhibited sFlt-1 secretion from 
endothelial cells, trophoblast cells and preterm preeclamptic placental explants 
(Brownfoot et al. 2016). Simvastatin also prevented pregnancy loss in a mouse model 
of anti-phospholipid syndrome (Redecha et al. 2008). These few studies reinforce the 
potential of simvastatin as a therapeutic for obstetric complications. 
The mean percentage of live born pups was increased when mice were administered 
40µg simvastatin and LPS. Consistently in these studies, if mice delivered preterm, the 
pups did not survive delivery. It is unknown if this was due to the LPS causing fetal 
death or because the pups were too premature to survive. In most cases, the dam would 
not remove the pup from the amniotic sac, suggesting that the fetus died in utero. In a 
study by Migale et al. (2015), the authors reported that this particular serotype of LPS 
(O111:B4) caused 100% fetal death, which was observed 6 hours after intrauterine 
LPS (20µg) administration. However, in this chapter, when the tissue collection 
studies were performed 6 hours after 1µg LPS was given, the pups were still alive. An 
observation from another study in our laboratory suggested that fetal death may begin 
roughly 12 hours after LPS administration. Although, this has not been quantified. In 
another study, a reduced dose of 10µg LPS (O111:B4) resulted in a slight reduction in 
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fetal demise. There was no evidence of fetal brain inflammation in these pups prior to 
death. The authors proposed that fetal death may be a result of reduced placental blood 
flow (Edey et al. 2016). If this hypothesis is correct, simvastatin may be able to restore 
this blood flow to the fetus as statins have vasodilatory properties and improved 
placental vascularisation in a mouse model of glucocorticoid overexposure (Pereira et 
al. 2003; Wyrwoll et al. 2016). Due to the evidenced severity of the O111:B4 LPS 
serotype, it is all the more remarkable that simvastatin was capable of counteracting 
this inflammatory insult in the majority of cases, preventing PTB and leading to the 
delivery of live pups. 
As previous studies have suggested that simvastatin can reduce inflammation, 
circulating IL-6 concentration, as well as the mRNA expression of multiple cytokines 
and chemokines, were investigated in the uterus. LPS-induced IL-6 concentration was 
reduced in the maternal serum with 40µg simvastatin treatment. Il-6, Cxcl1 and Ccl2 
expression were significantly reduced with 40µg simvastatin, when compared to the 
LPS group, suggesting that simvastatin treatment was capable of reducing LPS-
induced inflammation in the uterus. Interestingly, Il-10 was also significantly reduced 
by 40µg simvastatin, compared to the LPS group. This was unexpected as, in the in 
vitro studies in Chapter 3, simvastatin treatment upregulated the expression of this 
anti-inflammatory gene in human myometrial cells. An important point to take into 
consideration is that it is unknown which, if any, of these mice would have delivered 
preterm. It is interesting to see a spread in the data collected from 40µg simvastatin 
and LPS treated mice, as it may give a clue to which pregnancies may have been 
rescued if the mice had been left to deliver. This may also give an indication of the 
influence of the anti-inflammatory effect of simvastatin in the prevention of PTB in 
this model. 
As outlined in section 2.8.5, many other tissues were collected from the PTB mouse 
model. These could be utilised to investigate the effect of simvastatin on the other 
processes of labour, such as fetal membrane rupture and cervical remodelling. In 
addition, the effect of simvastatin treatment on neutrophil and macrophage infiltration 
into the uterus could be investigated. Fetal tissues, such as brain, heart and lung, were 
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also collected. They could be examined for signs of fetal inflammation or injury 
following LPS administration and the effect of simvastatin on this.  
The anti-inflammatory effects of simvastatin outlined in this chapter are in agreement 
with another study where pregnant mice were pre-treated with simvastatin prior to 
intraperitoneal LPS administration. Basraon et al. (2012) reported lowered Il-1β and 
Il-6 mRNA expression levels in the uterus, reduced Il-6 and Tnf mRNA expression in 
the cervix and a multitude of inflammatory mediators were reduced in the maternal 
serum, with simvastatin treatment. In contrast to the results in this chapter, the authors 
also found IL-6 concentration was increased in the amniotic fluid 6 hours after LPS 
administration and this was reduced by the addition of simvastatin treatment (Basraon 
et al. 2012).  
TLRs are key recognition components of pathogen-associated molecular patterns. Tlr4 
expression was investigated in the mouse uterus, as TLR4 is the signalling receptor for 
LPS (Poltorak et al. 1998). A TLR4 antagonist has recently been shown to delay PTB 
and prevent perinatal death in a mouse model (Chin et al. 2016). There was no 
difference in the mRNA expression of Tlr4 with LPS stimulation or with simvastatin 
treatment. However, the O111:B4 serotype of LPS is not TLR4 specific, as it may also 
bind to TLR2. It would be interesting to investigate if Tlr2 expression was altered, as 
both Tlr2 and Tlr4 have been associated with the timing of labour (Montalbano et al. 
2013; Wahid et al. 2015). Furthermore, simvastatin has been shown to inhibit TLR4-
mediated LPS signalling, subsequently reducing cytokine release (Hodgkinson and Ye 
2008). Simvastatin treatment also prevented LPS-induced upregulation of TLR2 and 
TLR4 on the surface of human monocytes in vivo (Niessner et al. 2006). By 
investigating the effect of simvastatin on TLR2, this may provide a mechanism by 
which this drug may be inhibiting LPS-induced inflammation and the subsequent 
initiation of labour. 
In addition to inflammatory genes, contraction-associated gene Cx43 was significantly 
reduced by 40µg simvastatin treatment, compared to the LPS group. CX43 gap 
junctions increase in size and abundance during parturition. They are crucial for the 
coordination of synchronous contractions in the myometrium (Doring et al. 2006). 
This suggests that simvastatin could be inhibiting myometrial contractions by 
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downregulating genes associated with this process. These results are in agreement with 
Chapter 4, where it was demonstrated that simvastatin treatment attenuated the LPS-
induced contraction of human myometrial cells. 
Progesterone concentration was investigated in the serum of D17 pregnant mice to 
assess whether simvastatin treatment would alter these levels. It is well established that 
progesterone has a crucial role in maintaining pregnancy and statins primarily inhibit 
the synthesis of cholesterol, the precursor to progesterone. The results were reassuring 
that, after 1 hour and 2 hours, simvastatin treatment did not affect progesterone 
concentration, when comparing to the PBS group. Progesterone concentration was also 
comparable to values reported in the literature at this stage of gestation in the mouse 
(Virgo and Bellward 1974). 
Progesterone concentrations were also determined in the serum collected from the PTB 
mouse model, which has not previously been investigated in our ultrasound-guided 
intrauterine model of PTB. Progesterone withdrawal initiates parturition in the mouse 
(Hall 1956). Therefore, it was interesting to observe proof of reduced progesterone 
concentration following LPS treatment in this mouse model of PTB. Progesterone 
concentration was also significantly reduced in the mice that received 20µg and 40µg 
simvastatin in addition to LPS, compared to PBS levels. Interestingly, there appeared 
to be a dose effect, where treatment with 40µg simvastatin and LPS resulted in a lesser 
reduction in progesterone concentration than observed in the LPS group. This suggests 
that simvastatin treatment may have been working to counteract the effects of LPS and 
prevent PTB in some of these mice. However, the mechanism of this is unknown. It 
would be interesting to investigate this in more detail, perhaps by assessing the 
histology of the corpus luteum, as it has been suggested that LPS induces apoptosis of 
the corpus luteum, causing progesterone levels to drop (Luttgenau et al. 2016). 
However, this is not directly comparable to humans as, in human parturition, 
circulating progesterone levels do not reduce. Alternatively, there is thought to be 
functional progesterone withdrawal, which may be mediated by a shift in progesterone 
receptor ratio (Allport et al. 2001; Condon et al. 2003; Merlino et al. 2007). Although, 
these results do allow us to better characterise our model of PTB. 
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A major obstacle for the application of statins to prevent PTB is that these drugs are 
contraindicated during pregnancy. A retrospective observational study by Edison and 
Muenke (2004) reported that there was an association with fetal limb defects after 
simvastatin exposure during the first trimester. However, this finding has since been 
criticised and challenged by larger studies, which found that there was no greater risk 
when comparing to population baseline levels of fetal malformations (Gibb and Scialli 
2005; Petersen et al. 2008; Bateman et al. 2015). Therapeutics for the prevention of 
PTB would likely be given in the second or third trimester, when organogenesis is 
mostly complete. In addition, PTB itself can result in life-long morbidity, as well as 
neonatal mortality. Therefore, it can be argued that the possible benefits of statin 
treatment outweigh the risks. 
Studies in vitro have raised concerns over the effect of simvastatin on the placenta 
during the first trimester, suggesting this treatment affects trophoblast proliferation and 
migration, as well as causing cytotrophoblast apoptosis (Kenis et al. 2005; Tartakover-
Matalon et al. 2007; Forbes et al. 2015). However, as previously discussed, PTB 
prevention would not take place during the first trimester. Furthermore, the results in 
this chapter suggest that simvastatin treatment may reduce inflammation in the 
placenta. Future studies could investigate the effects of simvastatin on the histology of 
the placenta and additional genes/protein could be assessed, as these tissues have been 
collected. To date, studies have not investigated the possibility that simvastatin could 
cross the placenta. However, it is likely given the ease at which simvastatin can enter 
cells. There is also a possibility that statin treatment would actually protect against 
fetal injury by reducing fetal inflammation. One study described protective effects of 
both pravastatin and simvastatin against brain injury, in fetuses from LPS-treated 
dams, evidenced by a reduction in the expression of cell death and neurodegeneration 
markers (Pedroni et al. 2014). 
In the PTB studies presented in this chapter, there appeared to be a dose-dependent 
effect of simvastatin treatment. The higher dose of 40µg simvastatin was more 
effective than the 20µg treatment at preventing PTB and resulted in more live born 
pups. A possible explanation for this may be due to this higher dose reducing the 
expression of uterine inflammatory and contraction-associated genes. However, 
The effect of statin treatment on preterm labour 
Chapter 5: Investigating the effect of statin treatment on an LPS-induced mouse model 
of PTB  194 
despite doubling the dose of simvastatin, the higher dose was only slightly more 
effective than the 20µg treatment at preventing PTB. Therefore, the timing of the 
simvastatin treatment needs to be further investigated to fully understand the optimal 
treatment regimen. These mice received one dose of statins the day before LPS and an 
additional dose 2 hours after LPS. This treatment protocol was chosen due to its 
previously reported success in other mouse models of pregnancy disorders (Redecha 
et al. 2008; Gonzalez et al. 2014; Pedroni et al. 2014). It is unknown which treatment 
played a more important role in these experiments. For example, the dose on 
gestational D16 could have primed the mice for an inflammatory insult or the treatment 
2 hours after LPS administration could have reduced the LPS-induced inflammation. 
It was shown in Chapter 3 that both pre- and post-treatment with simvastatin can have 
anti-inflammatory properties. In a mouse model of sepsis, simvastatin treatment was 
able to improve survival in both a pre-treatment cohort and in a post-treatment cohort, 
providing additional evidence that the anti-inflammatory benefits of this drug are not 
restricted to certain treatment windows (Merx et al. 2004; Merx et al. 2005). 
Performing such experiments will be important for determining the best clinical 
application of this treatment. 
Finally, the mechanism by which simvastatin is preventing PTB also needs to be 
investigated. Other studies in animal models of inflammatory conditions reported that 
simvastatin reduced NF-κB activation (Jacobson et al. 2005; Fraunberger et al. 2009). 
Although, it has been reported that PTB induced with O111:B4 LPS is due to AP-1 
activation rather than NF-κB activation (MacIntyre et al. 2014; Migale et al. 2015). It 
is also possible to investigate the mechanism of action by supplementing components 
of the mevalonate pathway, as performed in Chapter 4. For example, mevalonate 
reversed the anti-inflammatory effect of simvastatin in a mouse model of allergic 
airway inflammation (Zeki et al. 2009). 
In summary, simvastatin treatment was capable of reducing the incidence of PTB in 
our refined intrauterine LPS-induced mouse model. Treatment with 40µg simvastatin 
also improved the survival of the pups. Pravastatin treatment did not prevent PTB or 
improve the percentage of live born pups. Simvastatin treatment alone did not affect 
maternal serum progesterone concentration. Progesterone withdrawal was evident in 
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the LPS-induced mouse model of PTB and simvastatin treatment concentration-
dependently counteracted this LPS-induced reduction in serum progesterone. 
The results of this chapter provide further evidence that simvastatin may be an 
effective therapeutic for the treatment of PTB. In addition to preventing PTB and 
improving pup survival, simvastatin reduced the expression of inflammatory and 
contraction-associated genes in the uterus, which is in agreement with the findings of 
Chapter 3 and Chapter 4. Furthermore, these results confirm the overall hypothesis of 
this thesis, that statin treatment would prevent PTB by reducing inflammation. 
Therefore, future experiments should refine the treatment regimen, as well as 
investigate the mechanisms of these effects. 
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Chapter 6: Discussion 
6.1 Summary of findings 
PTB remains a major clinical problem. It affects approximately 5-18% of births 
worldwide and is the leading cause of childhood morbidity and mortality (Blencowe 
et al. 2012; Harrison and Goldenberg 2015). Intrauterine infection and inflammation 
are implicated in at least 25-40% of PTB cases (Goldenberg et al. 2008). Despite 
advancements in medical research, PTL is still difficult to predict and current 
treatments are ineffective at preventing PTB and improving the outcomes of premature 
neonates (Haas et al. 2014). The development of new treatments should aim to target 
the underlying mechanisms of PTL. Statins may be an ideal candidate treatment for 
PTL, as these drugs exhibit anti-inflammatory effects in conditions such as 
hyperlipidaemia and atherosclerosis (Zhou and Liao 2010). In addition, they can 
inhibit the contraction of smooth muscle cells (Kuzuya et al. 2004; Perez-Guerrero et 
al. 2005; Nasu et al. 2009). 
The hypothesis of this thesis was that statin treatment will prevent PTB by inhibiting 
the inflammatory processes that trigger PTL. This thesis investigated the effect of 
statin treatment on PTL, with specific aims to (i) assess the effects of statins on 
inflammation in human myometrial cells in vitro, (ii) examine the effect of statins on 
the contractility of a human myometrial cell line, (iii) investigate the mechanisms by 
which statins affect either contractility or inflammation in PTL and (iv) determine 
whether statins can prevent PTB or improve neonatal outcome in an LPS-induced 
mouse model of PTB. The main findings are summarised below: 
 Pravastatin treatment of human myometrial cells did not increase or decrease 
LPS-induced inflammatory mediator mRNA concentration or protein 
production.  
 Simvastatin treatment reduced LPS-induced inflammation in myometrial cells 
by downregulating the mRNA concentration and protein production of pro-
inflammatory mediators, as well as increasing the mRNA expression of anti-
inflammatory cytokines.  
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 Simvastatin attenuated the basal contraction of myometrial cells in vitro. 
Simvastatin also reduced LPS-induced contraction of myometrial cells. This 
effect was reversed by the addition of mevalonate and GG-PP but not F-PP. 
Therefore, this was a cholesterol-independent effect. Simvastatin treatment 
inhibited the phosphorylation of MLC by inhibiting the Rho/ROCK pathway. 
 The ultrasound-guided, intrauterine LPS-induced mouse model of PTB was 
refined by lowering the concentration of LPS from 20µg to 1µg. Lowering the 
dose of LPS led to the reduction of pro-inflammatory mRNA concentration in 
the uterus. 
 Simvastatin treatment prevented PTB and increased the percentage of live born 
pups in the refined 1µg LPS-induced PTB mouse model. Simvastatin also 
reduced LPS-induced circulating IL-6 concentration and attenuated the 
expression of pro-inflammatory and contraction-associated genes in the uterus. 
Pravastatin treatment did not prevent PTB or increase the percentage of live 
born pups. 
 Progesterone withdrawal took place in the 1µg LPS-induced mouse model of 
PTB. Simvastatin treatment concentration-dependently counteracted this LPS-
induced reduction in serum progesterone. Simvastatin treatment alone did not 
alter maternal serum progesterone concentration. 
6.2 The effect of statins on inflammation 
Inflammatory processes have been associated with both term and PTL. There is an 
influx of leukocytes into the uterus and an increase of pro-inflammatory mediators, 
such as cytokines and chemokines (Thomson et al. 1999; Young et al. 2002). 
Therefore, statins may be a novel approach to prevent PTB, as these drugs have anti-
inflammatory properties. We investigated the effect of pravastatin and simvastatin 
treatment on inflammation in human myometrial cells and assessed the effect of 
simvastatin treatment on inflammation in an LPS-induced mouse model of PTB. 
Pravastatin did not alter LPS-induced inflammatory mediator expression in 
myometrial cells. This was most likely because pravastatin requires specific uptake 
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into cells by the transporter protein, OATP1B1, which is exclusively expressed in the 
liver (Hamelin and Turgeon 1998; Corsini et al. 1999). Simvastatin treatment reduced 
pro-inflammatory mediator gene expression and release, as well as upregulating anti-
inflammatory gene expression. These findings concur with other studies that 
demonstrate the anti-inflammatory effect of simvastatin in a number of cells types, 
such as vascular smooth muscle cells, macrophages and epithelial cells (Rezaie-Majd 
et al. 2002; Dichtl et al. 2003; Veillard et al. 2006; Xu et al. 2006; Iwata et al. 2012). 
Most studies have focused on cells associated with the cardiovascular system, as 
statins are normally used for the treatment of high cholesterol, which is associated with 
atherosclerosis and cardiovascular disease. The mechanisms by which statins have 
anti-inflammatory effects are not fully elucidated. However, it is likely that these 
effects are a result of the inhibition of protein isoprenylation within the mevalonate 
pathway (Wang et al. 2008).  
There have also been studies that have investigated the effect of statins on 
inflammation in tissues more relevant to our studies. For example, in the endometrium, 
the inner lining of the uterus, in the context of endometriosis. Simvastatin reduced 
CCL2 expression in human endometriotic cells in a nude mouse model with 
endometriotic implants (Cakmak et al. 2012). Simvastatin also reduced the secretion 
of a range of pro-inflammatory cytokines from LPS-stimulated human fetal 
membranes. In this study, pre-treatment with simvastatin prior to LPS stimulation was 
more effective at reducing inflammatory cytokine release than co-treatment or post-
treatment (Basraon et al. 2015). However, the results presented in this thesis are the 
first, to our knowledge, to assess the effect of statins on inflammation in human 
myometrial cells. As these cells were collected from a pregnant women at term, they 
have already been exposed to an increasingly pro-inflammatory environment and 
hormonal changes in preparation for labour and these cells will have already 
experienced a degree of stretch, making this a highly relevant in vitro model of the 
pregnant myometrium at term.  
Future studies should focus on determining the mechanisms by which simvastatin is 
having anti-inflammatory effects. Metabolites of the mevalonate pathway, such as 
mevalonate, GG-PP and F-PP, can be supplemented into the cultures to determine 
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which branch of the pathway is implicated to produce these anti-inflammatory effects, 
as performed in the contraction experiments in Chapter 4. Other studies in the literature 
have demonstrated that statins can inhibit the binding activity of the transcription 
factor, NF-κB, and inhibit the nuclear translocation of NF-κB, in cells stimulated by 
LPS (Hilgendorff et al. 2003; Shyamsundar et al. 2009). This could be investigated in 
the human myometrial cells by performing an electrophoretic mobility shift assay to 
assess binding activity. Alternatively, the degradation and phosphorylation of the 
inhibitor protein, IκBα, can be assessed by Western blotting. 
Furthermore, as chemokines and the chemotaxis of leukocytes have a prominent role 
in labour, it would be of interest to investigate the effect of simvastatin on the 
production of other chemokines. As reported in this thesis, LPS-induced IL-8 secretion 
from the myometrial cells was attenuated by simvastatin treatment in vitro, so it can 
be hypothesised that simvastatin would reduce the expression and production of other 
chemokines. Furthermore, inflammation can also be increased by uterine 
overdistension, inducing PTL (Adams Waldorf et al. 2015). Therefore, the effect of 
simvastatin on inflammation caused by mechanical stretch of the human myometrial 
cell line could also be investigated. 
In the PTB mouse model, 40µg simvastatin treatment reduced the concentration of 
LPS-induced IL-6 in the maternal serum, as well as reducing the mRNA concentration 
of cytokines and chemokines in the uterus. These results are broadly consistent with 
other studies, where simvastatin and other statins have been shown to reduce 
inflammation in mouse models of sepsis (Merx et al. 2004; Merx et al. 2005). Statins 
also have an immunomodulatory effect in some animal models, whereby leukocyte 
chemotaxis is altered and there is a shift in Th1 to Th2 phenotype. For example, in 
mouse models of inflammatory arthritis and allergic asthma (Leung et al. 2003; 
McKay et al. 2004). This could be addressed in the PTB mouse model by investigating 
the infiltration of leukocytes, such as neutrophils and monocytes/macrophages, in the 
myometrium by immunohistochemistry.  
A study by Basraon et al. (2012) investigated the effect of simvastatin pre-treatment 
in a mouse model of PTB induced by intraperitoneal administration of LPS, creating a 
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model of systemic infection. This study reported that simvastatin treatment reduced 
inflammation in the maternal serum, uterus and cervix of LPS-treated mice, which 
agrees with our findings described in Chapter 5.  
Inflammatory mediators have also been associated with cervical ripening and fetal 
membrane rupture, which are important processes for successful labour. Future studies 
could assess the anti-inflammatory effect of simvastatin on other tissues, such as the 
cervix and fetal membranes, which have already been collected from these mice. As 
well as investigating inflammatory mediators in these tissues, the effect of simvastatin 
on MMPs and collagen degradation can be determined, to assess whether simvastatin 
also prevented cervical ripening and fetal membrane rupture. Fetal tissue, such as the 
heart, lung and brain, was also collected and could be investigated to determine if 
simvastatin prevented any LPS-induced fetal inflammation or injury. 
Deciphering the underlying mechanisms of simvastatin anti-inflammatory properties 
is a key next step, as discussed in relation to the myometrial cell in vitro experiments. 
Previous studies have demonstrated the reversal of statin effects in other mouse models 
by the administration of mevalonate (Christensen et al. 2006; Sharyo et al. 2008). 
However, it may be more informative to concentrate on specific mechanisms 
downstream of the mevalonate pathway. Both transcription factors, NF-κB and AP-1, 
have been implicated in the upregulation of inflammatory pathways in term and PTL. 
The effect of simvastatin on LPS-induced activity of these transcription factors could 
be investigated in the uterus of the PTB mouse model by Western blot analyses of the 
transcriptionally active, phosphorylated forms of the NF-κB subunit, p65, and the AP-
1 subunit, c-Jun. However, one study reported that the serotype of LPS used in this 
thesis (O111:B4) selectively activates AP-1, not NF-κB in CD1 mice (MacIntyre et al. 
2014; Migale et al. 2015). It is unknown if this mechanism applies to our C57Bl/6 
mice. 
In summary, simvastatin, but not pravastatin, reduced LPS-induced inflammation in a 
human myometrial cell line and simvastatin reduced inflammation in a mouse model 
of PTB. These are the first studies to characterise the anti-inflammatory effects of 
statins in human myometrial cells and in an intrauterine LPS-induced PTB mouse 
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model. These results suggest that simvastatin treatment could inhibit the inflammatory 
cascade associated with PTL. Future experiments should focus on elucidating a 
mechanism for these anti-inflammatory effects.  
6.3 The effect of simvastatin on myometrial 
contraction 
Uterine contraction is a key process during labour, required to safely expel the fetus. 
In recent years, the role of inflammation in the stimulation of contractions has emerged 
(Mackler et al. 2003; Hutchinson et al. 2014). During labour there is an increase in 
pro-inflammatory mediators, such as cytokines and prostaglandins as well as 
contraction-associated proteins, in the uterus (Crankshaw and Dyal 1994; Young et al. 
2002). Tocolytic drugs are administered to inhibit contractions. However, they only 
delay labour for a short time (Haas et al. 2012; Haas et al. 2014). In Chapter 4, we 
demonstrated that simvastatin can attenuate basal myometrial cell contraction, as well 
as LPS-induced contraction and finally, we described the mechanism involved. This 
provides further evidence that simvastatin could be a useful tocolytic treatment for 
PTL. 
In the collagen gel contraction assay, simvastatin prevented the contraction of the 
myometrial cells embedded in the gels, both alone and in the presence of LPS. This 
was reversed by mevalonate and GG-PP but not F-PP, which suggests that this anti-
contraction effect was due to the inhibition of Rho geranylgeranylation. Simvastatin 
treatment also reduced the levels of pMLC in the myometrial cells, which is the final 
step required for actin and myosin cross-bridging. This confirmed the anti-contraction 
effect at a molecular level. These results again highlighted the importance of GG-PP 
inhibition for anti-contractile effects, suggesting that statins prevent contraction by 
inhibiting the Rho/ROCK pathway (Figure 4.15). 
The anti-contractile effect of statins has not previously been assessed in myometrial 
smooth muscle cells. However, our findings are in agreement with some other studies 
that have mostly reported anti-contractile effects in vascular smooth muscle cells and 
aortic rings, which is not unexpected due to the primary use of statins being to lower 
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LDL cholesterol concentration and prevent cardiovascular diseases (Kuzuya et al. 
2004; Mraiche et al. 2005; Perez-Guerrero et al. 2005; Alp Yildirim et al. 2016; Chen 
et al. 2016). Previous studies have also identified the inhibition of the Rho/ROCK 
pathway and the subsequent prevention of MLC phosphorylation, as a mechanism of 
these effects, adding strength to our findings (Zeng et al. 2005; Nagaoka et al. 2007; 
Kidera et al. 2010; Alp Yildirim et al. 2016). The most relevant cells to have undergone 
contraction studies following statin treatment are endometriotic stromal cells. 
However, a mechanism was not elucidated for the anti-contractile effect of these 
uterine cells (Nasu et al. 2009). Notably, the effect of statins on LPS-induced 
contraction has not previously been investigated.  
As it is well established that the influx of Ca2+ into cells is integral for smooth muscle 
contraction, future studies could investigate the effect of simvastatin on [Ca2+]i in the 
myometrial cells by performing a colorimetric assay, using calcium indicator dye. 
Recent studies have suggested that statins can affect [Ca2+]i (Kang et al. 2014; Ali et 
al. 2016; Chen et al. 2016). This could also provide another mechanism to explain the 
anti-contractile effects we measured using myometrial cells. To extend these cellular 
assays, organ bath studies could also be performed on human myometrial strips treated 
with simvastatin. Some experiments have been reported in the literature but these did 
not investigate the impact of statins on the intensity of myometrial contractions 
(Gonzalez et al. 2014). Chapter 4 demonstrated how simvastatin prevented the 
phosphorylation of MLC by inhibiting the Rho/ROCK pathway, via GG-PP inhibition. 
However, understanding of the effect of simvastatin on this pathway could be 
strengthened by specifically investigating the effect on RhoA-GTP, which should be 
reduced by simvastatin treatment. 
In our refined mouse model of PTB, 40µg simvastatin treatment significantly reduced 
the mRNA concentration of the contraction-associated gene, Cx43, in the uterus. The 
effect of statins on Cx43 expression has not been assessed in other animal models of 
PTB. As treatment with simvastatin reduced the incidence of PTB, we speculate that 
this might be due to a reduction in myometrial contractions. When considering the 
mechanisms that might contribute to this observation, the reduction in LPS-induced 
inflammation resulting from simvastatin treatment is one of several possibilities. The 
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expression of other proteins, such as PGF2α and the oxytocin receptor, both of which 
have been implicated in the regulation of contractions, could be investigated in the 
uterus of the simvastatin-treated PTB mouse model. In addition, uterine pressure could 
be assessed directly by telemetry studies, where transmitters are implanted into the 
uterine horn. However, the equipment for such studies is costly and would require 
additional surgery and careful validation to avoid off-target impacts of the presence of 
the transmitters. 
To summarise, simvastatin attenuated both the basal and the LPS-induced contraction 
of human myometrial cells and reduced the expression of contraction-associated gene, 
Cx43, in an LPS-induced mouse model of PTB. These data provide further rationale 
to support the proposal that simvastatin treatment could be a novel treatment for PTL, 
as this drug has anti-contraction effects, as well as reducing inflammation. 
6.4 Statins as a treatment for PTL 
This thesis describes for the first time the effect of statins on an intrauterine model of 
LPS-induced PTB. Simvastatin treatment prevented PTB in many cases and more pups 
were born alive, as a result. These findings extend those of another study where PTB 
was prevented in mice given an intravaginal injection of LPS serotype 055:B5 on D15 
of pregnancy, when treated with 20µg simvastatin 24 hours before and 2 hours after 
LPS (Gonzalez et al. 2014). Notably, in our mouse model, we used a different serotype 
of LPS (O111:B4), as well as a different route of administration. We reported a 
positive outcome of simvastatin treatment on the delivery of live born pups, as well as 
maternal inflammation. Furthermore, our studies were performed in a larger cohort of 
mice. 
In our study, pravastatin treatment did not prevent PTB in our mouse model, which is 
in contrast to the results reported by Gonzalez et al. (2014). It is unlikely that this was 
just because of the inability of pravastatin to enter certain cells, as the pleiotropic 
effects of pravastatin are thought to be due to a reduction of circulating isoprenoid 
concentration (Zhou and Liao 2010). The concentration of pravastatin and the 
treatment regimen could be modified in future experiments. Pravastatin has been the 
preferred statin for preeclampsia treatment due to its safety profile. Therefore, it 
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warrants further investigation as a potential treatment for PTL, using additional 
approaches to those described in this thesis.  
A limitation of both the original and our refined PTB mouse model described in this 
thesis is that there is 100% fetal death, which does not make it relatable to the human 
condition, where premature babies are mostly born alive (Rinaldi et al. 2015b). A study 
that analysed the effect of different LPS serotypes in an intrauterine PTB mouse model 
found the O111:B4 serotype used in our studies to be the most severe, as PTB was 
induced more rapidly in pregnant mice and there was increased fetal demise, in 
comparison to other serotypes (Migale et al. 2015). Although, this does highlight the 
efficacy of the simvastatin treatment, as it can overcome this insult by preventing PTB 
and preventing fetal death, in our refined mouse model. The relevancy of our model to 
humans could be improved by using a different serotype of LPS, which does not cause 
widespread fetal death, to determine whether simvastatin treatment has more subtle 
fetal protective effects that were being lost with the severity of the O111:B4 LPS. It is 
plausible that statins would have beneficial effects on fetuses, as other studies have 
reported that statins can prevent fetal death in mouse models of recurrent miscarriage 
and antiphospholipid syndrome (Redecha et al. 2008; Redecha et al. 2009). 
Alternatively, combination therapy may be a possibility. For example, a previous study 
from our laboratory found the pro-resolution mediator, 15-epi-lipoxin A4, to have fetal 
protective effects but this treatment was not sufficient to prevent PTB (Rinaldi et al. 
2015a). Although, these experiments were performed on the original laparotomy 
mouse model, utilising 20µg LPS to induce PTB. Nevertheless, treating mice with both 
simvastatin and 15-epi-lipoxin A4 could improve pup survival, even if the mice deliver 
preterm.  
Future studies should investigate the fetal outcomes from this refined mouse model in 
more detail. This could be performed by examining fetal tissues for signs of injury 
following LPS administration and whether this is ameliorated by simvastatin 
treatment. In addition, behavioural tests could be conducted. A recent article presented 
a number of neonatal motor tests that can be performed in mice from post-natal day 2-
14. This includes grasping reflex, surfacing righting and hindlimb suspension. This 
particular study assessed motor function in a neonatal mouse model of cerebral palsy, 
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induced by inflammation, ischemia and hypoxia, and found hindlimb weakness and 
defects in fine motor skills (Feather-Schussler and Ferguson 2016). This is particularly 
relevant to our model where inflammation plays an important role in instigating PTB. 
Moreover, prematurity in humans is associated with long term behavioural and 
neurological disorders, such as cerebral palsy. Performing these experiments would 
allow us to characterise motor defects associated with our intrauterine model of PTB 
and whether simvastatin could prevent these adverse neonatal outcomes. 
Further experiments are required to refine the concentration and timing of simvastatin 
treatment required to prevent PTB. Interestingly, 40µg simvastatin was not 
substantially more effective than 20µg simvastatin at preventing PTB and improving 
neonatal outcome. Although, the higher concentration was more effective at reducing 
inflammation. Therefore, treatment timing may have been a contributing factor. The 
treatment regimen for our PTB mouse experiments involved both a pre-treatment and 
a post-treatment with statins. This protocol was selected due to previously 
demonstrated success in other mouse models of obstetric complications (Redecha et 
al. 2008; Gonzalez et al. 2014; Pedroni et al. 2014). However, it is unknown which of 
these treatments was more influential in lowering inflammation and delaying the 
labour process until term. It can be hypothesised that the post-treatment with 
simvastatin may have been the more influential treatment, given the short, two hour 
half-life of simvastatin. Notably, Basraon et al. (2012) reported that pre-treatment with 
pravastatin and simvastatin reduced inflammation in an intraperitoneal LPS-induced 
mouse model of PTB. However, there was no information in their paper as to whether 
this treatment prevented PTB in these mice. As there have been no follow up studies 
since this paper was published in 2012, one can speculate that statin pre-treatment did 
not prevent PTB in that model.  
An alternative route of treatment should also be investigated, as statins would normally 
be administered orally in women. In mice, oral treatments can be given via gavage. 
Although, this may be stressful for the mouse, particularly during pregnancy. 
Alternatively, treatments can be hidden in palatable mixtures, such as flavoured 
gelatine, and ingested voluntarily by the mouse.  
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The next step would then be to perform safety testing and assess pharmacokinetics in 
pregnant women during a normal pregnancy. This could assess how well statins are 
tolerated and investigate any gene, protein or histological changes of maternal-fetal 
tissues, such as the uterus, placenta and fetal membranes, with this treatment. Small 
trials have already treated women at high risk of preeclampsia with statins and no 
safety concerns have been reported to date (Costantine et al. 2016; Lefkou et al. 2016). 
Human placental perfusion experiments have been conducted with pravastatin but not 
simvastatin (Nanovskaya et al. 2013; Zarek et al. 2013). This experiment could also 
be performed to examine how simvastatin is transferred between the maternal and fetal 
compartments and this could also indicate the concentration of simvastatin that the 
fetus may be exposed to. 
In the current study, LC-MS/MS revealed progesterone withdrawal had occurred in 
our PTB mouse model, something which had not been investigated before when LPS 
was administered by ultrasound-guided intrauterine injection. Although this is not 
directly relatable to human labour, it was reassuring that simvastatin treatment alone 
did not affect circulating progesterone levels, despite cholesterol being the precursor 
to this essential pregnancy hormone. Simvastatin treatment appeared to partially 
reduce LPS-induced progesterone withdrawal, which suggests a mechanism by which 
PTB may have been prevented and merits further study. It is unknown how the drug 
would have this effect but the histology of the corpus luteum could be assessed in the 
future to determine if simvastatin protects against LPS-induced damage of this tissue. 
The effect of simvastatin treatment on PTB induced by the progesterone receptor 
antagonist, RU486, could also address this. This study would determine the effect of 
simvastatin treatment on non-infection induction of PTB and would aid better 
understanding of the mechanisms responsible for these effects. 
In summary, simvastatin treatment reduced the number of preterm deliveries in our 
refined intrauterine LPS-induced mouse model of PTB and more pups were born alive. 
Pravastatin treatment did not have these beneficial effects in either the 20µg LPS or 
the 1µg LPS, refined mouse model of PTB. Further studies are required to establish 
the underlying mechanisms leading to the prevention of PTB by simvastatin. 
Although, we hypothesise that the reduction in maternal inflammation may have 
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played a key role in preventing labour. The treatment regimen must also be refined to 
improve the efficacy and to fully understand the optimal concentration and timing of 
treatment, so that this can be translated for human use. 
6.5 Conclusions 
The studies described in this thesis investigated the effect of statin treatment on PTL 
by utilising pregnant human myometrial cells as an in vitro model and in an ultrasound-
guided intrauterine LPS-induced mouse model of PTB. The experiments performed 
produced a number of novel and interesting findings. Simvastatin treatment reduced 
LPS-induced inflammation in myometrial cells, as well as attenuating both basal and 
LPS-induced contraction of these cells. These findings were further validated in our 
mouse model, where simvastatin prevented PTB and more pups were born alive as a 
result of this treatment. In addition, simvastatin treatment reduced LPS-induced 
inflammation in the uterus. Pravastatin treatment did not exhibit anti-inflammatory 
properties or have beneficial effects in the mouse studies. Simvastatin treatment 
demonstrated a number of useful properties, suggesting this drug would be an ideal 
candidate for the treatment of PTL, by targeting underlying inflammation, inhibiting 
myometrial contractions and subsequently preventing PTB.  
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